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INTRODUCTION
1. The immune system
Immunity originates from the Latin term immunis, meaning “exempt”, which refers to all the 
mechanisms used by the body as protection against invasion by agents that are foreign to 
the body. These agents may be infectious pathogens, foods, chemicals, drugs, and, in terms 
of transplantation, organ grafts from another individual (allograft). The immune system consists 
of two functionally distinct arms: the innate immunity arm and the adaptive immunity arm.
The innate immunity refers to all those elements with which an individual is born and that 
are always present and available at short term to protect the individual from challenges 
by foreign invaders. This response is nonspecific and occurs rapidly upon ligation to innate 
immune receptors (e.g. Toll-like receptors or C-type lectin receptors) (1). The cell types 
expressing these receptors and hence participate in the cellular innate immune response 
include dendritic cells (DCs), macrophages, e.g. Kupffer cells and splenic macrophages, 
granulocytes and natural killer (NK) cells (2-4). A fundamental defense mechanism car-
ried out by these cells is phagocytosis, but also production of cytokines to affect other 
cells, or release of perforin/granzyme for extracellular killing. In humoral innate immunity, 
the complement system is the main component. Specific activation of complement by 
pathogens leads to a cascade of proteolytic reactions that coats pathogens with comple-
ment fragments. Complement-coated pathogens are recognized and bound by specific 
complement receptors on macrophages, taken up by phagocytosis, and destroyed (5). 
The adaptive immunity is more specialized and is supplemental to the protection 
provided by the innate immune system. The advantages of this system are the ability to 
provide antigen-specific protection and the generation of long-lasting memory against the 
pathogen. During the first exposure to the pathogen, the induction of response is slow (can 
take up to days). However, by induction of memory cells, during a second exposure to the 
same pathogen a rapid and more effective response follows. Cells that are involved in the 
adaptive immune response include B cells and T cells. B cells can bind to antigens by their 
expression of B cell receptors, which are antigen specific membrane immunoglobulin (Ig) 
molecules. Once ligated, the B cell initiates an antibody response by secreting Ig molecules, 
whose purpose is to eliminate the antigen from the host. IgG facilitate the “clean up” of 
pathogens that they bind to, since cells from the innate immune system can recognize 
immune complexes by ligation of its Fcγ receptors (FcγRs) to the Fc part of IgG which stimu-
lates phagocytosis. Unlike B cells, T cells recognize antigens when they are processed into 
peptides which are presented by an antigen presenting cell (APC) in association with MHC 
molecules. T cell activation by APC requires three signals. The first signal is the interaction 
between the peptide MHC molecules with T cell receptor. This interaction itself is insufficient 
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for T cell activation; it will need a second signal, which comprises the interaction of co-
stimulatory molecules on APC, mainly CD80/CD86, with CD28 expressed on T cells. The third 
signal is the production of pro-inflammatory or anti-inflammatory cytokines by APCs. Upon 
activation, T cells release cytokines to either help B cells to produce antibody, activate other 
immune cells, or direct killing of pathogens by phagocytes (e.g. by IFN-γ secretion). 
2. Liver transplantation
Liver transplantation (LTx) is a life-saving treatment that replaces a diseased and poorly 
functioning liver with either a whole or a portion of a healthy donated liver. The first suc-
cessful transplantation of a liver in humans was performed by Thomasz Starzl in 1967 (6). 
The clinical use of transplantation has proceeded rapidly since a Consensus Development 
Conference of the National Institutes of Health concluded in June 1983 that liver transplan-
tation had become an accepted treatment for end-stage liver diseases and was no longer 
an experimental procedure (7). This has made the management of both chronic and acute 
hepatic diseases possible. The most important indications for liver transplantation in Europe 
from 1986-2009 were cirrhosis (52% with 21% related to hepatitis B or C viral infections), pri-
mary liver tumors (14% with 12% of hepatocellular carcinoma), cholestatic disease (11%), 
and acute hepatic failure (8%) (8). With the improved survival rate after surgery achieved, 
the success of liver transplantation was not determined anymore by surgical techniques, 
but by the next challenge: immunological rejection of the allograft.
3. The process of allograft rejection
Upon transplantation, the allograft from another individual (=allogeneic) is recognized as 
non-self and thereby induces an immune response. The discrimination between self and 
non-self is mainly the result of genetic differences in expression of MHC molecules. The MHC 
locus in humans encodes two major classes of proteins: HLA class I and HLA class II. HLA class 
I molecules are expressed on the surface of all nucleated cells, whereas class II molecules 
are expressed mainly by DCs, macrophages and B cells. Upon IFN-γ stimulation, HLA class II 
can also be upregulated on a variety of cells, including epithelium, endothelium and T cells. 
Since the MHC locus is highly polymorphic, HLA molecules expression is quite unique for 
each individual. T cells that are responsive to allogeneic MHC molecules (1-10%) will rapidly 
react when encountering a non-self MHC molecule (9, 10).
The immunological response during rejection that causes damage to the graft is very 
complex and constitutes a multifaceted network among organ resident cells, infiltrating 
cells, cytokines, antibodies, and other molecular mediators contributing to the injury of the 
graft.
Clinically, allograft rejection fall into three major categories (see also Table 1):
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1. Hyperacute rejection. This occurs within few minutes to a few hours of transplanta-
tion, since it is the result of preformed donor-specific antibodies, mainly directed against 
incompatible MHC antigens. Such antibodies are already produced in the recipient before 
transplantation, induced by a previous transplantation, by pregnancy or blood transfusion. 
These cytotoxic antibodies induce major graft damage by activation of the complement 
system and platelet activation and deposition, resulting in organ failure. After liver transplan-
tation, hyperacute rejection is very rare, as it is believed that the liver absorbs and eliminates 
donor-derived antibodies by Kupffer cells and the presence of dual circulation providing 
immense vascular reserve (11-13). However, in the last decade, cases of acute antibody-
mediated rejection after ABO-compatible liver transplant have been reported (14, 15).
2. Acute rejection. This occurs mostly within days or weeks after transplantation. This 
response is mainly cell-mediated, in particular T cells (16). Histologically, intense infiltration 
of lymphocytes and macrophages at the rejection site is seen. This response is inhibited by 
immunosuppressive therapy, and can be treated successfully by high-dose corticosteroid 
therapy. Until recently, preformed donor-specific antibodies were considered to be clinically 
irrelevant to the outcome of liver allograft compared to other solid organ transplants (17). 
However, increasing evidence suggests that donor-specific antibodies also play a significant 
role in acute rejection of liver allograft (18). In liver biopsies of unexplained dysfunctional liver 
allograft in patients positive for donor-specific antibodies, the presence of C4d and anti-HLA 
antibodies deposition have been seen, suggesting involvement of antibodies in acute liver 
graft rejection (19). However, since not all patients with donor-specific antibodies show graft 
TABlE 1 . Types of liver allograft rejection 
Type histological 
features
Infiltrating immune 
cells 
Onset Prevalence after 
lTx
Hyperacute 
rejection
Inflammation of 
portal tract, bile 
duct and portal 
vein
Lymphocytes (mainly 
T cells)
‘Blast’ cells
Macrophages
Neutrophils
Eosinophils
Minutes Rare
Acute rejection Inflammation of 
portal and central 
vein branches, 
lymphocyte 
infiltration of 
portal tracts and 
bile duct injury
T cells
Macrophages
Eosinophils
Days to weeks, 
but incidentally 
also years after 
transplantation
20-40%
Chronic rejection Loss of small 
bile ductuli, 
arteriopathy, 
presence of foam 
cells and absence 
of significant 
cellular infiltrate
T cells
Macrophages
B cells?
Months to years ~2%
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failure, positive cross-match for donor-specific antibodies is not a strict contraindication for 
LTx. Evidence of effective anti-humoral agents in LTx recipients is quite limited, but in renal 
transplant recipients, antibody-mediated responses are managed with plasmapheresis, 
intravenous immunoglobulin (IVIg) or rituximab.
3. Chronic rejection. This occurs within months or years after transplantation. This 
response is mainly cell-mediated, but antibody-mediated reaction may also play a role (16, 
20). Histologically, this response leads to inflammation of the small arteries and interstitial fi-
brosis and disappearance of small bile ductuli. Since the damage has already taken place, 
immunosuppressive treatment during this phase is not very helpful anymore.
For liver allograft rejection, the cell-mediated acute rejection is principally responsible 
(21). During such response two cell types play a pivotal role, which are APCs and T cells. 
APCs activate the immune response by presenting alloantigens (mainly HLA molecules) of 
the transplant to the recipient T cells. Allorecognition by T cells occurs by two different path-
ways. The first pathway is by direct allorecognition, the so called direct pathway (Figure 1). In 
this pathway, APCs that are present in the donor graft, also known as passenger leukocytes, 
leave the graft and migrate through the blood circulation to the recipient lymph nodes 
and spleen. Here, donor APCs directly activate recipient T cells by presenting intact non-self 
MHC molecules on their surface. Notably, select alloreactive T cells can recognize allo-MHC 
molecules regardless of which peptide is contained in the binding groove (22). Alloreactive 
T cells involved in the direct pathway may make up as many as 5% to 10% of the total pool of 
peripheral T cells. The second way of alloantigen recognition is the indirect pathway. In this 
pathway, donor alloantigens are shed from the graft, taken up and processed by recipient 
TCR 
MHC 
A B 
TCR 
MHC 
fIGURE 1 . Pathways of allorecognition. 
A) In the direct pathway, T cells recognize intact major histocompatibility molecules on donor antigen-
presenting cells. B) In the indirect pathway, T cells recognize processed alloantigen in the form of peptides 
presented by recipient antigen-presenting cells. MHC is referred to MHC class I and MHC class II. Adapted 
from the original figure of Briscoe DM and Sayegh MH, Nature Medicine, 2002.
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APCs, which then present them to T cells by their self-MHC molecules. Upon activation, 
naïve T cells proliferate and differentiate into effector T cells (Teff) which are specific for the 
alloantigens, and migrate via the circulation to the graft. Once in the graft they attack the 
graft tissue by direct lysis of graft cells, or by production of cytokines, among which IFN-γ, 
that stimulate macrophages to phagocytose graft tissue or B cells to produce antibodies 
(21, 23). Although both CD4+ and CD8+ T cells participate in acute cellular rejection, the re-
jection response is primary mediated by CD4+ T cells (20). Important counterparts of Teff are 
regulatory T cells (Tregs). They suppress the alloreactive immune response by inhibiting Teff 
activation and proliferation, and by preventing DC maturation and their immunostimulatory 
properties (24-26). 
The relative contributions of the two pathways in graft rejection are not fully known. The 
direct pathway is generally assumed to play a critical role in graft rejection during the early 
phase after transplantation, while the indirect pathway may become predominant later 
and presumably represents the driving force of graft destruction late after transplantation. 
In the current thesis, we will mainly focus on two cell types that play a key role in inducing 
and controlling the allograft rejection response, which are DC and Treg, respectively.
3.1 Dendritic cells
Dendritic cells (DCs) are the most potent APCs and play a crucial role in both direct and 
indirect allorecognition. DCs arise from both myeloid and lymphoid progenitors within the 
bone marrow and are present in blood, lymph, lymphoid organs and non-lymphoid organs. 
There are two distinct types of DCs: Myeloid DCs (mDCs), which play an important role 
in antigen presentation and activation of naïve T cells, and plasmacytoid DCs, which are 
particularly involved in type I Interferon responses to viral infections. mDCs are activated 
though binding of their pattern recognition receptors (PRRs) to their respective ligands. Toll-
like receptors and NOD-like receptors are well-described PRRs (27). The ligands of PRRs are 
either derived exogenously or endogenously. Exogenously derived molecules are called 
pathogen-associated molecular pattern (PAMPs), a well-known PAMP is lipopolysaccharide 
(LPS). Endogenous molecules are damage-associated molecular patterns (DAMPs), which 
are released from necrotic cells or from cells under stress (28). They function as important 
mediators of sterile inflammation, e.g. during graft rejection. In addition to direct recogni-
tion, mDCs can be indirectly activated by opsonized pathogens or antigens via ligation 
of immune-complexes to their activating Fcγ receptors (FcγRs), mainly FcγRIIa (CD32a). 
As a counter balance, DCs express the inhibitory Fcγ receptor IIb (CD32b) and a greater 
relative expression and ligation of FcγRIIb is sufficient to inhibit mDC activation induced by 
positive signaling through FcγRIIa (29, 30). Upon activation, mDCs increase their synthesis of 
MCH class II molecules and begin to express the costimulatory molecules CD80 and CD86 
facilitating activation, expansion and differentiation of naive pathogen-specific T cells.
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The importance of the mDC in graft rejection was demonstrated by early studies in ro-
dents. Grafted tissue depleted of mDC showed prolonged or even indefinite graft survival in 
the absence of immunosuppression, proven an essential role for DCs (31, 32). Donor-derived 
mDC migrate from transplanted liver grafts to recipient lymphoid tissues, where they stimu-
late recipient T cells by presenting donor type HLA-molecules (33, 34).
3.2 Regulatory T cells
Important regulators of immune responses, e.g. transplant rejection, are regulatory T-cells 
(Treg). These “central regulators” have the ability to inhibit proliferation and production of 
cytokines of Teff, consequently limiting the damage caused by donor-specific Teff. Tregs are 
CD4+ cells that also express CD25 (the α chain of the IL-2 receptor) and FOXP3 transcrip-
tion factor. Inhibition of Teff or conventional T cells (Tconvs) by Tregs is mainly exerted in 
a contact-dependent fashion and by secretion of cytokines, e.g. IL-10 and TGF-β (24-26). 
In addition, Tregs can also inhibit DC activation and maturation and immunostimulatory 
capacity, which is mainly exerted in a contact-dependent manner (24, 35).
Interestingly, high numbers of Tregs in liver grafts are associated with graft acceptance 
(36). Hence, depending on the balance between activation of Teff and Treg, the graft is 
either rejected or accepted. 
Importantly, experimental animal models have established that activated Treg not only 
temporarily prevent allograft rejection, but can even induce operational tolerance—de-
fined as a state of permanent immunologic unresponsiveness to the allograft in the ab-
sence of immunosuppressive drugs (37). This implies that proper expansion and activation of 
Treg in human organ transplant recipients may durably protect against transplant rejection 
without the need for life-long treatment with immunosuppressive drugs. Therefore, finding 
a compound that activates Treg would greatly benefit patients. Unfortunately, current im-
munosuppressive drugs do not only suppress Teff, but they also have negative effects on 
Tregs by inhibiting FOXP3 expression and their suppression function (38).
3.3 Monocytes and macrophages
Other cells involved in allograft rejection are monocytes and macrophages. Monocytes 
are precursors of macrophages, but by themselves they play an important role in innate 
immunity by production of cytokines. During rejection, monocytes are recruited to the 
graft by local production of chemokines (e.g. MCP-1, MIP-1α, MIF) produced by infiltrating 
leukocytes and parenchymal cells (39). The numbers of monocytes within the allograft are 
dramatically increased when acute rejection develops (40). Monocytes can be classified 
into CD14++CD16- (classical) and CD14+CD16++ (non-classical or “pro-inflammatory”) sub-
populations (41). The numbers of CD14+CD16++ monocytes are highly increased in patients 
with sepsis, rheumatoid arthritis or Kawasaki disease (41, 42). Recently, increased numbers of 
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CD14+CD16+ monocytes have also been reported after renal transplantation (43, 44), which 
is likely to be associated with acute rejection (44).
Macrophages are resident in almost all tissues and are the mature form of monocytes, 
which circulate in the blood and continually migrate into tissues, where they differentiate 
to macrophages. Tissue macrophages act as local surveillance and response cells to tissue 
damage and invading pathogens via several mechanisms, including phagocytosis, antigen 
presentation, cytokine production and secretion, and tissue repair. Macrophages are classi-
fied as M1 or classically activated cells with “pro-inflammatory” profile or M2 for alternatively 
activated cells with “regulatory” profile (45). While the M1/M2 differentiation is intriguing, the 
relative contribution of these cells in allograft rejection is not known. To date, numeral studies 
have indicated the accumulation of macrophages in both acute and chronic allograft re-
jection models, most of which are identified in renal transplant models. Damage to allograft 
is promoted by the production of pro-inflammatory cytokines, including IFN-γ, TNF-α and 
IL-1 (46-48). The production of reactive nitrogen and oxygen species by the inflammatory 
macrophage are also likely to contribute to tissue damage during acute rejection (49, 50). 
The precise mechanisms involved in tissue recognition and destruction by macrophages are 
largely unknown.
4. Current immunosuppressive drugs and side effects
The liver allograft is an immunologically privileged organ, which is illustrated by the low 
incidence of graft loss due to acute or chronic rejection and by its resistance to antibody-
mediated injury (51). Approximately 20% of stable liver transplant recipients (> 2-3 years 
after LTx) can be withdrawn from all immunosuppressive therapy and still maintain normal 
graft function and not experience rejection (52-60). However, to date, there is no validated 
tool to identify these patients, and therefore, liver graft recipients still are mandated to use 
immunosuppressive drugs for life-long (61). 
The current immunosuppressive drugs used in LTx act to inhibit the cellular rejection. Clas-
sical agents are corticosteroids, calcineurin inhibitors (CNI), mycophenolate mofetil (MMF; 
IMPDH inhibitor) and rapamycine (inhibitors of mTOR) (62). Most importantly, since their 
introduction in the 1980s, CNI have been the cornerstone of immunosuppressive treatment 
after organ transplantation (63). By inhibition of calcineurin signalling, IL-2 production by T 
cells is suppressed. 
In the early years of clinical practice of LTx, acute rejection occurred in up to 75% of 
patients. Due to new immunosuppressive drugs as mentioned above, and improvements in 
treatment management, since 2000 the incidence of acute liver rejection has decreased to 
15% (23). However, the need for life-long use of immunosuppressive drugs is accompanied 
by many side effects, such as hypertension, osteoporosis, cardiovascular diseases and renal 
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insufficiency (61, 62, 64). Moreover, by overall suppression of the immune system, patients 
suffer from major complications, such as cancer and infectious diseases. 
One of the leading causes of late mortality in liver transplant recipients is the development 
of de novo malignancy (65). Growing evidence shows a higher risk for cancer in liver trans-
plant recipients compared to the general population, with an incidence varying between 
3 to 26% (64-69). With regard to the type of malignancy, unique types of malignancy occur 
more often after transplantation. Skin and lip tumors, and relatively rare tumors, such as 
post-transplant lymphoproliferative disease (PTLD), Kaposi’s sarcoma, renal carcinomas, in 
situ carcinoma of the uterine cervix, hepatobiliary carcinomas, anogenital carcinoma and 
various sarcomas are prone to develop in transplant patients (70). In addition, recurrence 
of primary hepatic malignancy is well documented to occur after transplantation, and im-
munosuppression can accelerate metastatic tumor growth (68).
The pathophysiology underlying the increased cancer risk is not only suppression of im-
munosurveillance, but there is also evidence that CNIs have pro-carcinogenic effects that 
are independent of their effects on the host’s immune response, including the inhibition of 
DNA repair, stimulation of tumor growth factor (TGF)-β and/or vascular endothelial growth 
factor (VEGF) synthesis, diminishing clearance of altered cells and transforming cancer cells 
into aggressive cancer cells (71-74). 
Not all immunosuppressive regimens may give the same rise in cancer risk. However, so 
far, it is a matter of controversy which immunosuppressive regimen may be correlated with 
a higher cancer risk.
5. Intravenous immunoglobulin (IVIg): alternative safe 
immunosuppressive therapy?
IVIg is a therapeutic preparation of human IgG antibodies purified from pooled human 
plasma derived from 1,000-10,000 blood bank donors. This mixture of IgG molecules, contain-
ing traces of the IgM and IgA antibody isotypes, represents the entire antibody repertoire 
of numerous individuals. Consequently, IVIg antibodies recognize many different antigens. 
IgG preparations were first used therapeutically in the 1950s as IgG replacement therapy 
by intramuscular administration. Due to technological advances in the fractionation of 
plasma, monomeric suspensions of IgG were developed that are suitable for intravenous 
use in the early 1980s. At that time, the only indication was for treatment of primary im-
munodeficiency disease (PID). PIDs are caused by mutations in any of the large number 
of genes that are involved in or control immune responses. Approximately 50% of PIDs are 
characterized by antibody deficiencies, including X-linked agammaglobulinemia (caused 
by Bruton tyrosine kinase deficiency), common variable immunodeficiency (CVID), and hy-
per IgM syndrome (75). CVID is the most frequent symptomatic PID in adults (76). In patients 
with CVID, the function of B and T cells is impaired, and there is usually a deficiency in IgG, 
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IgM and IgA. The cause of the disease is not entirely clear and is probably not uniform. For 
severe disease, with many recurrent or chronic infections, IVIg treatment is indicated. IVIg is 
believed to be beneficial as it contains a broad spectrum of antibody specificities against 
bacterial, viral, parasitic, and mycoplasma antigens that are capable both of opsonization 
and neutralization of microbes and toxins. The recommended initial dose of IVIg for PID is 
400–600 mg/kg (77, 78). After the initial treatment, IVIg dosing is altered to achieve a tar-
geted trough level of 500 mg/dl. Since the half-life of IVIg is 21 days, IVIg infusion is repeated 
approximately every 3-4 weeks. Current data increasingly indicate that optimal treatment 
of PID is based on individualizing the dose of immunoglobulin for each patient to prevent 
recurrent infection and pneumonia, rather than to achieve defined through levels (79, 80). 
The use of IVIg to treat autoimmunity began after the first observation by Paul Imbach 
that IVIg administration to two patients who had agammaglobulinemia also improved their 
coexisiting thrombocytopenia. In 1981, he reported in several pediatric patients with immune 
thrombocytopenic purpura (ITP) receiving high-dose IVIg therapy a dramatic recovery from 
their thrombocytopenia (81, 82), which was also confirmed in adult patients (83). Since 
these first observations that IVIg exerts immunosuppressive properties, IVIg is increasingly 
used to treat various autoimmune diseases, including Guillain-Barré syndrome, Kawasaki 
disease and chronic inflammatory demyelinating polyneuropathy (CIDP) and other off-
label indications (Table 2). The efficacy of administering IVIg in the various autoimmune 
TABlE 2 . Autoimmune diseases for which IVIg administration is recommended
Condition Evidence Grade Usage (% total)
Patients Volume
Neuromuscular 31.54% 43.77%
Chronic inflammatory demyelinating polyradiculoneuropathy IA A 10.28% 21.65%
Multifocal motor neuropathy IA A 7.58% 11.13%
Guillain-Barré syndrome IA A 4.27% 4.34%
Myasthenia gravis IA B 4.10% 3.27%
Inflammatory myopathies IIB B 1.53% 1.78%
Paraprotein-associated demyelinating neuropathy IB A 0.47% 0.78%
Stiff person syndrome IB A 0.42% 0.67%
hematological 17.46% 11.13%
Immune thrombocytopenic purpura, acute and persistent IIB B 11.92% 7.10%
Autoimmune hemolytic anemia III C NR 0.04%
Other autoimmune 5.51% 3.27%
Kawasaki disease IA A 2.69% NR
Immunobullous diseases III C 2.02% 1.13%
Data derived from the 2011 clinical guidelines and the 2012 IVIg database report of the UK National Health 
System (NHS). The relative impact of each condition on IVIg usage in 156 NHS Trusts in years 2011–2012 are 
shown: numbers indicate the % of a total of 9458 patients (including patients with primary or secondary 
immunodeficiency) treated with a total volume of 2,613,076 grams IVIg. Sources: Clinical Guidelines for 
Immunoglobulin Use, 2nd Edition (2011), National Services Division of NHS Scotland Update, March 2012. 
Adapted from the original table of Petta et al., Current Opinion in Pharmacology, 2014.
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diseases is well-established (84). Side effects of IVIg are mostly mild and nonanaphylactic. 
They are typically characterized by back or abdominal pain, nausea, vomiting, diarrhea, 
rhinitis, chills, low grade fever, myalgias, and/or headache (78, 85, 86). Slowing or stopping 
the infusion will reverse many reactions. Hence, IVIg is a relatively safe therapy for life-long 
treatment. 
Interestingly, IVIg has also demonstrated to be effective in preventing allograft rejection. 
In our clinic it has been observed that prophylactic treatment of hepatitis B virus (HBV)  re-
currence with anti-HBs IVIg in patients receiving transplants for HBV-related cirrhosis resulted 
in significantly less risk of cell-mediated acute rejection (87). This finding was later confirmed 
in a multi-center study (88). Similar effects of IVIg have been observed in renal transplant pa-
tients (89). Interestingly, the mechanisms behind the immunosuppressive effects of IVIg are 
different from current immunosuppressive drugs. Our research group and other investigators 
have established that IVIg does not inhibit Teff directly, but indirectly by targeting mDC and 
Treg. IVIg effectively inhibits mDC function and promotes killing of mDC, thereby inhibiting 
presentation of allo-antigens to Teff (87, 90-92). Additionally, IVIg stimulates expansion of 
Treg and enhances their suppressive function in vitro and in animal models (93-95). Impor-
tantly, in the context of transplantation, our research group has shown that IVIg treatment 
can effectively prevent allogeneic skin graft rejection in mice (95). 
In renal transplant patients, IVIg has already been used for decades in patients who 
are sensitized with high titers of donor-specific anti-HLA antibodies in order to prevent 
antibody-mediated allograft rejection (Box 1). These patients are often treated with IVIg 
in combination with plasmapheresis, anti-lymphocyte antibody (rituximab or bortezomib) 
or immunoadsorption techniques (96-99). The beneficial effect of IVIg in prevention or 
treatment (100) of antibody-mediated allograft rejection includes enhancement of auto-
antibody clearance by blocking the neonatal FcR (FcRn),  neutralizing anti-idiotypic effects 
and blocking of complement activation (101, 102). Interestingly, modulation of FcγRs may 
play a role in prevention of acute allograft rejection. In several antibody-mediated immune 
disease models, upregulation of the inhibitory FcγRIIb expression by IVIg on macrophages is 
an important effector mechanism (103-106). In an arthritis animal model, glycosylated IgG 
binding to macrophages in the spleen results in upregulation of FcγRIIb expression on effec-
tor macrophages, resulting in reduced activation via auto-antibody immune complexes 
(107, 108). Recent research showed that FcγRIIb upregulation was exerted by a cascade 
of enhanced IL-33 production in the spleen induced by IVIg, which in its turn stimulates 
IL-4 and IL-13 production by basophils, and thereby enhanced expression of the FcγRIIb 
on effector macrophages in the joint in an auto-antibody mediated mice model (109). In 
context of allograft rejection, upregulation of FcγRIIb on macrophages may lead to inhib-
ited phagocytosis of donor-specific anti-HLA antibodies bound to allograft cells. In addition, 
upregulation of FcγRIIb on mDCs can result in reduced uptake of immune complexes of 
anti-donor IgG and donor HLA, resulting in decreased presentation of donor HLA peptides 
INTRODUCTION AND OUTlINE Of ThE ThESIS 23
C
h
A
P
T
E
R
 1
by recipient mDCs and suppressed mDC activation (30). In a cardiac transplant model, it 
has recently been suggested that the loss of FcγRIIb expression leads to enhanced chronic 
alloantibody -mediated allograft arteriopathy (120).  
Collectively, there is evidence that IVIg is able to modulate cells involved in graft rejec-
tion, including inhibition of APC functions, in particular of mDCs, and activation of Tregs. 
Figure 2 summarizes some proposed mechanisms of action of IVIg on cells involved in graft 
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fIGURE 2 . An overview of the proposed mechanisms of immunomodulation of IVIg on cells involved in 
allograft rejection.  
IgG in IVIg preparations can modulate the expression of activating FcγR or block the binding of immune-
complexes or cells opsonized by IgG to activating FcγR, thereby inhibiting endocytosis and phagocytosis by 
1) DCs and 2) macrophages. Also, IVIg inhibits DC differentiation and pro-inflammatory cytokine production, 
while increasing anti-inflammatory cytokine secretion. In addition, IVIg inhibits 3) T-cell activation by DCs via 
intracellular interference of IgG with presentation of antigens by MHC molecules. IgG binding to the C-type 
lectin SIGN-R1 on mouse splenic macrophages induces the expression of the inhibitory FcγRIIb on effector 
macrophages at sites of inflammation via increased IL-33 production. Via binding to FcγRIII, IVIg suppresses 
expression of IFNγR2 on macrophages, thereby inhibiting their functions. Furthermore, binding of IgG to 
CD22, a Siglec family member expressed on 4) B cells, IVIg reduces B cell receptor signaling and enhances 
B cell apoptosis. IgG dimers suppress macrophage and B-cell functions by ligating the inhibitory FcγRIIb. 
Additionally, IVIg induces antigen-specific 5) Tregs by tolerogenic DCs from non-Treg CD4+ T cells by binding 
of sialylated IVIg to DCIR expressed on DCs, and induces PGE2 secretion by DCs which stimulates expansion 
of Tregs. The latter process is at least partially mediated by F(ab’)2 binding to the human C-type lectin 
DC-SIGN. Presentation of Treg-activating peptides derived from the Fc part of IgG (Tregitopes) by antigen-
presenting cells activates Tregs. The immunological effects depicted are not mutually exclusive and are likely 
to work in synergy. DC, dendritic cell; MØ, macrophage; Teff, effector T cell; Treg, regulatory T cell; SIGN-R1, 
specific ICAM-3 grabbing nonintegrin-related 1; DC-SIGN, dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin; DCIR, dendritic cell immunoreceptor; PGE2, prostaglandin E2
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rejection. These features are unique compared to conventional immunosuppressive drugs, 
which mainly act on Teffs. 
However, most evidence for the immunomodulatory effects of IVIg on mDC and Treg are 
derived from in vitro or mouse model studies. Since humans and mice differ significantly in 
their immunology, it is highly questionable whether these mechanisms are translatable to 
humans. In addition, since few studies addressed the immunological effects of IVIg therapy 
in patients, it is largely unknown whether the mechanisms of action of the immunomodula-
tory effects of IVIg identified using human cells in vitro are operational in humans in vivo.
AIMS AND OUTlINE Of ThE ThESIS
Since the major side effects of current immunosuppressive drugs counterbalance the suc-
cess of LTx, there is a pressing clinical need for a safer immunosuppressive treatment in order 
to improve the long-term outcome. IVIg is a very promising option, since there is clinical 
evidence for protective effect against acute rejection. Importantly, long-term treatment 
with IVIg has no severe side effects (78, 85, 86). However, much knowledge still needs to 
be gained to understand the mechanisms behind the immunomodulatory effect of IVIg 
that are operational in humans. The current major drawback in the implementation of IVIg 
in standardized protocol post-transplantation is the predicted global shortage of human 
plasma and the high costs (119). Therefore, in order to enable long-term use of the immu-
nosuppressive properties of IVIg, a major goal is to synthesize small molecules or biologicals 
that exert anti-inflammatory effects equivalent to IVIg preparations. Such compounds will 
obviate the need for human plasma. To accomplish this, we first need to understand the 
BOX 1 
Current applications of IVIg in organ transplantation
• Treatment of sensitized patients with high titers of donor-specific anti-HLA 
antibodies, often in combination with plasmapheresis, immunoadsorption or 
anti-lymphocyte antibody (110, 111).
• Treatment of ABO-incompatible organ transplantation (in order to shorten the 
waiting time), often in combination with plasmapheresis, immunoadsorption 
or anti-lymphocyte antibody (112-114).
• Treatment of antibody-mediated rejection after organ transplantation (115).
• Treatment of steroid-resistant rejection in kidney transplant recipients (116, 117).
• Prophylactic HBV treatment in patients receiving liver transplants for HBV-relat-
ed diseases using anti-HBV surface antigen-specific IVIg (anti-HBs IVIg) (118) .
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cellular and molecular pathways by which IVIg suppress the immune system in humans in 
vivo.
The overall aim of this thesis was to identify the mechanisms by which intravenous im-
munoglobulin therapy modulates the immune system in humans, that could explain the 
clinical benefits seen in patients with autoimmune and inflammatory diseases as well as the 
prevention of graft rejection in transplant recipients. In addition, we identified an artifactual 
issue that influences results in studies on the effects of IVIg on mDC in vitro, as well as an 
artifact caused by one of the IVIg manufacturing processes to produce IVIg that affects its 
immunomodulatory capacity. 
In the first part of this thesis (chapter 2), we first studied one of the emerging complications 
of immunosuppressive drugs in liver transplant recipients, which is the development of de 
novo cancer. We described the relative risk for development of de novo cancer in our LTx 
cohort and examined the risk factors associated with developing de novo cancer. Impor-
tantly, we determined whether there was a correlation with changes in immunosuppressive 
exposure over time.
In the second part of the thesis we studied possible mechanisms by which IVIg therapy 
exerts immunosuppressive effects in patients. mDCs are the most potent APCs and medi-
ate both direct and indirect T-cell priming in alloreactive immune responses. In chapter 3, 
we studied the effect of IVIg therapy on mDC function in humans in vivo. We examined 
whether IVIg treatment stimulates production of IL-33 and Th2 cytokines and thereby modu-
lates expression of FcγRs and IFN-γ receptor on mDCs in humans in vivo. In addition, we 
explored the effects of Th2 cytokines on the expression of FcγRs and IFN-γ receptor on mDCs 
and the functional consequences in vitro. Tregs are important immune regulators and 
possible strategies to induce and maintain transplant tolerance by Tregs is currently being 
investigated. In chapter 4, we studied the in vivo effect of IVIg therapy on activation of Tregs 
in patients. In addition we assessed whether IVIg therapy induces the suppressive capacity 
of Tregs ex vivo. In chapter 5 we assessed whether high-dose IVIg therapy can modulate 
pro-inflammatory monocytes in patients, as has been recently suggested. To explore the 
dose-dependent effects, in all patient studies we have divided the patients into two groups: 
low-dose IVIg treatment (average 0.43 g/kg) and high-dose IVIg treatment (average 1.24 
g/kg). In chapter 6, we reviewed several immunomodulatory mechanisms of action of IVIg 
in humans, and focus on important immunological differences between mice and men that 
differentially impact how IVIg exerts anti-inflammatory activities in both species. This review 
warrants careful interpretation of studies derived from mouse studies and illustrates the need 
for human in vivo studies to unequivocally address which mechanisms of action of IVIg are 
in fact operational upon treatment in humans.
In the third part, we focused on potential factors that might influence the immunomodu-
latory effects of IVIg or the examination of effects of IVIg on immune cells. In chapter 7, we 
highlighted discrepancies between current reports on the effect of IVIg on DC maturation 
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and cytokine production in vitro. We examined whether IgG absorption to culture plastic 
plate may artifactually mimic immune-complex mediated activation of FcγR-expressing 
cells. In chapter 8, we studied whether the manufacturing process may influence the 
biological activity of IVIg, demonstrated by comparing two hyperimmunoglobulin prepara-
tions, Cytotect® with Cytotect® CP, which are IVIg preparations enriched for CMV-specific 
antibodies. Both studies warn for artifactual influences in studying immunomodulatory ef-
fects of IVIg.
Finally, in chapter 9, we summarized and discussed our results and described future per-
spectives.
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ABSTRACT
The goal of the study was to determine the risk factors for de novo cancer after liver trans-
plantation (LTx). Retrospective analyses were performed in 385 LTx patients transplanted 
between 1986 and 2007. In total, fifty (13.0%) recipients developed de novo malignancy. The 
cumulative incidence of de novo cancer at 1, 5, 10 and 15 years post-LTx was 2.9 (±0.9)%, 10.5 
(±1.8)%, 19.4 (±3.0)% and 33.6 (±6.8)%, respectively. The standardized incidence ratio (SIR) of 
malignancy in LTx patients compared to the general population was 2.2 (95% confidence 
interval [CI]: 1.6–2.8). After excluding PTLD and skin cancer, de novo cancer patients had a 
significantly lower survival rate as compared to recipients who remained cancer-free. The 
identified univariate risk factors for de novo cancer were cyclosporine (CsA) treatment, time 
period of LTx, and recipient age. In multivariate analysis, only CsA treatment emerged to be 
independent risk factor for de novo cancer, which moreover attributed to more aggressive 
cancer types. A surprising finding was that CsA treatment specifically enhanced cancer 
risk in patients transplanted after 2004, when C2 monitoring was introduced. Additionally, 
these patients showed a significantly lower acute rejection rate, which might reflect a more 
robust immunosuppressive status caused by CsA-C2. Considering age, only patients ≤50 
years had a higher cancer rate when treated with CsA compared to tacrolimus (TAC). Our 
data suggest that, compared to TAC treatment, CsA treatment with C2 monitoring or in 
younger patients of ≤50 years is associated with a higher early de novo cancer risk after LTx.
ASSOCIATION BETwEEN CyClOSPORINE AND CANCER AfTER lTX 39
C
h
A
P
T
E
R
 2
INTRODUCTION
The 1-year survival after liver transplantation (LTx) has dramatically increased in the past 
three decades. Nowadays, over 80% of the patients are alive 1 year after LTx (1, 2). In con-
trast, the long-term outcome has improved less impressively and its improvement is one of 
the main focuses in modern transplantation medicine (1). Importantly, malignancy is one 
of the major leading causes of late death after LTx (2-5). The reported risk for de novo can-
cer in liver transplant recipients is up to 2.1- till 4.3-times higher compared to the matched 
general population with an incidence varying between 3 and 26%.(3-10) The higher cancer 
risk after organ transplantation has been reported to be directly related to the intensity as 
well as the cumulative dose of immunosuppression (11). A dose reduction of cyclosporine 
(CsA) to maintain a trough blood level from 200 to 100 ng/ml in kidney transplant recipients 
resulted in a significant reduction in the de novo cancer incidence (12). Furthermore, a 
history of usage of immunosuppressive drugs prior to liver transplantation was a significant 
risk factor for development of de novo malignancy (13). The cancer pathogenesis induced 
by immunosuppressants includes direct damage to the host DNA and impairment of the 
recipients’ immunosurveillance, which reduces their anti-tumor and anti-viral immunity (14, 
15). Considering other risk factors, a higher age had been reported to play a significant role 
in the development of cancer after LTx (8, 13, 16).
Since their introduction in the eighties, calcineurin inhibitors (CNI) have been the cor-
nerstone of immunosuppressive treatment after transplantation. The relationship between 
cancer and the use of different CNI,  such as CsA or tacrolimus (TAC), is still to be elucidated 
(1). Several studies found no difference in the incidence of de novo cancer between CsA 
based and TAC based regimens (17-19), while other studies reported a higher de novo 
cancer risk for CsA (20, 21) or TAC (8) based immunosuppressive protocols. Thus, the role of 
different CNI in the occurrence of de novo cancer after LTx is still a matter of controversy.
As the therapeutic window between efficacy and toxicity of CsA is small, blood level 
monitoring to guide dosing is an essential tool (22). Traditionally, CsA dose adjustment was 
based on trough blood level (C0). In more recent years, numerous studies have reported that 
2 hours post-dose level monitoring (C2) is a more effective monitoring strategy compared to 
C0 level, as the absorption phase of CsA occurs within 2 hours and the concentration peak 
level is a better predictor of freedom from graft rejection (23, 24). Using CsA-C2 monitoring, 
the overall incidence of biopsy-proven acute rejection (22-28%) appeared to be lower 
compared to CsA-C0 monitoring (36-59%) (25-28). Therefore, in 2005, the CsA-C2 monitoring 
strategy was introduced in our center.
In the present study, we describe the incidence of de novo cancer after LTx in our centre 
and determine the risk factors associated with de novo cancer risk. Since immunosuppres-
sive regimens have changed over time and a delicate balance exists between effective 
prevention of rejection and over-suppression of immune surveillance, we additionally stud-
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ied the incidence of de novo cancer over time and determined its correlation with changes 
in immunosuppressive regimens. 
PATIENTS AND METhODS
Patients
Between October 1986 and December 2007, 565 liver transplantations were performed in 
500 adults in the Erasmus MC University Medical Centre Rotterdam, The Netherlands. As ma-
lignancy is a time-dependent event, patients with a follow-up shorter than 4 months (n = 99) 
at the time of analysis were excluded. In addition, patients who underwent auxiliary LTx (n = 
13), those who received a liver with the presence of occult malignant cells (n = 2) and those 
who had a cholangiocarcinoma in the native liver (n = 1) were excluded. Consequently, 
385 patients were included in our cohort, which represented 3121 person years of follow-up. 
A retrospective analysis was performed using the LTx database and medical records of the 
recipients. Analyzed data included age of recipient at time of transplantation, gender of 
recipient, primary LTx indication, type of primary immunosuppressive therapy, de novo ma-
lignancy post transplantation, interval from LTx to diagnosis of malignancy, interval from LTx 
or diagnosis of cancer to death and interval from LTx to diagnosis of the first acute rejection, 
which was defined as biopsy-proven rejection (Snover-grade ≥ 2, or rejection activity index 
(RAI)-score ≥ 6) with a rise in transaminases and/or bilirubin, which responded to treatment 
with methylprednisolone, and in some patients with OKT3 or rabbit ATG. All patients were 
followed until December 2008. 
The primary endpoint was de novo malignancy, which was defined as the development of 
cancer other than recurrent primary liver cancer. Recurrence cancer was not accepted as 
an endpoint, as this is not exclusively dependent on the immunosuppression state, but also 
on the aggressiveness of the primary liver cancer. Diagnosis of malignancy was confirmed 
histologically, and the date of histological diagnosis was taken as date of malignancy. 
Data were collected from follow-up examinations in the outpatient clinic at month 6 and 
every 12 months after transplantation. Prior to LTx, all patients had undergone a routine tu-
mor screening, which included chest radiography, mammography, abdominal ultrasound, 
gastroscopy and colonoscopy. After LTx, all patients participated in a yearly repeated clini-
cal, laboratory and radiology (ultrasound and chest x-ray) study. Women participated in a 
routine cervical cytology study on a yearly basis. Other studies were done on an individual 
patient basis. Epstein-Barr virus (EBV) IgG in serum before LTx were recorded for 346 out of 
385 patients. 
All patients declared not to object for using their data in the study.
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Primary immunosuppression
The choice of certain immunosuppressive protocols in our center over the years was based 
on the general development and new insights in immunosuppressive drugs (based on clini-
cal trials) in the liver transplantation medicine. During the first 10 years of the study, dual and 
triple CsA-C0 based maintenance immunosuppressive regimens have been routinely use. 
Dual therapy consisted of CsA and prednisolone, and in the triple regimen azathioprine was 
added. Between 1994 and 1999, the microemulsion formulation of CsA (Neoral; Novartis, 
East Hanover, NJ) has been altered with the oil-based CsA (Sandimmune; Novartis). From 
1999, the microemulsion formulation of CsA was routinely used. After CsA was initiated 
within 24 hr post-reperfusion in a dose of 10-15 mg/kg/day, the dosage was adjusted to 
pre-dose level according to a range between 200 and 400 ng/mL during the first 3 months 
and thereafter between 100 and 200 ng/mL. Moreover, CsA dosage was adjusted in case of 
rejection or CsA-related toxicity as described previously (29). Since the introduction of TAC in 
1990, a dual TAC-based regimen with prednisolone has been alternated with dual or triple 
CsA-based regimens. The monitoring of TAC was based on trough levels with a target range 
between 5 and 15 ng/ml. Started from 2000, dual therapy with TAC and prednisolone was 
used as standard regimen. 
Since the introduction of CsA-C2 level monitoring strategy in 2005, CsA-C2 based im-
munosuppressive regimen was used as standard regimen interchanged with TAC based 
immunosuppressive regimen. The CsA-C2 treated patients received an initial dose of 10-15 
mg/kg/day, which was adjusted based on the C2 target level of 800-1200 ng/ml during the 
first 3 months. Thereafter, target levels were maintained at 700-900 ng/ml at 4 till 6 months 
and 480-720 ng/ml thereafter. Dosing strategy of TAC remained unchanged. 
In the induction immunosuppressive regimen, polyclonal antithymocyte globulin (ATG) 
(n=16) or monoclonal antilymphocyte antibody OKT3 (n=3) was used in the first decade 
of the study. Since 1998, these induction therapies have been replaced by IL2 receptor 
antagonists (IL2-RA).
Prior to LTx, all patients with autoimmune cirrhosis were treated with prednison and aza-
thioprine.
Statistical analyses
Statistical analyses were performed using SPSS software package version 15.0 (SPSS, Chi-
cago, IL). The cumulative incidences of de novo malignancy and survival were assessed 
by the Kaplan-Meier method. For the analysis of malignancy, the starting point was the 
first LTx and the endpoint was the first malignancy. When reviewing the interval from LTx to 
specific cancer types, we firstly categorized cancer into three groups based on the highest 
incidence in our center, which were non-melanoma skin cancer, PTLD and other cancer. 
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Then the end points were defined as (I) non-melanoma skin cancer, (II) PTLD and (III) other 
cancer. In all analyses, patients were censored in case of death and lost to follow-up. Un-
derlying this approach was the assumption that patients were alive, therefore at risk, in the 
follow-up.
For survival analysis comparing patients who developed de novo cancer with those 
remained cancer-free, de novo cancer was considered as a time-dependent factor, since 
cancer developed at various follow-up times. This means that all patients entered at time 0 
as cancer-free. At the time of the development of de novo cancer the patient was censored 
in the cancer-free group and entered the de novo cancer group. In this way, the period 
that a patient lived as cancer-free was calculated as the “event-free survival period” in the 
Kaplan-Meier analysis. The same method was used to estimate the association of different 
types of cancer with the patient survival. Patients could have more than one malignancy, 
but only the first malignancy was included in the survival analysis. 
Univariate Cox regression and log-rank analyses were used to identify risk factors as-
sociated with de novo cancer development. To investigate whether these factors were 
independently associated with cancer development, all risk factors with P ≤ 0.05 were used 
as a covariate in a multivariate Cox regression model. P ≤ 0.05 was considered significant. 
The distribution of categorical variables was compared using the Chi-square test and differ-
ences between means were compared by Student’s t-test. 
In the analyses of the transplantation period as a risk factor for de novo cancer, malig-
nancy incidence curves were made of the different LTx time periods containing 4 years-
intervals. The recent LTx time period consisted of 3 years in order to provide more equal 
numbers in the groups, as a large number of LTx were performed in the latest years. The first 
LTx period starts at 1989, since all LTx performed in our centre before 1989 were auxiliary LTx. 
For analyses of the mean daily dose of CsA in mg/kg at different time intervals within the 
first 12 months post-LTx, cumulative daily doses were divided by the mean body weight and 
the number of days in the same time interval. Differences between means were compared 
by Student’s t-test. 
The standardized incidence ratio (SIR) of malignancy was calculated by comparing 
the observed number of cancers in the study cohort with expected number of cancers 
based on age and gender specific rates for the Netherlands. The Dutch incidence rates of 
cancer were obtained from the Comprehensive Cancer Centre in The Netherlands (30) for 
the calendar year 1997, which is the median of our study period. We assume that the SIR 
estimation will not differ considerably when we matched our population with calendar-year 
specific rates in The Netherlands, as the Dutch cancer rates have not changed significantly 
over time (30). Then, the incidence rates were stratified into 5-year age groups per 100,000 
person-years for both genders. The expected numbers of cases were calculated by the 
multiplication of the Dutch cancer incidence rate in both genders and age group by the 
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number of person-years in the corresponding period of observation. The standard error for 
hazard ratio was calculated for estimation of the 95% confidence interval (CI). 
RESUlTS
Incidence of de novo malignancy
Patient characteristics are summarized in Table 1. From the 385 liver graft recipients, who 
had at least 4 months of follow-up after the first LTx, 50 (13.0%) patients developed at least 
one de novo cancer. The cumulative incidence of de novo malignancy at 1, 5, 10 and 
15 years after LTx was 2.9 (±0.9)%, 10.5 (±1.8)%, 19.4 (±3.0)% and 33.6 (±6.8)%, respectively 
(Figure 1). 
In the Dutch population, the expected number of age- and gender- matched individuals 
with de novo malignancy in the same follow-up period as our cohort, was calculated to 
be 22.8. As our observed number of de novo cancer was 50, the standardized incidence 
ratio (SIR) of de novo malignancy in liver transplant patients in comparison with the general 
population was 2.20 (95% CI: 1.59 – 2.80).Figure 1 
196 345 1371No. at risk 
fIGURE 1 . Cumulative incidence of de novo malignancy during the first 15 years after LTx in liver graft 
recipients transplanted in the Rotterdam LTx cohort (n = 385). 
The grey lines represent the standardized error. Kaplan-Meier method was used under the assumption that 
patients were at risk during follow-up.
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Types of cancer
In total, 66 de novo malignancies appeared in 50 recipients. Table 2 shows the distribution 
of the types of cancer in our study. Most common cancer types were non-melanoma skin 
cancer (55%) and PTLD (21%). Skin cancer included basal cell carcinoma (41%, 27/66) and 
TABlE 1 . Patient characteristics
N %
Median age at LTx (range) 49 (16-69)
Median follow-up in years (range) 5.0 (0.3-19.1)
Gender
Male 220 57
Female 165 43
Primary LTx indication 
Viral cirrhosis 1 65 17
Cholestatic disease2 96 25
Autoimmune cirrhosis 14 4
Alcoholic cirrhosis 39 10
Acute liver failure 62 16
Cancer3 44 11
Other 65 17
Time periods of LTx 
1989-1992 25 6
1993-1996 67 17
1997-2000 94 24
2001-2004 101 26
2005-2007 98 25
Primary immunosuppressive drug4
Cyclosporin 167 52
Tacrolimus 202 43
Induction therapy
ATG/OKT3 19 5
IL-2 RA 230 60
EBV IgG prior to LTx
Positive 334 87
Negative 12 3
Unknown 39 10
LTx, liver transplantation; ATG, anti-thymocyte globulin; IL-2 RA, IL-2 receptor antagonist; EBV, Epstein-Barr 
virus; IgG, immunoglobulin G
1Viral cirrhosis: sum of hepatitis B cirrhosis (n =24), hepatitis BD cirrhosis (n =7) and hepatitis C cirrhosis (n 
=34). 
2Cholestastic disease: sum of primary biliary cirrhosis (PBC; n =25), primary sclerosing cholangitis (PSC; n 
=64) and secondary biliary cirrhosis (n =7)
3Cancer: sum of hepatic cellular carcinoma (n =43) and hepatic epithelioid hemangioendothelioma (n =1)
4Sixteen patients did not have either cyclosporine or tacrolimus
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squamous cell carcinoma (14%, 9/66). The cumulative incidences of non-melanoma skin 
cancer, PTLD and other cancer are depicted in Table 3.
Influence of cancer on survival
Patients who developed de novo malignancy after LTx had a significantly shorter survival 
than those who remained cancer-free, which was at 10 year post-cancer diagnosis 50.8 
(±8.6)% in the cancer group versus 79.0 (±2.9)% in the cancer-free group at 10 year post-LTx 
(P < 0.001).
With regards to the type of cancer, the survival was not impaired in patients who devel-
oped non-melanoma skin cancer and PTLD compared to patients who remained cancer-
free (P = 0.12 and P = 0.33, respectively)(Figure 2). However, a highly reduced survival was 
found in patients who developed the other cancer types summed in Table 2, including the 
more aggressive gastrointestinal, lung and gynaecological tumors (P <0.001). The 1-year 
survival in these patients after diagnosis of cancer was 28.6% (±1.2)%. None of the patients 
who developed non-melanoma skin cancer and PTLD died from their disease, whereas 9 
patients (64%, 9/14) who developed the remaining cancer types died due to cancer.
TABlE 2 . Type of de novo cancer in patients after liver transplantation
Type Number of tumors Total (%)
Non-melanoma skin 36 55
PTLD 14 21
Gastrointestinal 4 6
Lung 3 5
Melanoma 2 3
Gynaecological 2 3
Kaposi sarcoma 1 2
Kidney 1 2
Liver 1 2
Other 2 3
Total 66 100
PTLD, post-transplant lymphoproliferative disorder
TABlE 3. Cumulative incidence of de novo cancer types in patients after liver transplantation 
Time after lTx
Type of cancer 1 year 5 year 10 year 15 year
Non-melanoma skin 0.8% 5.1% 10.2% 19.7%
PTLD 1.3% 2.8% 6.4% 8.3%
Other cancer1 0.5% 2.6% 4.4% 10.1%
1Other cancer includes the remaining cancer types. PTLD, post-transplant lymphoproliferative disorder.
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Risk factors for malignancy after transplantation
Analyzing potential factors influencing the development of de novo cancer after LTx by 
univariate analyses, age > 50 year (P = 0.025), immunosuppressive treatment with CsA (P = 
0.035), and the time period of LTx (P = 0.049) emerged to be significant risk factors (Table 4). 
In order to see how the period of transplantation influenced the appearance of de novo 
cancer, malignancy incidence curves were made of the different LTx time periods contain-
ing 3 and 4 year-intervals (Figure 3). A high incidence was found in patients transplanted 
in the earliest LTx period (1989 till 1992). Comparing this period with the period 2001 till 2004, 
patients transplanted between 1989 and 1992 had a significantly higher risk for cancer (P = 
0.004). After this earliest LTx period, a considerable decline of the incidence of de novo can-
cer was observed after each period of transplantation. In contrast, in patients transplanted 
in the most recent period of 2005 till 2007 an increase of the incidence of de novo malig-
nancy was observed. Patients transplanted in this period had a significantly higher rate of de 
novo malignancy compared to those transplanted in the period of 2001 to 2004 during the 
first 4 years post-transplantation (P = 0.022). The rise in the de novo cancer incidence was 
particularly seen in the first year after LTx, which was 7.2 (±2.6)% in LTx period of 2005 till 2007 
versus 1 (±1.0)% in LTx period of 2001 till 2004. Identifying which cancer types were increased 
Cancer-free, n=385
Skin cancer, n=22
PTLD, n=14
Other cancer, n=14
*
**
***
fIGURE 2 . Estimated survival in patients who developed different types of cancer (after diagnosis of de 
novo cancer) and those who remained cancer-free (after LTx). All survival rates were compared with the 
survival rate of cancer-free recipients (*P = 0.122; **P = 0.330, ***P < 0.001).
ASSOCIATION BETwEEN CyClOSPORINE AND CANCER AfTER lTX 47
C
h
A
P
T
E
R
 2
in recent period, we found that the incidence of all cancer types, rather than a specific 
cancer type, increased (data not shown). 
In order to see which variables were independently associated with a higher cancer 
risk after LTx, a multivariate analysis was performed including factors that in the univariate 
analyses were associated with de novo cancer. In this Cox-regression analysis, CsA treat-
ment remained a significant risk factor (P = 0.029), while LTx period (P = 0.401) and age > 
50 years (P = 0.219) failed to show an independent association with the development of 
cancer. This data indicates that CsA treatment was the only independent risk factor for 
de novo cancer after LTx and that the effects of both LTx period and age on cancer risk 
were related to CsA treatment. Remarkably, when studying the types of cancer appearing 
in patients who were treated with CsA compared to TAC, we observed that CsA treated 
patients had a 2.5-times higher risk to develop more aggressive cancer types that do not 
belong to the non-melanoma skin cancer and PTLD summed in Table 2 (data not shown). 
This data indicate that CsA is not only associated with a higher early de novo cancer risk, but 
also with cancer types having a worse prognosis. 
**
*
1989-1992, n=25
1993-1996, n=67
1997-2000, n=94
2001-2004, n=101
2005-2007, n=98
fIGURE 3. Cumulative incidence of de novo cancer of LTx patients transplanted in different time periods.
A higher risk of de novo malignancy was observed in liver graft recipients transplanted in 1989-1992 and 
2005-2007 compared to 2001-2004 (*P = 0.004 and **P = 0.022 compared to 2001-2004).
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TABlE 4. Risk factors associated with de novo cancer development (univariate Cox regression model)
Risk factor hazard ratio (95% CI) P- value
Age 
<50 year 1 0.025
>50 year 1.92 (1.09-3.38)
Gender 
Male 1 0.431
female 0.79 (0.45-1.41)
Indication for LTx
Viral cirrhosis 1 0.753
Cholestatic disease 1.03 (0.45-2.35)
Autoimmune cirrhosis 0 (0-∞)
Alcoholic cirrhosis 0.99 (0.33-2.95)
Acute liver failure 0.71 (0.27-1.86)
Cancer 1.80 (0.63-5.11)
Other 0.74 (0.26-2.10)
Immunosuppressive regimen 
Dual 1 0.795
Triple 1.10 (0.62-1.89)
Primary immunosuppressive drug 
Tacrolimus 1 0.035
Cyclosporine 2.02 (1.05-3.87)
Induction immunosuppressive treatment
Non- IL-2 receptor antagonist 1 0.070
IL-2 receptor antagonist 0.55 (0.29-1.05)
Time period of LTx
1989-1992 0.83 (0.28-2.45)
1993-1996 0.51 (0.19-1.40)
1997-2000 0.37 (0.13-1.02)
2001-2004 0.22 (0.07-0.71)
2005-2007 1 0.049
EBV IgG prior to LTx
Positive 1 0.514
Negative 2.51 (0.89-7.07)
Unknown 1.12 (0.52-2.42)
LTx, liver transplantation; EBV, Epstein-Barr virus; IgG, immunoglobulin G
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Increased cancer rate in CsA treated patients was only observed in 
recent years
To investigate how the influence of the LTx period on the cancer risk was related to CsA 
treatment, we compared the incidence of de novo cancer in CsA treated patients with TAC 
treated patients in the different LTx periods. As depicted in Figure 4, in the LTx period before 
2005 we could not find a difference in the cancer rate between CsA and TAC treated pa-
tients. Strikingly, CsA treated patients transplanted from 2005 showed a significantly higher 
de novo cancer risk in the early phase after LTx compared to the TAC treated patients, 
which was 9.9-fold (95% CI 1.2 – 80.5, P = 0.032) higher compared to patients treated with 
TAC. These data indicate that only the specific CsA treatment used in recent years was 
associated with a higher risk for early development of de novo cancer. 
In patients transplanted from 2005, 7 CsA treated patients developed de novo cancer, of 
which 3 non-melanoma skin cancer, 3 PTLD and 1 epithelioid sarcoma. In the TAC treated 
group, only one bone marrow metastasis from unknown origin occurred.
To see whether the CsA group was comparable with the TAC group in the LTx period from 
2005, Chi-square tests were performed, showing that there were no differences in age (≤50 
CsA from 2005, n=42
TAC from 2005, n=51
CsA before 2005, n=125
TAC before 2005, n=151
*
**
fIGURE 4. Cumulative incidence of de novo malignancy in CsA and TAC treated liver graft recipients 
transplanted before and from 2005. 
Only CsA treatment in patients transplanted from 2005 showed a significantly higher early de novo cancer 
rate compared to TAC treatment. In this period, 7 de novo cancers occurred in the CsA treated group versus 
1 de novo cancer in the TAC treated group.  (*P = 0.009 compared to TAC from 2005, **P = 0.255 compared 
to TAC before 2005). 
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years of age: 41.5% in CsA group versus 58.5% in TAC group; P = 0.10), gender (male: 46.4% 
in CsA group versus 53.6% in TAC group; P = 0.18) and LTx indication (P = 0.35) between both 
treatment groups. Next, to determine whether CsA was more frequently used in a triple 
immunsuppressive regimen, a chi-square test was performed calculating the distribution 
of CsA and TAC in triple versus dual immunosuppressive regimens. We found that CsA and 
TAC were equally distributed in triple as well as in dual immunosuppressive regimens (data 
not shown). 
From January 2005, CsA dosing based on the conventional C0 level monitoring was re-
placed by dosing based on C2 levels monitoring in all de novo LTx patients. As the CsA blood 
level monitoring was the only major change in the CsA treatment in the recent LTx period, 
our data suggests that the C2 monitoring strategy was the reason for the increased early de 
novo cancer risk. In order to see whether CsA-C2 treated patients received a higher dose 
that could have caused the higher cancer risk, the mean daily CsA doses of CsA-C2 and 
CsA-C0 treated patients were compared. Analysis was performed at different time intervals 
within the first 12 months after LTx, as all malignancies in CsA-C2 treated patients occurred 
within the first year post-LTx. During the induction phase (first 14 days after LTx), CsA-C2 
treated patients received a significantly higher dose than CsA-C0 treated patients, which 
was in average 11.76 mg/kg/day in CsA-C2 treated patients versus 9.79 mg/kg/day in CsA-
C0 treated patients (P = 0.043). Thereafter, no differences in daily CsA dose were observed 
between patients treated with CsA-C2 and CsA-C0 up to 6 months post-LTx (5.26 mg/kg/
day in CsA-C2 versus 6.05 mg/kg/day in CsA-C0, P = 0.157). However, at 12 months post-LTx, 
patients treated with CsA-C2 received a significantly lower dose than patients treated with 
CsA-C0 (3.69 mg/kg/day in CsA-C2 versus 5.24 mg/kg/day in CsA-C0, P < 0.001).
Nevertheless, CsA doses given to patients may not adequately represent drug exposure 
due to inter- and intrapatient variability in CsA absorption. A better surrogate marker for 
drug exposure is the rejection rate, which is strongly correlated with CsA bioavailability (31-
34). Therefore, analyses were performed comparing acute rejection rates during the first 
year post-LTx between CsA and TAC treated patients transplanted before and after 2005. 
At 1 year post-LTx, CsA treated patients transplanted from 2005 showed a low incidence of 
acute rejection (9.6%), while this is significantly higher in CsA treated patients transplanted 
before 2005 (35.2%, P = 0.002), and TAC treated patients transplanted from 2005 (27.5%, P = 
0.030) and before 2005 (23.9%, P = 0.047). 
Increased cancer risk for CsA treatment was associated with younger 
recipient age
In order to see how recipient age was correlated with the difference in cancer rate between 
CsA and TAC treatment, we compared the incidence of de novo cancer between CsA and 
TAC treated patients in different age groups, of which 50 years was the best discriminating 
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cut-off value (data not shown). We found that CsA treated patients in both age groups 
(≤ 50 and >50 years) had a high de novo cancer risk (18.3% > 50 years versus 18.8% in ≤ 50 
years, P = 0.560), which was statistically not different in TAC treated patients who were older 
than 50 years (9.2%, P = 0.459). In contrast, TAC treatment in patients who were 50 years or 
younger resulted in a significantly lower cancer risk as compared to CsA treatment in the 
same age group (5.2% in TAC versus 18.8% in CsA, P = 0.027). These data indicate that only 
in the younger patients a higher cancer risk was found for CsA treatment compared to TAC 
treatment. 
Factors predisposing to the development of specific cancer types 
We questioned whether the risks of the individual cancer types were associated with the 
same risk factors or might be influenced by confounding factors, like EBV-seronegativity for 
development of PTLD. Patients who were EBV-seronegative prior to LTx had a 4.95-fold (95% 
CI: 1.06 – 23.15, P = 0.042) higher risk to develop PTLD. By performing Chi-square test and 
Kaplan-Meier analysis, we found that there were no differences in the EBV status pre-LTx (P 
= 0.337) nor in the incidence of PTLD (P = 0.823) among the older and younger CsA treated 
patients. This suggests that the higher cancer risk in the younger CsA treated patients was not 
due to a negative EBV status pre-LTx. In addition, the rise of PTLD incidence in CsA treated 
patients transplanted from 2005 could not be explained by the influence of EBV serology 
status prior to LTx, since the EBV serology did not differ between the CsA and the TAC treated 
patients transplanted in this recent LTx period (P = 0.362). The risk for non-melanoma skin 
cancer appeared to be 3.08-fold (95% CI: 1.31 – 7.24, P = 0.01) higher in patients who were 
older than 50 years. For the development of the other cancer types summed in Table 2, we 
found that the only independent risk factor appeared to be CsA treatment (HR 4.79, 95%CI 
1.01 – 22.66, P = 0.048). 
DISCUSSION
In the present study, we found that CsA in comparison to TAC treatment is the most im-
portant risk factor for de novo malignancy after LTx. This higher cancer risk was, however, 
not observed in all CsA treated patients, but CsA specifically enhanced development of 
de novo cancer in patients transplanted in more recent years (2005-2007), and in younger 
patients (≤50 years of age). In addition, we showed that CsA treatment particularly resulted 
in more aggressive types of cancer compared to TAC, with a 1-year survival rate less than 
30%. Interestingly, the incidence of de novo malignancies after LTx in our centre consider-
ably decreased over time after the first LTx period (1989-1992), but increased again in liver 
graft recipients transplanted in the most recent years (2005-2007).
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The high incidence of de novo cancer in patients transplanted in the earliest LTx period 
might be explained by the ATG induction treatment in 16 out of 25 LTx-patients, since ATG 
induction therapy has been described to be associated with post-transplantation cancer 
(17, 19, 35, 36). However, because the numbers of ATG treated patients were small, this 
association could not be confirmed in our cohort. Thereafter, since 2005, the trend of the 
decreasing de novo cancer incidence was noticeably turned into an increasing incidence, 
which was significantly related to CsA treatment. From January 2005, CsA dosing based on 
the conventional C0 level monitoring was replaced by dosing based on C2 levels monitoring 
in all de novo LTx patients. As the CsA blood level monitoring was the only major change in 
the CsA treatment in the recent LTx period, our data suggest that the C2 monitoring strategy 
was the reason for the increased early de novo cancer risk. 
We were not able to compare the incidence of de novo cancer risk in CsA-C0 and CsA-C2 
treated patients head to head, since these dosing strategies were used in different time 
periods in our center. Therefore, we compared CsA-C0 and CsA-C2 treated patients, respec-
tively, with TAC treated patients transplanted within the same time period, since TAC dosing 
strategy has not changed over time. This comparison corroborates that only in the period of 
C2-based CsA dosing, patients treated with CsA had a higher risk of cancer compared to 
TAC treated patients (Figure 4). 
Our finding that all malignancies in the CsA-C2 treated patients occurred within the first 
year after LTx suggests that CsA-C2 treated patients were exposed to a high dose during the 
early post-LTx phase. We found that CsA-C2 treated patients received a significantly higher 
dose, but only during the induction phase after LTx. However, a far better correlate of drug 
exposure is the incidence of acute rejection, as CsA dose is dependent on drug absorption. 
Interestingly, we found a lower incidence of acute rejection during the first year after LTx in 
CsA treated patients transplanted from 2005 with C2 based monitoring (9.6%), compared 
to CsA treated patients transplanted before 2005 with C0 based monitoring (35.2%). Fur-
thermore, to exclude a bias from the different LTx periods, the acute rejection rates were 
compared within the same LTx period (2005-2007) between CsA and TAC treated patients, 
showing that within this period the CsA group had a lower acute rejection incidence (9.6% in 
CsA versus 27.5% in TAC group). Corroborating our observations, several studies have shown 
that CsA-C2 monitoring is associated with a lower acute rejection rate compared to CsA-C0 
(25, 26, 37). Collectively, these observations indicate that dosing of CsA based on CsA-C2 
monitoring results in more robust immunosuppression compared to CsA-C0 based treatment, 
which consequently might impair immunosurveillance of developing malignancies. Regard-
ing to the types of cancer arising in the CsA treated patients transplanted in recent years, 
we found a relative rise in the non-melanoma skin cancer and PTLD. The higher PTLD risk is 
not a consequence of negative EBV serology prior to LTx, since EBV status was not different 
in the CsA compared to TAC treated patients transplanted in this recent LTx period 
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Compared to TAC, CsA treatment was only unfavourable in younger patients with regards 
to de novo cancer development after LTx. This higher cancer risk in the younger CsA treated 
patients was not attributable to EBV seronegativity prior to LTx, since no difference in EBV 
status was present in the different age groups. Moreover, the younger CsA treated patients 
did not develop more PTLD.
Till now, it has been stated that the basis for the higher cancer incidence after LTx is the 
long-term immunosuppressive state, and not the specific immunosuppressive protocol that 
is used (9). Our data showed that CsA treatment is a strong determinant for de novo cancer 
development after LTx. First, we found that CsA compared to TAC treatment resulted in 
a higher de novo cancer risk in younger patients, of which is known that they have a low 
cancer risk (8, 13, 16). Secondly, we found that the dosing strategy does influence cancer 
development, since the intense dosing in the CsA-C2 treatment protocol resulted in a more 
rapid development of de novo malignancy within the first year after LTx. Both observations 
suggest that not only the duration of immunosuppressive state, but also the immunosuppres-
sive treatment protocol influences the development of cancer. Additionally, we observed 
that CsA treatment resulted in more aggressive types of cancer.
There is evidence that CsA has pro-carcinogenic effects that are independent of its effect 
on the host’s immune response, including the inhibition of DNA repair, stimulation of tumor 
growth factor-β and/or vascular endothelial growth factor synthesis, diminishing clearance 
of altered cells and transforming cancer cells into aggressive cancer cells (15, 38, 39). While 
TAC has been reported to have similar pro-metastatic mechanism described for CsA (38, 
40), there is also evidence that TAC has anti-metastatic effects not seen with CsA (41). Our 
observation that CsA treatment resulted in more diverse and aggressive types of cancer 
supports the notion that CsA may promote a higher level of carcinogenesis than TAC. 
In contrast to other studies (5, 42) gender was not significantly associated with a higher 
cancer risk. Furthermore, we did not find pre-transplant use of immunosuppressive drugs 
to be correlated with a higher cancer risk, as all auto-immune cirrhotic patients received 
immunosuppressive drugs prior to LTx, which did not result in a higher de novo cancer risk.
(13) In agreement with other reports, we found that IL-2RA as an induction therapy did not 
result in a higher incidence of cancer (19, 42, 43).
Overall, we found a 2.2-fold higher risk for de novo cancer development in the entire 
cohort of liver graft recipients compared to the age- and gender- matched Dutch popula-
tion. Although this risk is high, it is within the lower part of the range of SIRs reported by other 
studies, which range from 2.1 to 4.3 (5, 6). The highest incidence of cancer was found for 
non-melanoma skin cancer and PTLD, which is consistent with other reports (5, 6, 9, 13, 14, 
19, 20, 42, 44-47). It was not surprising that we found a relation between EBV seronegativity 
prior to LTx and PTLD development, as PTLD is mainly related to EBV infection (48), and trans-
mission of EBV is frequent when the naïve transplant recipient receives an organ from an 
EBV-infected donor. Since a high frequency of the donor population (>85%) is EBV seroposi-
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tive, mismatching for EBV is common (49). However, as discussed previously, EBV-negativity 
before LTx did not explain the higher cancer risk induced by CsA treatment. Considering 
the survival, it was remarkable that we did not find a higher mortality rate for recipients who 
developed PTLD compared to cancer-free recipients, while various studies showed a low 
survival for PTLD patients (40.8% at 5 year) (44, 50, 51). Our observed high survival rate of PTLD 
patients may be explained by successful treatment of PTLD by reduction of immunosup-
pressive drugs, rituximab and systemic chemotherapy. Indeed, disease management with 
adequate immunosuppression reduction is associated with improved survival of patients 
with PTLD (14).
In summary, we have shown that CsA treatment in comparison to TAC treatment is the 
most significant risk factor for development of de novo cancer in LTx patients. However, this 
effect was confined to CsA-C2 treated patients and to patients of 50 years and younger. Fur-
thermore, CsA treatment gave rise to more aggressive behaviour cancer types compared 
to TAC treatment. So far, to our knowledge, our study is the first study suggesting that CsA 
treatment based on C2 monitoring in de novo LTx patients and CsA treatment in younger 
patients were associated with a significantly higher early de novo cancer risk compared to 
TAC. The limitations of our study include the retrospective study design, the limited numbers 
of patients and the lack of opportunity to compare C0 and C2 treatment within the same 
time period. So, larger randomized trials with long-term follow-up are needed to confirm 
this hypothesis. The ongoing international randomized trial comparing TAC with CsA-C2 in 
hepatitis C related liver transplant patients might provide support to our finding. This study 
highlights the importance of re-evaluation and optimization of currently used immunosup-
pressive regimens. 
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ABSTRACT
High-dose intravenous immunoglobulin (IVIg) is a prominent immunomodulatory therapy for 
various autoimmune and inflammatory diseases. Recent mice studies suggest that IVIg in-
hibits myeloid cell function by inducing a cascade of IL-33-Th2 cytokine production causing 
upregulation of the inhibitory FcγRIIb, as well as by modulating IFN-γ signaling. The purpose 
of our study was to explore whether and how these mechanisms are operational in IVIg-
treated patients. We show that IVIg in patients results in increases in plasma levels of IL-33, 
IL-4 and IL-13, and that increments in IL-33 levels correlate with rises in plasma IL-4 and IL-13 
levels. Strikingly, no upregulation of FcγRIIb expression was found, but instead a decreased 
expression of the activating FcγRIIa on circulating myeloid dendritic cells (mDCs) after high-
dose, but not after low-dose, IVIg treatment. In addition, expression of the signalling IFNγR2 
subunit of the IFN-γR on mDCs was downregulated upon high-dose IVIg therapy. In vitro ex-
periments suggest that the modulation of FcγRs and IFNγR2 on mDCs is mediated by IL-4 and 
IL-13, which functionally suppress the responsiveness of mDCs to immune complexes or IFN-γ. 
Human lymph nodes and macrophages were identified as potential sources of IL-33 during 
IVIg treatment. Interestingly, stimulation of IL-33 production in human macrophages by IVIg 
was not mediated by DC-SIGN. In conclusion, high-dose IVIg treatment inhibits inflammatory 
responsiveness of mDCs in humans by Th2 cytokine-mediated down-regulation of FcγRIIa 
and IFNγR2, and not by upregulation of FcγRIIb. Our results suggest that this cascade is 
initiated by stimulation of IL-33 production that seems DC-SIGN- independent. 
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INTRODUCTION
Intravenous immunoglobulin (IVIg) is used for the treatment of several autoimmune and 
systemic inflammatory diseases caused by autoantibodies and/or derailment of the cellular 
immune system (1-7). Importantly, the anti-inflammatory effects of IVIg require treatment 
with high doses, which exceed those used for replacement therapy in immune deficiencies 
(3, 8-10). Although the clinical benefit of IVIg is evident, the mechanisms by which IVIg can 
suppress different types of immune responses have not yet been fully elucidated. Effects 
of IVIg on antibody-mediated immune responses include prevention of immune complex 
binding to activating Fcγ receptors (FcγRs), and enhanced clearance of autoantibodies 
by saturation of the neonatal Fc receptor (4, 5, 8). The beneficial effects of IVIg on diseases 
caused by hyperactivity of cellular immunity are mediated by modulation of regulatory T 
cells (5, 11-14), macrophages (15, 16) and dendritic cells (12, 17, 18).
In several mouse models of antibody-induced inflammatory diseases, the anti-inflamma-
tory effects of IVIg are initiated by binding of 2,6-sialylated IgG molecules to SIGNR1 on 
splenic marginal zone macrophages, resulting in upregulation of the inhibitory FcγRIIb on 
macrophages at the site of inflammation, thereby preventing their activation by pathogen-
ic immune complexes (IC) (19). Recent research has uncovered the missing link between 
these two types of macrophages in a serum-induced arthritis model by showing that IVIg 
stimulates IL-33 production in the spleen, which induces production of the Th2 cytokines IL-4 
and IL-13 by basophils, which on their turn up-regulate expression of the inhibitory FcγRIIb on 
effector macrophages in the joints (20). However, the question whether and how this anti-
inflammatory mechanism of IVIg also plays a role in humans is actually far from trivial. Firstly, 
the structural organization of the human spleen differs from the murine spleen, especially 
with regard to the marginal zone. The marginal zone macrophage, the postulated source 
of IL-33 production upon binding of 2,6-sialylated IgG molecules to SIGNR1, is absent in the 
human spleen (21). Secondly, splenectomized ITP patients do still respond to IVIg therapy, 
arguing against an indispensable role for the spleen in mediating the protective effects 
of IVIg in humans (22). Thirdly, recent studies in ITP mouse models demonstrated that the 
inhibitory effects of 2,6-sialylated IgG molecules were not impaired upon splenectomy (23, 
24), and were even independent of IL-33 and IL-4 signaling (23). Collectively, these observa-
tions warrant a study to determine whether IVIg stimulates the IL-33-Th2-FcγRIIb pathway in 
humans.
Therefore, the first aim of the current study was to investigate the effects of IVIg therapy 
on IL-33 and Th2 cytokines as well as its effects on the expression of FcγRs on myeloid cells 
in humans in vivo. Since IVIg treatment has been shown to down-regulate expression of the 
signaling IFN-γ receptor 2 unit (IFNγR2) on murine macrophages, thereby rendering them 
refractory to activation by IFN-γ (16), we also studied the effects of IVIg-treatment on IFNγR 
expression on circulating myeloid cells. To discern whether the effects of IVIg depend on 
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treatment dose, we included patients treated with high or low dose of IVIg in our study. 
In the second part of the study, we investigated whether a causative relation may exist 
between IVIg, IL-33, Th2 cytokines, receptor expression on myeloid cells, and the functional 
responsiveness of these cells, using human cells in vitro.  
MATERIAl AND METhODS
Patients 
Twenty-nine patients (22 female/7 male) with either immunodeficiency or autoimmune 
disease and treated with IVIg were included in this study, and subdivided into two groups: 
those who received “low-dose” IVIg (LD) and those who received “high-dose” IVIg (HD). 
Since supplemental dose treatment started initially with 0.4-0.6 g/kg, we defined “low dose” 
IVIg as ≤0.6 g/kg, and “high dose” IVIg as >0.6 g/kg. The indications for IVIg treatment in 
these patients are depicted in Table 1A, B. Twenty-two patients were on IVIg monotherapy, 
and 6 patients received additional corticosteroid treatment. All patients showed clinical 
improvement after treatment. After approval by the local institutional ethical review board, 
written informed consent was obtained from all participants.
TABlE IA . Patient characteristics of low-dose IVIg-treated patients
IVIg treatment indication
Number of 
patients
Age in years, 
median (range)
IVIg dose in g/kg, 
median (range)
Common variable immunodeficiency 5 33 (20-57) 0.38 (0.30-0.48)
Hypogammaglobulinemia 7 60 (40-77) 0.39 (0.25-0.59)
Agammaglobulinemia 1 30 0.25
TABlE IB. Patient characteristics of high-dose IVIg-treated patients
IVIg treatment indication
Number of 
patients
Age in years, median 
(range)
IVIg dose in g/kg, 
median (range)
Refractory polymyositis* 3 41 (33-56) 1.00 (0.67-1.67)
Hypogammaglobulinemia 3 68 (40-69) 0.86 (0.66-0.86)
Common variable immunodeficiency 2 40 (37-43) 0.68 (0.65-0.70)
Immune trombocytopenic purpera 2 68 (65-71) 1.00
Acquired von Willebrand syndrome* 2 52 (40-63) 0.95 (0.93-0.98)
Polyserositis e.c.i.* 1 24 0.78
Polychondritis* 1 68 0.69
Refractory dermatomyositis* 1 46 1.71
Systemic vasculitis e.c.i.* 1 64 1.4
* IVIg treatment was indicated based on unresponsiveness to conventional treatment.
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Intravenous immunoglobulins
The IVIg preparations received by the patients were Nanogam (n= 13; Sanquin, Amsterdam, 
The Netherlands), Kiovig (n= 11; Baxter, Deerfield, IL), Flebogamma (n= 4, Grifols, Barcolona, 
Spain) and Octagam (n= 1; Octapharma, Lachen, Switzerland). 
For in vitro experiments, we used Intratect (Biotest Pharma, Dreieich, Germany), which 
was a kind gift from the company. IVIg was dialyzed against large volumes of RPMI at 4˚C 
using Slide-A-Lyzer gamma-irradiated dialysis cassettes (Pierce, Rockford, USA) to remove 
stabilizing agents and to obtain neutral pH. In all experiments IVIg was used at a concentra-
tion of 10 mg/ml, which is similar to the median increment in serum IgG concentration we 
observed in the IVIg-treated patients. To avoid artificial immune-complex mediated activa-
tion of mDCs due to adsorption of the IgG molecules to the culture plates, we pre-coated 
round-bottom 96-wells cell culture plates (Greiner Bio-One , The Netherlands) with fetal calf 
serum (FCS) to prevent IgG binding (25). After 24 hours, the plates were extensively washed 
with PBS, remaining liquid was removed and mDCs, splenocytes or lymph node cells were 
cultured as described below. To control for the elevated levels of protein upon addition of 
IVIg to cell cultures, we used equimolar amounts of human serum albumin (HSA, Sanquin) 
as described previously (6).
Sample collection and preparation
Heparin-decoagulated blood samples were collected from healthy blood donors and from 
patients immediately before IVIg infusion, immediately after IVIg infusion (LD: 4-6 hours and 
HD: 24-30 hours after the start of the infusion), and 7 days after infusion. Plasma and PBMCs 
were isolated from whole blood by density gradient sedimentation using Ficoll-Paque (GE 
healthcare, Uppsala, Sweden). Until further analysis, plasma samples were stored at -80 
degrees and PBMC samples at -135 degrees. To minimize possible inter-assay variation, 
measurements on PBMCs and plasma obtained at different time points from the same 
patient were performed on the same day. Since we did not have sufficient PBMCs from all 
patients, measurements of different receptor expression on mDCs were performed on 10 LD 
and 11 HD patient samples.
Human splenic tissue (n=6) and hepatic lymph nodes (n=6) were obtained during organ 
procurement from liver donors. Lymph nodes were dissected from the hepatoduodenal 
ligament. Spleen tissue and lymph nodes were sliced into small pieces and passed over 
a 100µm nylon mesh filter to obtain a single cell suspension. Mononuclear cells were then 
obtained by Ficoll-Paque density centrifugation.
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Antibodies and flow cytometry 
For identification of CD20-BDCA1+ mDC in blood of patients, PBMCs were stained with 
anti-CD20-Pacific Blue (eBioscience, San Diego, CA) and anti-BDCA1-PE (Miltenyi, Bergisch 
Gladbach, Germany), and for identification of monocytes with anti-CD14 PE-Cy7 (eBiosci-
ence). To detect expression of FcγRIIa and FcγRIIb on their surface, we used FITC-conjugated 
or Alexa Fluor 488-conjugated anti-CD32a/FcγRIIa mAb (clone IV.3, StemCell Technologies, 
Grenoble, France) and human-mouse chimeric anti-CD32b/FcγRIIb-FITC (clone ch2B6N297Q 
(26, 27) which was kindly provided by MacroGenics, Rockville, Maryland, USA). IFNγR chain 
2 was stained by using anti-IFNGR chain 2 mAb (clone MMHGR-2, PBL biomedical laborato-
ries, Piscataway, NJ) followed by FITC-conjugated rabbit anti-mouse IgG1 (DAKO, Glostrup, 
Denmark). To prevent non-specific binding, cells were incubated for 15 minutes with rabbit 
serum prior to FITC-conjugated rabbit anti-mouse IgG1 staining, followed by incubation with 
mouse serum prior to staining with mouse antibodies specific for leukocyte markers. The 
rather low expression of IFNγR2 on circulating immune cells was not due to insensitivity of the 
anti-IFNγR2 mAb (clone MMHGR-2) used, since another mAb (clone 2HUB-159, Biolegend, 
San Diego, CA) showed similar results, and is in agreement with previous studies (28). IFNγR 
chain 1 was stained by using anti-IFNGR chain 1 mAb (Biolegend). 
In order to assess the maturation status of mDCs in in vitro experiments, cells were stained 
with anti-HLA-DR-APC-Cy7, CD38-APC (BD Pharmingen), CD83-APC, CD86-Pacific blue 
(both from Biolegend), CD80-FITC (Beckman, Brea, CA), and CCR7-FITC (R&D systems).
For surface labeling, cells (1x106) were incubated with mAB in 50µl PBS (Lonza, Verviers, 
Belgium) + 1% bovine serum albumin + 0.02% sodium azide (both from Sigma, Brooklyn, NY) 
for 30 min on ice and protected from light. Then, cells were washed and resuspended in 
100µl PBS supplemented with 7-amino actinomycin D (7-AAD; BD Biosciences) for measure-
ment by flow cytometry (FACsCanto, BD Biosciences, San Jose, CA). A minimum of 3 x 105 
MNC were acquired. Analyses were performed by FACS Diva software (BD Biosciences, San 
Jose, CA). Viable MNC were gated based on forward/side scatter and exclusion of 7-AAD. 
For each sample we used matched isotype control mAB to set gates for analysis. 
ELISA
Plasma and/or culture media concentrations of IL-33, IL-5 (Biolegend, San Diego, CA, USA), 
IL-4, IL-13, IL-6 (Pelikine, Sanquin, Amsterdam, The Netherlands), IFN-γ (Abcam, Cambridge, 
UK), TNF-α, IL-10 (Quantikine HS, R&D systems, MN, USA) and IP-10 (Invitrogen, Toronto, On-
tario, Canada) were measured by ELISA according to the manufacturer’s instructions. IVIg 
present in plasma did not interfere with cytokine detection, since addition of IVIg (10 mg/ml) 
to samples with known cytokine levels did not alter the measured concentrations.  
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mDC isolation and macrophage generation
BDCA1+CD20-mDCs were purified from fresh heparinized blood of healthy volunteers by 
positive selection with PE-conjugated anti-CD1c mAb and anti-PE MACS-beads, after de-
pletion of B cells with CD19-conjugated MACS-beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) (18). The purity of mDCs as analyzed by flow cytometry was 92±8%. Macrophages 
were generated in vitro by culturing human monocytes, which were purified by positive 
selection using anti-CD14 MACS-beads (Miltenyi Biotec), with M-CSF (20ng/ml) for 6 days. 
Fresh medium and cytokines were replenished every 2 days. 
Effect of cytokines on receptor expression and function in vitro
To analyze the effects of IVIg, IL-33, IL-4 and IL-13, mDCs or macrophages (1x105/200µl) were 
cultured in 96-well round-bottom plates (Greiner Bio-One, The Netherlands) with IVIg (10mg/
ml), human rIL-33 (50ng/ml, Enzo Life Sciences, Farmingdale, NY), rIL-4 (10ng/ml, eBiosci-
ence, San Diego, CA) or rIL-13 (100ng/ml, Invivogen, San Diego, CA) in RPMI supplemented 
with penicillin, streptomycin and 10% fetal bovine serum for 24 hours. 
To assess the responsiveness of mDCs to IC, IgG was immobilized by overnight incubation 
of IVIg (1mg/ml) in 200µl PBS in wells of 96-well round bottom plates at 4°C for 24 hours 
(26), and mDCs either or not pre-treated with IL-4 or IL-13 were cultured in these plates for 
another 48 hours. To determine their responsiveness to IFN-γ, pre-treated mDCs were re-
cultured for 24 hours in the presence of rIFN-γ (250U/ml, Miltenyi Biotec). Maturation of DCs 
was stimulated by addition of 50ng/ml LPS (derived from S. Minnesota; Ultrapure, Invivogen, 
San Diego, California).
Effect of IVIg on cytokine gene expression in vitro
To identify the source of IL-33 or IL-4 production induced by IVIg, freshly isolated human 
splenocytes or lymph node cells (2x106/2ml), or M-CSF-induced monocyte-derived mac-
rophages (1x106/2ml) were cultured with or without IVIg (10mg/ml) in 6-wells plates in RPMI 
supplemented with penicillin, streptomycin and 10% fetal bovine serum. LPS was used at 
1µg/ml to stimulate the cells. Cells were harvested after 24 hours and relative IL-33 mRNA 
levels were determined by quantitative RT-PCR. RNA was isolated from the cells using a 
Machery-Nagel NucleoSpin RNA II kit (Bioké, Leiden, The Netherlands) and quantified using 
a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total RNA using an 
iScript cDNA Synthesis Kit from Bio-Rad (Bio-Rad Laboratories, Stanford, CA, USA). TaqMan 
gene expression assays were performed to measure the mRNA levels of IL-33 or IL-4 as the 
gene of interest, and GAPDH as the housekeeping gene using primer/probe sets from Ap-
plied Biosystems (Foster City, Calif., USA). As positive control for IL-33, we used RNA isolated 
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from tonsils obtained during routine tonsillectomies, which was a kind gift from Dr. T. Cupedo 
(Hematology Department, Erasmus MC, Rotterdam, The Netherlands). As positive control 
for IL-4, we used RNA isolated from CD3+ T cells stimulated with PMA and ionomycin. All 
reactions were performed in duplicate. Relative expression was calculated by the cycling 
threshol
Statistical analyses
Differences in measured variables in blood between time points before and after IVIg treat-
ment were pairwise analyzed using the Wilcoxon Signed Rank test. Differences in measured 
variables obtained from cell cultures were pairwise analyzed using the Student’s t-test, since 
the differences were normally distributed. Regression analyses were performed by using 
the Spearman correlation test. Statistical analyses were performed using GraphPad Prism 
5.0 (GraphPad Software, San Diego, CA). For all tests, P-values <0.05 were considered as 
significant.
RESUlTS 
Increased IL-33, IL-4 and IL-13 plasma concentrations after IVIg 
treatment in vivo
LD patients, defined as patients who were treated with IVIg dose ≤0.6 g/kg, received a 
median dose of 0.38 g/kg (range: 0.25-0.59) and HD patients, defined as patients who were 
treated with IVIg dose >0.6 g/kg, received a median dose of 0.90 g/kg (range: 0.65-1.71). 
Plasma IgG levels increased to significantly higher concentrations in HD patients compared 
to LD patients (data not shown).
Following IVIg treatment, plasma IL-33 significantly increased for at least 7 days in both LD 
patients (+215% immediately after, +169% at day 7) and HD patients (+152% immediately 
after, +70% at day 7) (Figure 1A). However, the rise of plasma IL-33 in LD patients did not ex-
ceed that of the baseline levels of HD patients, and post-treatment levels were significantly 
higher in the HD patients compared with those in LD patients. The higher baseline IL-33 level 
in HD patients (3-fold compared to LD patients) may be explained by the active inflamma-
tion in these patients. Likewise, plasma IL-4 concentrations significantly increased for at least 
7 days after IVIg infusion in both LD (+115% immediately after, +52% at day 7) and HD (+227% 
immediately after, +136% at day 7) patients (Figure 1B), and also reached significantly higher 
post-treatment concentrations in HD patients than in LD patients. IL-13 plasma levels were 
significantly elevated in HD patients after IVIg therapy (+574% immediately after, and +524% 
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fIGURE 1 . IVIg treatment enhances and sustains IL-33, IL-4 and IL-13 levels in plasma. 
In plasma samples collected from LD (n=13) and HD (n=16) patients before, after, and at day 7 after IVIg 
treatment, (A) IL-33 (B) IL-4 and (C) IL-13 were determined by ELISA. Spearman regression analyses were 
performed to investigate the correlations between the rise in IL-33 plasma levels and the rise in plasma levels 
of (D) IL-4 and (E) IL-13 immediately after IVIg treatment. Th1 cytokines (F) IL-6, (G) TNF-α, (H) IFN-γ and (I) 
the anti-inflammatory cytokine IL-10 in plasma samples, similar to those in (A-C). *P <0.05, **P < 0.01, ***P < 
0.001. Horizontal lines represent median.
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at day 7) but not in LD patients (Figure 1C). In contrast, we could not detect IL-5 in plasma in 
any of the patients (Human IL-5 ELISA, Biolegend; sensitivity 2 pg/ml). Among HD patients, 11 
were treated with IVIg for autoimmune disease and 5 for immunodeficiency, and elevations 
in IL-33 and Th2 cytokine levels were observed for both patient groups (data not shown).
The rise in plasma IL-4 and IL-13 significantly correlated with the rise in IL-33 levels (Figures 
1D-E), supporting the hypothesis that IL-33 stimulates Th2 cytokine production in humans in 
vivo. To elucidate whether IVIg therapy selectively enhances plasma IL-33 and Th2 cytokine 
concentrations, we measured plasma levels of Th1 cytokines and of the anti-inflammatory 
cytokine IL-10. IL-6 plasma level did not increase upon IVIg treatment, while transient in-
creases were observed for TNF-α in HD patients, IFN-γ in both LD and HD patients and IL-10 
levels in LD patients, but all these cytokines returned to baseline levels at day 7 after treat-
ment (Figures 1 F-I). Together, these data show that IVIg therapy upregulates IL-33, IL-4 and 
IL-13 plasma levels up to at least one week after IVIg infusion, while not or only transiently 
enhancing plasma levels of Th1 cytokines and IL-10. 
IVIg treatment reduces expression of activating FcγRIIa and IFNγR2 
on circulating mDCs in vivo
We hypothesized that the sustained increase in Th2 cytokine levels induced by IVIg treat-
ment might modulate the expression of FcγRIIb or FcγRIIa on myeloid cells, as has been 
previously shown in mice (20, 29) and for human monocytes in vitro (30, 31). Therefore, we 
measured the expression of the inhibitory FcγRIIb and activating FcγRIIa on circulating mDCs 
and monocytes, defined as CD20-BDCA1+ and CD14+ leukocytes, respectively. IVIg treat-
ment did not affect FcγRIIb or FcγRIIa expression on circulating monocytes (data not shown). 
However, clear effects were observed on the expression of these receptors on circulating 
mDCs in HD patients, but not in LD patients. FcγRIIb expression decreased directly after 
infusion, but expression was restored at day 7 (Figures 2A-B). In contrast, a stepwise decline 
of the activating FcγRIIa expression was observed, which became statistically significant 
(-30%) at day 7 after IVIg treatment (Figures 2A, C). These decreases were not attributable 
to interference of IVIg with anti-FcγRIIa or anti-FcγRIIb mAB binding (Supplemental Figures 
1A, B). 
Next, we studied IFNγR expression on mDCs and monocytes. A median of 97% (range: 84-
100) of mDCs expressed the ligand-binding IFNγR1 subunit at baseline, which did not change 
after IVIg treatment (data not shown). In contrast, expression of the signaling IFNγR2 subunit, 
which was restricted to 4.9% of total mDCs at baseline, stepwise declined after treatment 
in HD patients (-51% at day 7), but not in LD patients (Figures 2A, D). This decrease was not 
attributable to interference of IVIg with anti-IFNγR2 mAB binding (Supplemental Figure 1C). 
A trend towards reduction of IFNγR2 expression was also observed for monocytes on day 
7, but did not reach statistical significance (P=0.11) (data not shown). Similar modulation 
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fIGURE 2 . High-dose IVIg treatment modulates expression of Fcγ receptor IIb (FcγRIIb), Fcγ receptor IIa 
(FcγRIIa) and IFN-γ subunit 2 (IFNγR2) on circulating mDCs. mDCs were identified by first gating on 7AAD- 
cells, followed by BDCA1+CD20-  cells. 
(A) FcγRIIa and FcγRIIb (histograms) and IFNγR2 (density plots) expression on BDCA1+CD20- mDCs of a 
representative patient before, after, and at day 7 after IVIg treatment. Mean of Fluorescence Intensities (MFI) 
of (B) FcγRIIb and (C) FcγRIIa on circulating mDCs and (D) percentages of circulating mDCs expressing 
IFNγR2 in LD (n=10) and HD (n=11) patients. *P < 0.05, **P < 0.01. Horizontal lines represent medians.
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of FcγRIIb, FcγRIIa and IFNγR on mDCs was observed in HD patients that received IVIg for 
either autoimmune or immunodeficient conditions (Supplemental Figures 1D-F). Prednisone 
treatment did not influence the effect of IVIg on FcγRIIb, FcγRIIa and IFNγR expression on 
mDCs, since all 6 patients that were co-treated with prednisone (low-dose n=2, high-dose 
n=4) showed comparable patterns as were observed in patients without prednisone treat-
ment (data not shown). 
Together these data show that upon high-dose, but not upon low-dose IVIg treatment, 
FcγRIIa and IFNγR2 expression on circulating mDCs is sustainably suppressed, while FcγRIIb 
expression is only temporary reduced. 
IL-4 and IL-13 reduce FcγRIIb, FcγRIIa, and IFNγR2 expression on 
human mDCs in vitro
To assess whether the decreased expression of FcγRIIb, FcγRIIa and IFNγR2 on circulating 
mDCs upon IVIg therapy may have been caused by the observed increase in IL-33, IL-4 or IL-
13 levels, or by IVIg itself, we cultured mDCs purified from blood of healthy donors with IVIg, 
rIL-33, rIL-4 or rIL-13 in vitro for 24 hours. Interestingly, FcγRIIb, FcγRIIa and IFNγR2 expression 
was reduced on mDCs cultured with rIL-4 or rIL-13, while their expression was not affected by 
rIL-33 or by IVIg (Figures 3A-C, Supplemental Figures 2A-C). IL-4 and IL-13 showed redundant 
roles in the modulation of these receptors as their expression did not further decrease in the 
presence of both cytokines in comparison to either cytokine alone (Supplemental Figures 
3A). Next, we assessed whether IL-4 and IL-13 could support downregulation of these recep-
tors during LPS-induced mDC maturation. mDCs were cultured for 24 hours in the presence 
of IL-4 or IL-13, followed by LPS stimulation for an additional 24 hours. LPS down-regulated 
the expression of FcγRIIb, FcγRIIa and IFNγR2 expression on mDCs, and we found that IL-4, 
IL-13 and LPS additively downregulate FcγRIIb, FcγRIIa and IFNγR2 expression (Supplemental 
Figures 3B). Collectively, these data suggest that the enhanced levels of IL-4 and IL-13 after 
IVIg infusion in vivo are primarily responsible for the modulation of FcγIIb, FcγIIa and IFNγR2 
expression on circulating mDCs.
Since the beneficial effects of IVIg in mice have been attributed to Th2 cytokine-me-
diated upregulation of FcγRIIb expression on macrophages (20), we also cultured human 
monocyte-derived macrophages with rIL-4 or rIL-13 for 24 hours. However, Th2 cytokines did 
not significantly affect FcγRIIa or FcγRIIb expression on human macrophages (Supplemental 
Figures 4A, B).
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IL-4 and IL-13 reduce responsiveness of human mDCs to IC and IFN-γ 
in vitro
The balance between the expression of FcγRIIa and FcγRIIb establishes a threshold for mDC 
activation by IC (26). In order to determine the functional effects of the downregulation of 
both activatory FcγRIIa and inhibitory FcγRIIb by IL-4 or IL-13, we cultured purified mDCs with 
rIL-4 or rIL-13 for 24 hours, and subsequently re-cultured them in the presence of immobilized 
IgG for 48 hours. Both rIL-4 and rIL-13 pre-treatment suppressed IC-mediated maturation, as 
assessed by CD83 upregulation (Figure 4A) and repressed pro-inflammatory IL-8 (Figure 4B) 
and TNF-α (Figure 4C) production after IC challenge. To determine the role of FcγRIIa and 
FcγRIIb in this effect, we blocked FcγRIIa or FcγRIIb ligation. Blockade of FcγRIIa prevented 
activation of mDCs by IC. Interestingly, blocking of FcγRIIb during IC stimulation of IL-4- or IL-
13- pre-treated mDCs resulted in a greater rise in CD83 expression (Figure 4A) and cytokine 
production (Figures 4B, C) compared to FcγRIIb blockade of control mDCs, indicating that 
FcγRIIb is relatively dominant over FcγRIIa in regulating the response of IL-4- or IL-13-treated 
mDCs to IC. Thus, downregulation of FcγRIIa by IL-4 or IL-13 reduces the responsiveness of 
mDCs to IC, despite simultaneous suppression of inhibitory FcγRIIb expression. 
To establish the functional effect of IFNγR2 downregulation by IL-4 and IL-13, we cultured 
purified mDCs with rIL-4 or rIL-13 for 24 hours, followed by IFN-γ stimulation for an additional 24 Figure 3
BA
C
FcγRIIa
Ct
rl 
IL-
33 IL-
4
IL-
13
0
1000
2000
3000
4000
5000
6000
7000
*** ***M
FI
IFNγR2
Ct
rl 
IL-
33 IL-
4
IL-
13
0
5
10
15
20
*** **
%
FcγRIIb
Ct
rl 
IL-
33 IL-
4
IL-
13
0
1000
2000
3000
4000
5000
6000
7000
** *M
FI
fIGURE 3. IL-4 and IL-13 treatment reduces FcγRIIb, FcγRIIa and IFNγR2 expression on mDCs in vitro. 
Freshly-isolated BDCA1+CD20- mDCs (1x105/200µl) from blood of healthy volunteers were cultured in 
96-wells round bottom plates with human rIL-33 (50ng/ml), rIL-4 (10ng/ml) or rIL-13 (100ng/ml) for 24 
hours. The expression of (A) FcγRIIb, (B) FcγRIIa and (C) IFNγR2 on mDCs was measured by flow cytometry 
as indicated in Fig. 2A. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to CTRL. Bars represent mean±SEM of 
8 independent experiments.
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hours. In contrast to mDCs pre-incubated in medium, mDCs pre-treated with rIL-4 and rIL-13 
could not upregulate CD86 (Figure 5A), CCR7 (Figure 5B) and CD38 (Figure 5C) expression 
after IFN-γ stimulation. Moreover, the production of interferon-induced protein-10 (IP-10)/
CXCL10, an important mediator of chemotaxis, apoptosis, cell growth and angiostasis (32) 
was significantly reduced in mDCs in response to IFN-γ after treatment with rIL-4 or rIL-13 
(Figure 5D). Of note, IFN-γ stimulation did not affect the expression of FcγRIIa, FcγRIIb and 
IFNγR2 on mDCs, suggesting that the transient increase of IFN-γ in plasma directly after IVIg 
administration in our patient cohort was not the cause for the observed modulation of these 
receptors on circulating mDCs (data not shown). 
Collectively, our data indicate that IL-4 and IL-13 treatment suppresses IC- and IFN-γ-
mediated mDC maturation and cytokine/chemokine production by suppression of FcγRIIa 
and IFNγR2 expression, respectively. 
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fIGURE 4. IL-4- and IL-13-treated human mDCs are less responsive to immune complexes in vitro. 
Purified BDCA1+CD20- mDCs (1x105/200µl) from blood of healthy volunteers were cultured with medium 
or rIL-4 (10ng/ml) or rIL-13 (100ng/ml) for 24 hours, extensively washed and re-cultured in 96-wells 
round bottom plates in the presence of immobilized human IgG for another 48 hours. After culture (A) 
the expression of maturation marker CD83 on mDCs was determined by flow cytometry, and secretion of 
(B) IL-8 and (C) TNF-α in the supernatants was assessed by ELISA. Percentages depict upregulation of 
described marker when comparing conditions treated with anti-FcγRIIb + IC to IC alone. *P < 0.05, **P < 0.01 
as compared to CTRL + IC, ns = non-significant. Bars represent mean±SEM of 4 independent experiments.
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Human lymph node is a potential source for IL-33 production
We made a first attempt to identify the source of the enhanced IL-33 plasma levels upon 
IVIg infusion in humans. We hypothesized that IVIg may induce IL-33 production in second-
ary lymphoid tissues, since IL-33 is expressed in human secondary lymphoid tissues (33), and 
up-regulation of this cytokine has been shown in murine spleen upon IVIg treatment (20). 
Therefore, we cultured freshly isolated human splenocytes or lymph node cells in vitro with 
or without IVIg. Since IL-33 expression can be induced by TLR4 ligation (34-36), cells were 
cultured in the absence or presence of LPS. We detected no IL-33 mRNA in splenocytes, but 
in lymph node cells IL-33 mRNA was detectable and markedly increased after incubation 
with IVIg in the presence of LPS (Figure 6A). However, IL-33 protein could not be detected in 
supernatants from the cell cultures by ELISA (Biolegend, sensitivity 4 pg/ml), indicating no or 
very low IL-33 secretion by the cells in vitro. No IL-4 mRNA was found in splenocytes or lymph 
node cells upon IVIg treatment (data not shown). 
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fIGURE 5. IL-4- and IL-13-treated human mDCs are less responsive to IFN-γ stimulation in vitro. 
Purified BDCA1+CD20- mDCs (1x105/200µl) from blood of healthy volunteers were treated with medium or 
rIL-4 (10ng/ml) for 24 hours and re-cultured with or without human rIFN-γ (250U/ml) for another 24 hours. 
The expression of maturation markers (A) CD86, (B) CCR7 and (C) CD38 on mDCs was determined by flow 
cytometry, and secretion of (D) IP-10 in the supernatant was assessed by ELISA. *P < 0.05, **P < 0.01, ***P < 
0.001, as compared to CTRL + IFN-γ. Bars represent mean±SEM of 8 independent experiments.
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Stimulation of IL-33 production in human macrophages by IVIg is DC-
SIGN independent
We hypothesized that a potential source of IL-33 production in lymph nodes could be 
macrophages, as it was shown that macrophages in human placenta are IL-33 producers 
(37). Since isolation of macrophages from lymph nodes was practically unattainable, we 
differentiated human macrophages from monocytes in the presence of M-CSF in vitro, and 
assessed whether these cells produced IL-33 mRNA. Similar to the observations on human 
lymph node cells, we found that human macrophages produced high levels of IL-33 mRNA 
in the presence of LPS and IVIg, but hardly any production was observed with LPS or IVIg 
alone (Figure 6B). As these macrophages express DC-SIGN (data not shown), a previously-
identified IVIg-binding target (20), we wondered whether the IVIg-mediated IL-33 produc-
tion was dependent on DC-SIGN. Using an approved DC-SIGN blocking antibody (AZN-D1) 
(38), we surprisingly found that IL-33 mRNA levels in human macrophages in the presence of 
IVIg and LPS were not affected when DC-SIGN was blocked (Figure 6B). Collectively, these 
data identify human macrophages as a potential source of IVIg-induced IL-33 production 
that is independent of DC-SIGN.
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fIGURE. 6. IVIg treatment induces IL-33 mRNA in human lymph node cells and macrophages. 
(A) Mononuclear cells isolated from fresh human hepatic lymph node cells (2x106/2ml) were cultured with 
medium or IVIg (10mg/ml) with or without LPS (1μg/ml) for 24 hours. RNA was isolated from the cells and 
mRNA levels of IL-33 were assessed by quantitative RT-PCR. Relative expression was compared to GAPDH 
housekeeping gene. *P < 0.05 as compared to CTRL + LPS. Bars represent mean±SEM of 6 independent 
experiments. (B) M-CSF-induced monocyte-derived macrophages (1x106/2ml) were cultured with medium, 
IVIg (10mg/ml), or HSA (4.5mg/ml) for 1 hour, after which LPS (100ng/ml) was added for 24 hours. Blocking 
of DC-SIGN was performed by pre-incubating macrophages for 30’ at 4°C with 10µg/ml anti-DC-SIGN 
antibody (AZN-D1). An irrelevant mouse IgG1 antibody was used an isotype control. Assessment of IL-33 
mRNA levels was performed as in (A). *P < 0.05; Bars represent mean±SEM of 4 independent experiments.
79IVIG MODUlATES DC VIA Th2-fCγR/IfNγR AXIS
C
h
A
P
T
E
R
 3
DISCUSSION
Although high-dose IVIg is increasingly being used to treat various autoimmune and inflam-
matory diseases, its mode of action is not fully understood. Recent mice studies have shown 
an essential role for a pathway involving IVIg-induced IL-33-IL-4 production that ultimately 
leads to upregulation of FcγRIIb expression on effector macrophages (20). However, whether 
this pathway is operational in humans is unknown, and is also questionable due to several 
fundamental physiological differences between mice and men. In the current study, we 
demonstrate that IVIg treatment in human results in a robust and selective increase of 
plasma levels of IL-33 and the Th2 cytokines IL-4 and IL-13, that lasts for at least one week. 
Although a causative relationship between IL-33 and Th2 cytokine production in humans 
in vivo is difficult to establish, the observed associations between the rise of IL-33 and the 
increases in Th2 cytokines plasma levels support the hypothesis that IVIg can stimulate the 
IL-33-Th2 axis in humans, as has been previously observed in mice (20). 
In contrast to mouse studies showing a stimulatory effect of IVIg treatment on inhibitory 
FcγRIIb expression on myeloid cells (4, 19, 20), we observed a rapid but transient decrease 
of FcγRIIb expression on circulating mDCs upon high-dose IVIg treatment in humans. Several 
studies have shown that FcγRIIb expression on circulating monocytes was not affected by 
IVIg treatment in humans (39-41), which we were able to confirm. In one human study an 
increase of FcγRIIb expression was observed on monocytes and B cells after IVIg treatment. 
It has to be noted that in this study FcγRIIb expression levels prior to IVIg treatment were in 
most cases diminished in comparison to healthy individuals, suggesting that IVIg treatment 
may enhance expression levels of FcγRIIb only when they were initially decreased (42). 
However, high-dose IVIg therapy reduced expression of the activatory FcγRIIa and of 
IFNγR2 on mDCs till at least 1 week after treatment. The discrepancies between the effect 
of IVIg on FcγRII expression between humans and mice may be related to the presence of 
both FcγRIIa and FcγRIIb in humans while mice have only FcγRIIb (43, 44). Thus, due to major 
structural differences in FcγR expression between mice and humans, the mechanism of 
FcγR modulation found in mice may not be fully recapitulated in humans. Receptor down-
regulation was only observed in patients treated with high-dose IVIg, which corresponds 
with the insufficiency of low-dose IVIg therapy for effective anti-inflammatory treatment. The 
plasma IL-4 levels reached in LD patients did not exceed the baseline levels of HD patients, 
and may therefore have been insufficient to down-regulate receptor expression on mDCs. 
In vitro experiments revealed that both IL-4 and IL-13, but not IL-33 or IVIg itself, can 
reduce the expression of FcγRIIb, FcγRIIa, and IFNγR2 on human mDCs. To our knowledge, 
we are the first to show an effect of Th2 cytokines on FcγR and IFNγR expression on human 
mDCs. Direct suppression of IFNγR2 expression on macrophages as was observed in a previ-
ous study (16), was probably caused by adsorbance of IgG to the culture plastic (25) which 
was prevented in our experiment by pre-coating of the culture wells with FCS. Our results 
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reveal that IVIg represses IFNγR2 on mDCs indirectly via stimulation of Th2 cytokine produc-
tion. Down-regulation of IFNγR2 expression on mDCs prevented upregulation of CD86, CCR7 
and CD38 as well as production of IP-10 upon IFN-γ stimulation, implicating reduced T cell 
co-stimulation, chemotaxis and migration. 
Although in vitro expression of both inhibitory FcγRIIb and activatory FcγRIIa were 
downregulated, IC-stimulated maturation and pro-inflammatory cytokine production of 
mDCs were strongly suppressed upon IL-4 or IL-13 treatment. These results, together with 
the experiments in which we blocked FcγRIIb, suggest that inhibitory FcγRIIb signaling be-
comes dominant over activatory FcγRIIa signaling when expression of both FcγRII isoforms is 
reduced. It would have been highly interesting to study the functional effects of modulated 
receptor expression on mDCs isolated from IVIg-treated patients ex vivo. However, this was 
not feasible, since numbers of circulating mDCs were very low (median mDC%: 0.67% of 
PMBC in our patients) and not sufficient PBMC from the patients were available to isolate 
the amounts of mDC required for functional experiments. Since our study cohort is rather 
heterogeneous, clinical outcomes cannot be standardized for all patients and a correlation 
study associating outcomes with cytokine or receptor levels is not reliable. However, in all pa-
tients included in the high-dose group, clinical improvement was reported, while increases 
of IL-33, IL-4 and IL-13 (except for one patient) were consistently observed in these patients. 
Although we cannot perform direct correlation testing, contribution of the increased IL-33 
and Th2 cytokines to the clinical improvement of patients is not unlikely.
Previous studies have reported that human basophils stimulated with IL-33 are able to 
produce IL-4 and IL-13 in vitro (45-47), and we have found similar results (data not shown). 
Moreover, basophils in mice can also produce IL-4 and IL-13 when stimulated with IL-33 (20). 
T cells (48), mast cells (49) and macrophages (50) are a less likely sources, since IL-33 induces 
production of IL-5 and IL-13, but not IL-4, in these cell types. 
Although it has been shown in mice that IgGs having 2,6-sialylated Fc induce IL-33 production 
by marginal zone macrophages in the spleen, recent studies show that the anti-inflammatory 
effects mediated by these IgG molecules in mouse ITP models were independent of IL-33 
and the presence of the spleen (23). Furthermore, the spleen has been found dispensable 
for the anti-inflammatory effects of IVIg in humans, while a human counterpart of the murine 
marginal zone macrophage has not been identified (21, 22). Nevertheless, we found that IVIg 
infusion in humans enhanced IL-33 levels in plasma. In a first attempt to identify the source of 
IL-33 production, we found that IVIg induces IL-33 gene expression in human lymph node cells, 
but not in human splenocytes in vitro, although additional TLR4 ligation by LPS was needed. 
We hypothesized that macrophages in lymph nodes may potentially be able to produce 
IL-33 in response to IVIg since recent data on human placenta revealed that placental and 
decidual macrophages are able to produce IL-33 (37). Since it was not feasible to isolate 
sufficient numbers of macrophages from lymph nodes, we differentiated human monocytes 
towards macrophages in vitro, and found that these cells produced high levels of IL-33 
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mRNA upon culture with IVIg and LPS. Hence, we suggest that macrophages are potential 
sources of IVIg-induced IL-33 in humans, although fibroblasts (51) and epithelial cells (52, 53) 
may be other sources of IL-33 production. Surprisingly, IL-33 production in our macrophage 
experiments was not dependent on DC-SIGN. In concert with recent findings by others (54-56) 
these data ask for a re-evaluation of the role for DC-SIGN and 2,6-sialylated Fc in the anti-
inflammatory effects of IVIg in humans. Moreover, further research is required to establish the 
role for and source of IL-33 production upon IVIg treatment in humans. 
In the present study, we show that the recently identified IL-33-Th2 pathway by which IVIg 
inhibits myeloid cells functions in mice may also, with some variations, be operational in humans. 
Instead of upregulating FcγRIIb, as has been observed in mice, IVIg downregulates FcγRIIa and 
IFNγR2 on circulating mDCs in humans, and stimulates IL-33 production by human macrophages 
probably via a DC-SIGN-independent mechanism. The current study, together with our previous 
report showing that high-dose IVIg therapy activates Tregs in humans (14), provide evidence 
that important anti-inflammatory mechanisms of action of IVIg identified in animal models are 
operational in humans. These modes of action observed in patients may at least partially explain 
the beneficial effects of high-dose IVIg treatment in various autoimmune diseases
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Supplementary figure 1. 
Freshly-isolated BDCA1+CD20- mDCs (1x105) from blood of healthy volunteers were incubated without 
or with 10mg/ml IVIg for 30’ at 4°C. The expression of (A) FcγRIIa, (B) FcγRIIb and (C) IFNγR2 on mDCs 
was measured by flow cytometry as indicated in Fig. 2A. Bars represent mean±SEM of 3 independent 
experiments. mDCs from HD IVIg-treated autoimmune disease (n=11) and immune deficiency (n=5) patients 
were analyzed for surface expression of (D) FcγRIIa, (E) FcγRIIb and (F) IFNγR2 by flow cytometry as in (A-
C). Horizontal lines represent medians. ns = not significant
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Supplementary figure 2. 
Freshly-isolated BDCA1+CD20- mDCs (1x105/200µl) from blood of healthy volunteers were cultured in FCS-
precoated 96-wells round-bottom plates with human serum albumin (HSA) as negative control, IVIg or IVIg 
with human rIL-4 (10ng/ml) or rIL-13 (100ng/ml) for 24 hours. The expression of (A) FcγRIIb, (B) FcγRIIa and 
(C) IFNγR2 on mDCs was measured by flow cytometry as indicated in Fig. 2A. *P < 0.05 as compared to 
HSA. Bars represent mean±SEM of 8 independent experiments.
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Supplementary figure 3. 
The expression of FcγRIIb, FcγRIIa and IFNγR2 on freshly-isolated BDCA1+CD20- mDCs from blood of healthy 
volunteers mDCs were measured by flow cytometry after indicated incubation time.
(A) mDCs (1x105/200µl) were cultured in 96-wells round bottom plates with human rIL-4 (10ng/ml) and rIL-13 
(100ng/ml), either cytokine alone or added both, for 24 hours. Bars represent mean±SEM of 6 independent 
experiments.
(B) mDCs (1x105/200µl) were cultured in 96-wells round-bottom plates with human rIL-4 (10ng/ml) or rIL-13 
(100ng/ml). After 24 hours, cells were cultured for another 24 hours with or without LPS (1µg/ml). Bars 
represent mean±SEM of 5 independent experiments.  *P < 0.05, **P < 0.01, ***P < 0.001.
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Supplementary figure 4. 
Monocyte-derived macrophages (MΦ) were cultured in 96-wells round-bottom plates (1x105/200µl) with 
medium, human rIL-4 (10ng/ml) or rIL-13 (100ng/ml) for 24 hours. The expression of (A) FcγRIIa and (B) 
FcγRIIb on MΦ was measured by flow cytometry. Bars represent mean±SEM of 6 independent experiments.
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ABSTRACT
Intravenous immunoglobulin (IVIg) is used to treat autoimmune and systemic inflammatory 
diseases caused by derailment of humoral and cellular immunity. Here we investigated 
whether IVIg treatment can modulate regulatory T cells (Tregs) in humans in vivo. Blood was 
collected from IVIg-treated patients with immunodeficiency or autoimmune disease who 
were treated with low-dose (n=12) or high-dose (n=15) IVIg before, immediately after, and at 
7 days after treatment. Percentages and activation status of circulating CD4+CD25+FOXP3+ 
Tregs and of conventional CD4+FOXP3- T-helper cells (Tconv) were measured. The sup-
pressive capacity of Tregs purified from blood collected at the indicated time points was 
determined in an ex vivo assay. High-dose, but not low-dose, IVIg treatment enhanced the 
activation status of circulating Tregs, as shown by increased FOXP3 and HLA-DR expression, 
while numbers of circulating Tregs remained unchanged. The enhanced activation was 
sustained for at least 7 days after infusion, and the suppressive capacity of purified Tregs 
was increased from 41% to 70% at day 7 after IVIg treatment. The activation status of Tconv 
was not affected by IVIg. We conclude that high-dose IVIg treatment selectively activates 
Tregs and enhances their suppressive function in humans in vivo. This effect may be one of 
the mechanisms by which IVIg restores imbalanced immune homeostasis in patients with 
autoimmune and systemic inflammatory disorders.
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INTRODUCTION
Intravenous immunoglobulin (IVIg) was initially introduced as a replacement therapy for 
patients with immune deficiencies, but high-dose IVIg is now widely used for the treatment 
of autoimmune and systemic inflammatory diseases caused by auto-antibodies and/or de-
railment of the cellular immune system (1, 2). Moreover, IVIg has shown efficacy in preven-
tion and treatment of organ allograft rejection and Graft-versus-Host Disease (GvHD) (3-6). 
Several possible mechanisms of action that explain the beneficial effects of high-dose IVIg 
in autoantibody- and immune complex-mediated diseases have been unraveled during 
the last decades. These mechanisms include inhibition of the binding of immune complexes 
or cell-bound IgG to activating Fcγ receptors, saturation of the neonatal FcR resulting in an 
enhanced clearance of auto-antibodies, and up-regulation of the inhibitory FcγRIIb (1, 2, 7). 
However, the mechanisms by which high-dose IVIg is effective in diseases which are mainly 
caused by cell-mediated immune responses, such as Kawasaki disease, dermatomyositis, 
GvHD, and acute transplant rejection, have not yet been fully elucidated. Recent in vitro 
and mice studies suggest that one of the mechanisms by which IVIg suppresses cellular 
immunity is by activating CD4+CD25+FOXP3+ regulatory T cells (Tregs) (8, 9).
Tregs are critical regulators of cell-mediated immune responses and suppress pathogenic 
immune responses in autoimmune diseases, transplantation, and GvHD (10). Current immu-
nosuppressive drugs used to treat or to prevent these diseases exert generalized inhibition 
of the immune system, thereby disabling protective immunity against pathogens and ma-
lignancies. Therapeutic modalities that stimulate Treg-mediated immune regulation without 
affecting global immune functions are attractive. Recently, we found that IVIg can activate 
both human and mouse CD4+CD25+FOXP3+ Tregs in vitro and increase their ability to sup-
press allogeneic T cell proliferation (11). By triggering functional activation of Tregs, IVIg 
prevented graft rejection in a fully mismatched skin transplant model. In line with our data, 
it has been shown that IVIg can prevent mice from developing experimental autoimmune 
encephalomyelitis (12) and herpes simplex virus-induced encephalitis (13) by enhancing 
the suppressive capacity and stimulating the expansion of Tregs. In addition, IVIg was found 
to enhance the suppressive capacity of human Tregs in vitro (14).
These data suggest that IVIg treatment can stimulate Treg expansion and function, and 
may therefore be an attractive tool to re-establish Treg-mediated immune regulation. How-
ever, the data on the effects of IVIg on Tregs are restricted to in vitro and mice experiments 
and it is unknown whether IVIg treatment actually affects Treg expansion and function in 
patients. Therefore, in the present study, we systematically analyzed the effects of either low- 
or high-dose IVIg treatment on the percentages, activation status and suppressive capacity 
of circulating Tregs in autoimmune and immunodeficient patients. We observed increased 
activation of Tregs after high-dose IVIg treatment, which was not observed for conventional 
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T cells (Tconv). Additionally, Tregs isolated after high-dose IVIg treatment showed enhanced 
suppressive capacity ex vivo.
MATERIAl AND METhODS
Patients
Twenty seven patients (21 female/6 male) who were treated with IVIg were included in 
this study. To assess whether IVIg had a dose-dependent effect on Treg activation, we 
subdivided the patients into two groups: those who received “low-dose” IVIg and those 
who received “high-dose” IVIg. Since patients with immunodeficiency started initially with a 
supplementary dose of 0.4-0.6 g/kg, we defined “low-dose” IVIg as a dose ≤0.6 g/kg, and 
“high-dose” IVIg as a dose >0.6 g/kg. The median dose of IVIg received by low-dose pa-
tients was 0.39 g/kg (range: 0.25-0.59) and that of high-dose patients was 0.98 g/kg (range: 
0.65-1.71). High-dose IVIg-treated patients showed a significantly higher rise in plasma IgG 
levels (+17.3 mg/ml) compared to low-dose IVIg-treated patients (+8.2 mg/ml) immediately 
after treatment (p<0.001), as quantified by immunoturbometric analysis (Roche Diagnostics 
GmbH, Mannheim, Germany). At day 7, plasma IgG levels dropped again in both groups 
(data not shown). The indications for IVIg treatment in these patients are depicted in Table 
1A-B. In the high-dose treatment group (Table 1B), five patients received IVIg for licensed in-
dications, including common variable immunodeficiency (n=2), hypogammablobulinemia 
(n=1) and idiopathic thrombocytopenic purpura (n=2). One patient with Good’s syndrome 
received high-dose IVIg as supplementary therapy for hypogammaglobulinemia. Other 
patients included in Table 1B received high-dose IVIg as anti-inflammatory therapy “off-
label”, since they did not respond to conventional immunosuppressive treatment. The IVIg 
preparations used for treatment were Nanogam (n= 13; Sanquin, Amsterdam, The Nether-
lands), Kiovig (n= 9; Baxter, Deerfield, IL), Flebogamma (n= 4, Grifols, Barcolona, Spain) and 
Octagam (n= 1; Octapharma, Lachen, Switzerland). With the exception of 3 patients, all 
patients had previously been treated with IVIg, with an average 28 days (range: 21-35 days) 
before this study. Twenty-one patients were on IVIg monotherapy and six patients received 
additional corticosteroid treatment. 
Ethics statement
The medical ethics committee of the Erasmus University Medical Centre approved the study, 
and written informed consent was obtained from all patients participating in the study.
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Sample collection and preparation
Heparin-decoagulated blood samples were collected from healthy blood bank donors, 
and from patients immediately before IVIg infusion, immediately after IVIg infusion (4 to 24 
hours after the start of the infusion) and 7 days after infusion. Due to practical issues we were 
unable to obtain blood samples from 1 patient immediately after IVIg treatment and from 
2 patients 7 days after treatment. Plasma and peripheral blood mononuclear cells (PBMCs) 
were isolated from whole blood by density gradient sedimentation using Ficoll-Paque (GE 
healthcare, Uppsala, Sweden). Plasma was collected from the gradient and centrifuged at 
3000 rpm for 10 min at 4°C to remove thrombocytes and debris. For storage of PBMC, the 
cells were cryopreserved in RPMI 1640 (Gibco BRL Life technologies, Breda, The Netherlands) 
supplemented with 20% heat-inactivated fetal bovine serum (Hyclone, Logan, UT, USA) and 
10% dimethylsulfoxide (DMSO; Sigma-Aldrich, St. Louis, MA). Until further analysis, the PBMC 
samples were stored at -135 degrees and plasma at -80 degrees. To minimize possible ef-
fects of inter-assay variation, measurements in plasma and on PBMC obtained at different 
time points from the same patient were performed on the same day. 
TABlE 1A. Patient characteristics in low-dose IVIg-treated patients
IVIg treatment indication
Number of 
patients
Age in years, 
median (range)
IVIg dose in g/kg, 
median (range)
Common variable immunodeficiency 5 41 (20-57) 0.38 (0.30-0.48)
Hypogammaglobulinemia 6 60 (45-77) 0.39 (0.25-0.59)
Agammaglobulinemia 1 30 0.25
TABlE 1B. Patient characteristics in high-dose IVIg-treated patients
IVIg treatment indication
Number of 
patients
Age in years, 
median (range)
IVIg dose in g/kg, 
median (range)
Polymyositis* 3 41 (33-56) 1.00 (0.67-1.67)
Common variable immunodeficiency 2 40 (37-43) 0.68 (0.65-0.70)
Immune trombocytopenic purpera 2 68 (65-71) 1.00
Acquired von Willebrand syndrome* 2 52 (40-63) 0.95 (0.93-0.98)
Hypogammaglobulinemia 1 40 0.66
Good’s syndrome/ Hypogammaglobulinemia 1 69 0.86
Polyserositis e.c.i. 1 24 0.78
Polychondritis* 1 68 0.69
Dermatomyositis* 1 46 1.71
Systemic vasculitis e.c.i.* 1 64 1.4
* IVIg treatment was indicated based on unresponsiveness to conventional treatment
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Antibodies and flow cytometry 
For identificiation of T cell subsets, PBMCs were stained with anti-CD3-AmCyan, anti-CD4-
APC-H7 and CD8-Pacific blue (all from BD Biosciences, San Jose, CA). Percentages and 
activation status of Tregs were determined by surface labeling with anti-CD4-APC-H7, anti-
CD25-PE-Cy7 (both from BD Biosciences), anti-CD127-PE (Beckman Coulter, Immunotech, 
Marseille, France), anti-CD38-Pacific Blue (ExBio antibodies, Czech Republic), anti-HLA-DR-
PerCP (eBioscience, San Diego, CA) mAb and proper isotype controls. For the detection 
of memory (CD45RO+) Tregs, we additionally labelled the cell surface using CD45RO-FITC 
mAb (Beckman Coulter). Cells (1x106) were incubated with the mAb in 50µl PBS (Lonza, 
Verviers, Belgium) for 30 min on ice and protected from light. Subsequently, intracellular 
FOXP3 staining was performed using anti-FOXP3-APC mAb (or rat IgG2a isotype control 
mAb) purchased from eBioscience according to manufacturer’s instructions. To study 
proliferation, intracellular labeling with anti-Ki-67-FITC (or mIgG1 isotype control mAb) from 
BD Biosciences was performed. After staining, the cells were washed and resuspended in 
100ml PBS for measurement by flow cytometry (FACS Canto, BD Biosciences, San Jose, CA). 
A minimum of 1.5x105 MNC were acquired. Analyses were performed by FACS Diva software 
(BD Bioscience). Viable MNC were gated based on forward/side scatter. For the calculation 
of percentages of cells expressing a certain marker, or for calculation of the geometric 
mean of fluorescence intensities (MFI), fluorescence of isotype-matched control mAb was 
subtracted from fluorescence of specific mAb.
Suppression assay
To determine the effect of IVIg treatment on the suppressive capacity of Tregs ex vivo, we 
collected additional blood from 7 patients in the study who received high-dose IVIg. To pu-
rify Tregs and T responder cells (Tresp), we first purified non-touched CD3+ cells from thawed 
PBMCs from each time point by performing immunomagnetic depletion of non-T cells using 
PE-conjugated antibodies against BDCA1 (Miltenyi Biotec, Bergisch Gladbach, Germany), 
CD14, CD56 (both from BD Bioscience) CD19, CD56, CD123 (all from Beckman Coulter Coul-
ter) as well as CD15- and CD235-microbeads (both from Miltenyi Biotec). The purified CD3+ 
cells were then stained with anti-CD3-AmCyan, anti-CD4-APC-H7, anti-CD25-APC, 7-AAD 
(all from BD Bioscience) and anti-CD127-PE mAb (Beckman Coulter Coulter). Subsequently, 
Tregs were obtained by flow cytometric sorting 7-AAD-CD3+CD4+CD127-CD25+ cells using 
FACS Aria (BD Biosciences). Purity of Tregs (defined as CD4+CD25+CD127-), as determined 
by flow cytometry, was 98±1%. Tresp were obtained by sorting both 7-AAD-CD3+CD4- and 
7-AAD-CD3+CD4+CD127+CD25- cells, which resulted in a purity of 99±0.4% (defined as 
CD3+CD127+CD25- cells), as determined by flow cytometry. Cells were recovered after cell 
sorting by incubation in culture medium (RPMI 1640 supplemented with penicillin (100U/ml), 
streptomycin (100mg/ml) and 10% fetal bovine serum (Hyclone, Logan, UT, USA)) at 37°C for 
at least 3hrs prior to co-culture. 
To compare their suppressive capacity, Tregs purified from the patient blood collected 
before IVIg treatment, immediately after treatment, and at day 7 after treatment, were 
co-cultured with Tresp (5x104) obtained before treatment that were stimulated with 1mg/ml 
phytohemagglutinin (PHA) in the presence of 40Gy irradiated autologous PBMC (5x104) at 
Treg:Tresp ratio’s of 1:4 in culture medium in round-bottom 96-well plates (Greiner Bio-One, 
The Netherlands). After 5 days, supernatants were collected and the cumulative IFN-γ secre-
tion by Tresp was quantified by ELISA (Ready-SET-Goâ, eBioscience) according to manufac-
turer’s instructions. Each condition was tested at least in triplicate from which means were 
calculated. These means were used to calculate the percentage of suppression using the 
formula: ((IFN-γ levelTresp-IFN-γ levelTresp+Treg)/IFN-γ levelTresp) x 100%.
Statistical analyses
Differences in measured variables between time points before and after IVIg treatment 
were pair-wise analyzed by using the Wilcoxon signed rank test. For analysis of the Treg 
suppression assay, we used the paired Student’s T-test as the differences in IFN-γ production 
by Tresp collected at different time points before and after IVIg treatment were normally 
distributed. Two-sided P-values <0.05 were considered as significant. Statistical analysis was 
performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). In accordance 
to the statistical test that is used, all data presented in dot plots show median values, but 
data on the suppressive capacity of Treg (Figure 2B) are depicted as means ± SEM.
RESUlTS 
IVIg selectively enhances the activation status of Tregs in vivo
IVIg treatment had no effect on the numbers of circulating CD4+ and CD8+ T cells (Figure 1A). 
To study the effects of IVIg treatment on Tregs, we measured the percentages and immu-
nophenotype of circulating Tregs. The gating strategy used to determine CD4+CD25+FOXP3+ 
cells is shown in Figure 1B. At baseline, we observed comparable percentages of circulating 
Tregs in patients who were treated with low-dose IVIg (n=12) or high-dose IVIg (n=15), and 
in healthy controls (n=10) (Figure 1C). In addition, baseline activation status of the Tregs in 
the low-dose and high-dose patients were comparable to healthy controls, as assessed by 
expression levels of FOXP3 (Figure 1D) and HLA-DR (Figure 1E). 
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streptomycin (100mg/ml) and 10% fetal bovine serum (Hyclone, Logan, UT, USA)) at 37°C for 
at least 3hrs prior to co-culture. 
To compare their suppressive capacity, Tregs purified from the patient blood collected 
before IVIg treatment, immediately after treatment, and at day 7 after treatment, were 
co-cultured with Tresp (5x104) obtained before treatment that were stimulated with 1mg/ml 
phytohemagglutinin (PHA) in the presence of 40Gy irradiated autologous PBMC (5x104) at 
Treg:Tresp ratio’s of 1:4 in culture medium in round-bottom 96-well plates (Greiner Bio-One, 
The Netherlands). After 5 days, supernatants were collected and the cumulative IFN-γ secre-
tion by Tresp was quantified by ELISA (Ready-SET-Goâ, eBioscience) according to manufac-
turer’s instructions. Each condition was tested at least in triplicate from which means were 
calculated. These means were used to calculate the percentage of suppression using the 
formula: ((IFN-γ levelTresp-IFN-γ levelTresp+Treg)/IFN-γ levelTresp) x 100%.
Statistical analyses
Differences in measured variables between time points before and after IVIg treatment 
were pair-wise analyzed by using the Wilcoxon signed rank test. For analysis of the Treg 
suppression assay, we used the paired Student’s T-test as the differences in IFN-γ production 
by Tresp collected at different time points before and after IVIg treatment were normally 
distributed. Two-sided P-values <0.05 were considered as significant. Statistical analysis was 
performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). In accordance 
to the statistical test that is used, all data presented in dot plots show median values, but 
data on the suppressive capacity of Treg (Figure 2B) are depicted as means ± SEM.
RESUlTS 
IVIg selectively enhances the activation status of Tregs in vivo
IVIg treatment had no effect on the numbers of circulating CD4+ and CD8+ T cells (Figure 1A). 
To study the effects of IVIg treatment on Tregs, we measured the percentages and immu-
nophenotype of circulating Tregs. The gating strategy used to determine CD4+CD25+FOXP3+ 
cells is shown in Figure 1B. At baseline, we observed comparable percentages of circulating 
Tregs in patients who were treated with low-dose IVIg (n=12) or high-dose IVIg (n=15), and 
in healthy controls (n=10) (Figure 1C). In addition, baseline activation status of the Tregs in 
the low-dose and high-dose patients were comparable to healthy controls, as assessed by 
expression levels of FOXP3 (Figure 1D) and HLA-DR (Figure 1E). 
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IVIg treatment had no effect on the percentages of circulating Tregs in both low- and 
high-dose IVIg-treated patients (Figure 1F). Although low-dose patients showed a slight 
increase of Treg percentages, this increase was not significant. Additionally, Ki-67 staining in 
Tregs showed no increased proliferation of Tregs after IVIg treatment in both groups (data 
not shown). However, in patients treated with high-dose IVIg, we did observe an increased 
expression level of FOXP3 in CD4+CD25+FOXP3+ Tregs immediately after IVIg treatment, with 
an average increase of 29% (Figure 1B and G, P=0.04). This increased FOXP3 expression level 
was sustained on day 7 after infusion (+35%, P=0.02). 
Next, we analyzed the expression of the activation marker HLA-DR on CD4+CD25+FOXP3+ 
Treg, gated as shown in Figure 1B. We found that the proportions of HLA-DR expressing Treg 
gradually increased after IVIg treatment, again only in high-dose treated patients, and was 
37% higher immediately after and 39% at day 7 after treatment (Figure 1B and H). Prednisone 
treatment did not influence the expression of FOXP3 and HLA-DR, since all 6 patients that 
were co-treated with prednisone (low-dose n=3, high-dose n=3) showed the same patterns 
as patients without prednisone treatment (data not shown). In addition, the same trends 
of Treg activation were found in patients with autoimmune disease and immunodeficient 
patients who were treated with high-dose IVIg (Supplementary Figure 1).
To determine whether IVIg also affects the activation status of Tconv, we measured 
HLA-DR expression on CD4+FOXP3- Tconv (Figure 1B and I). Compellingly, HLA-DR expres-
sion remained low on Tconv after IVIg treatment, even in high-dose IVIg-treated patients, 
which may suggest that IVIg treatment selectively activates CD4+CD25+FOXP3+ Tregs, but 
not CD4+FOXP3- Tconv in humans in vivo. 
To study the effect of IVIg on the differentiation stage of Tregs, we measured CD45RO 
expression on Tregs. We found no effect of IVIg treatment on numbers of CD45RO+ Tregs in 
peripheral blood in both groups, suggesting that IVIg did not drive conversion from naïve 
into memory Treg within the time frame of the study (data not shown). 
IVIg increases the suppressive capacity of Tregs ex vivo
To investigate whether IVIg treatment stimulates the suppressive capacity of Tregs, we 
isolated CD3+CD4+CD25+CD127- Tregs and autologous CD3+CD25-CD127+ responder T cells 
(Tresp) from PBMCs of seven patients who received high-dose IVIg that were collected 
before, after and at day 7 after IVIg treatment. The gating strategy for flow cytometric purifi-
cation of these cells is depicted in Figure 2A. Tresp isolated from blood collected before IVIg 
infusion were stimulated with PHA and co-cultured with Tregs purified from blood samples 
collected before, after and at day 7 after treatment in a Treg:Tresp ratio of 1:4. After 5 days 
of culture, cumulative IFN-γ production by Tresp was determined. Tregs that were isolated 
before treatment showed a suppression of IFN-γ production of 41%, while Tregs isolated at 
day 7 demonstrated a suppression of 70% (P=0.001, Figure 2B). Thus, in accordance with the 
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fIGURE 1 . IVIg treatment selectively activates circulating Tregs, but not conventional T helper cells (Tconv).
A) Percentages of CD3+CD4+ and CD3+CD8+ in PBMCs did not alter after IVIg treatment. B) Density plot 
shows the gating strategy of Tregs and Tconv after gating on CD4+ cells. Histograms show intracellular 
FOXP3 expression in Tregs and surface expression of HLA-DR on Tregs and Tconv obtained before, 
immediately after, and at day 7 after IVIg treatment of a representative patient. C) Baseline percentages 
of CD25+FOXP3+ Tregs within circulating CD4+ T cells, D) MFI of FOXP3 in Tregs and E) percentages of 
Tregs expressing HLA-DR from healthy blood donors (n=10) and patients treated with low-dose IVIg 
(n=12) or high-dose IVIg (n=15). F) Percentages of CD25+FOXP3+ Tregs within the CD4+ population before, 
immediately after, and 7 days after IVIg treatment in patients who received low-dose (n=12) or high-dose 
IVIg (n=15). (G-I): G) MFI of FOXP3 in Tregs, H) percentages of Tregs, and I) percentages of Tonv expressing 
HLA-DR before, immediately after, and 7 days after IVIg treatment in patients who received low-dose (n=12) 
or high-dose IVIg treatment (n=15). Horizontal lines represent median. *P <0.05.
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fIGURE 2 . Enhanced suppressive activity of Tregs purified from blood after IVIg treatment. 
A) Tregs were obtained by flow cytometric sorting on 7-AAD-CD3+CD4+CD127-CD25+ cells (Treg) from 
PBMC collected from 7 high-dose IVIg-treated patients before treatment, immediately after treatment, and 
at day 7 after treatment, and Tresp were obtained by sorting both 7-AAD-CD3+CD4- (Tresp I) and 7-AAD-
CD3+CD4+CD127+CD25- (Tresp II) cells from autologous PBMC collected before IVIg-treatment. B) Tregs 
purified from the patients before, after, and at day 7 after treatment were co-cultured with Tresp (5x104) 
obtained before treatment that were stimulated with 1mg/ml phytohemagglutinin (PHA) in the presence of 
40Gy irradiated autologous PBMCs (5x104) at a Treg:Tresp ratio of 1:4 in culture medium in round bottom 
96-well plates. After 5 days, supernatants were collected and the cumulative IFN-γ production by Tresp was 
quantified by ELISA. Each condition was tested at least in triplicate from which means were calculated. From 
each patient, these means were used to calculate the percentage of suppression using the formula: (IFN-γ 
levelTresp-IFN-γ levelTresp+Treg)/IFN-γ levelTresp x 100%. Bar graphs represent mean ± SEM. *P <0.05, as compared 
to Tresp alone. 
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observed increased Treg activation status at day 7 after IVIg treatment, Tregs isolated at 7 
days also showed a higher suppressive capacity. These data suggest that IVIg treatment 
may stimulate the suppressive function of circulating Tregs up to at least 1 week after treat-
ment. 
DISCUSSION
Multiple on-going studies are being performed to induce Treg expansion or stimulate Treg 
function in order to control T cell-mediated disorders. Interestingly, the current study suggests 
that high-dose IVIg treatment may be useful to enhance Treg activation and suppressive 
function in vivo. We show that IVIg treatment enhances both the activation status and 
suppressive function of Tregs in patients. Upon high-dose IVIg treatment, a gradual rise in 
FOXP3 and HLA-DR expression in circulating CD4+CD25+FOXP3+ Tregs was found, with the 
highest expression on day 7 after infusion. This finding indicates that IVIg treatment activates 
Tregs for at least 1 week, when IVIg levels already declined. Treg activation was clearly 
dependent on the IVIg dose, since patients who received low-dose IVIg (≤0.6g/kg) did not 
show significant effects. Activation of Treg was not restricted to patients with autoimmune 
disease, as immunodeficient patients who received high-dose IVIg also showed a rise in 
FOXP3 and HLA-DR expression on Tregs. Thus, our data support the generally accepted idea 
that high-dose treatment regimen is required in order to gain anti-inflammatory activity (7).
Our ex vivo functional assays showed that IVIg treatment may not only stimulate the 
activation status, but may also enhance the suppressive function of circulating Tregs. We 
observed an increased suppressive function of Tregs that was highest on day 7 after IVIg 
treatment, which is in line with the time-dependent increase of the activation status after 
treatment. Supporting our data, previous studies have shown that Tregs with a higher HLA-
DR (11) and FOXP3 (15, 16) expression exert higher suppressive capacity. Further studies are 
warranted to confirm this finding, since suppressive function was studied in a small numbers 
of patients. Moreover, it will be highly interesting to monitor the activation status and sup-
pressive function of Tregs after high-dose IVIg therapy over a longer time period to study the 
durability of this effect. 
In order to assess the suppressive capacity of Tregs, we did not use proliferation as  the 
classical read-out, since IL-2 produced by Tresp in the co-culture system may influence 
proliferation of Tregs, hence affecting overall 3H-thymidine incorporation (17). Therefore, we 
analyzed IFN-γ secretion by Tresp, which is independent of the extent of Tregs hyporespon-
siveness and may therefore be more unbiased. 
While a few previous studies have shown an increase of circulating Treg numbers in patients 
treated with IVIg (18-21), we show an increase in both the activation status and functional 
suppressive capacity of Treg upon high-dose IVIg therapy in humans in vivo. Although the ef-
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fects are moderate, this finding may be of importance, since in several autoimmune diseases 
the numbers of Tregs are normal, yet these cells display a functional defect (22-24). A possible 
explanation for the fact that we did not find an increase in the circulating Treg numbers after 
IVIg treatment is that our patients did not have a deficit of Treg numbers compared to healthy 
subjects (Figure 1C), while the previous studies included patients with acute inflammatory 
diseases which had decreased numbers of circulating Tregs before IVIg treatment (18-20).
Compellingly, high-dose IVIg treatment selectively activated CD4+CD25+FOXP3+ Tregs, 
but not CD4+FOXP3- Tconv. This observation may be interesting for the clinic, as conventional 
immunosuppressive drugs used for treating autoimmune diseases and allograft rejection, in 
particular calcineurin inhibitors, do not only suppress Tconv, but also Tregs (25-32). By selec-
tive activation of CD4+CD25+FOXP3+ Tregs, but not Tconv, IVIg may be superior to classical 
immunosuppressive drugs. Similar observations were also found in vitro and in mice models 
(11, 12, 14). In addition, IVIg selectivity for Tregs has also been suggested by Maddur and 
colleagues (33), who showed that IVIg inhibited Th17 cell differentiation and amplification, 
while it increased the numbers of Tregs among memory T cells. 
The mechanism by which IVIg selectively activates Tregs is still unclear. Our previous data 
(11) together with the study of Ephrem et al. (12) suggest that the activation may be medi-
ated by direct binding of IVIg to an unknown “IVIg receptor” present on Tregs but not on 
Tconv. Since we observed that human Tregs do not express classical Fcγ receptors (11), 
this receptor must be a non-classical IgG-binding molecule. Alternatively, IVIg may bind 
to specific surface receptors by its F(ab’)2 fragment, as suggested by Maddur et al (33), 
or IVIg may contain Tregitopes that can activate Tregs by presentation on MHC II+ antigen 
presenting cells towards Tregs, as proposed by De Groot and colleagues (34, 35).
The current study focused on patients treated with IVIg for different indications. Although 
the underlying diseases are variable, the positive effect of high-dose IVIg on Treg activation 
is consistently seen in patients treated with high-dose IVIg. These results suggest that the 
effects of IVIg on Treg activation are not restricted to a certain disease, but to high-dose 
treatment. It would, however, be interesting to confirm the dose-dependent effect of IVIg in 
patients with the same treatment indication in the future.
In summary, we have demonstrated that high-dose IVIg therapy in humans in vivo can 
selectively activate Tregs and enhance their suppressive capacity. Since the effects in 
our patient cohort were moderate, we propose that Treg stimulation may be one of the 
mechanisms by which IVIg controls inflammation in patients with autoimmune and systemic 
inflammatory disorders, but other mechanisms are probably also required to restore imbal-
anced immune homeostasis. The data presented in this study underline the multifaceted 
character of the immunomodulatory mechanisms of IVIg. 
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To the Editor:
With great interest we have read the paper of Siedlar et al (1), in which a new mechanism 
of action of intravenous immunoglobulins (IVIg) is presented. This mechanism includes a re-
duction of the numbers of “pro-inflammatory” CD14+CD16++ monocytes and suppression of 
their TNF-α production. Modulating the numbers of CD14+CD16++ monocytes is of particular 
clinical importance in inflammatory diseases (e.g. sepsis, hemophagocytic syndrome and 
Kawasaki disease), where the numbers of this subset are dramatically increased. Therefore, 
the authors suggest that declining the numbers of CD14+CD16++ monocytes may contribute 
to the anti-inflammatory effects of high-dose IVIg treatment (1-2 g/kg) in patients with in-
flammatory conditions. However, the study of Siedlar et al (1) was not performed in patients 
receiving the “anti-inflammatory” dose of 1-2 g/kg, but in patients with common variable 
immunodeficiency (CVID) that received a replacement dose of 0.4 g/kg IVIg. 
Therefore, to explore the effects of high-dose IVIg on the numbers of CD14+CD16++ mono-
cytes in patients with inflammatory diseases, we performed a comparative study including 
patients with inflammatory disorders treated with “high dose” IVIg (average 1.24 g/kg ±0.34, 
n=7) and patients with immunodeficiency disorders receiving a “low dose” (average 0.43 g/
kg ±0.16, n=7). The indications for high-dose IVIg treatment were: acquired von Willebrand 
syndrome (n=2), immune thrombocytopenic purpura (n=1), dermato(poly)myositis (n=2), 
CREST syndrome (n=1), vasculitis (n=1). Treatment with low-dose IVIg was given for the 
following indications: CVID (n=5) and immunoglobulin IgG1 and IgG3 subclass deficiency 
(n=2). Blood was collected before infusion and 4 to 24 hours after infusion. In addition, to 
study the effect of IVIg on longer term, we collected blood 7 days after IVIg infusion. By flow 
cytometry, we determined the percentages of inflammatory CD14+CD16++ monocytes and 
the classical CD14+CD16- monocytes, according to the gating strategy used by Siedlar et 
al., excluding CD56+ cells. 
At baseline, the numbers of CD14+CD16++ cells were similar in patients receiving high dose 
(11.7%±11.5) and low dose (10.4%±6.1) IVIg (p=0.81). In line with the observations of Siedlar et 
al, we found a significant decline of the numbers of CD14+CD16++ cells immediately after IVIg 
infusion in patients that received low-dose IVIg (Figure 1A, average decrease: 42%, P<0.05). 
After 7 days, the numbers of inflammatory monocytes were still reduced in 4 of 6 patients 
measured. To our surprise, in patients treated with high-dose IVIg, no significant reduction 
of the numbers of CD14+CD16++ monocytes was observed (Figure 1B, before versus after 
IVIg: P=0.69; before versus day 7: P=1.00). Of the patients receiving low-dose IVIg, 4 from 7 
patients showed a decline, of which all had CVID. Therefore, the described effect by Siedlar 
et al. appears to be more specific for CVID patients and the amount of IVIg administered. 
Similar to Siedlar et al., we did not observe changes in the classical CD14+CD16- monocytes 
after IVIg treatment in both groups. 
As Dr. M. Berger mentioned in his editorial (2), the relationship between the observed 
decrease in numbers of pro-inflammatory monocytes in blood of IVIg-treated CVID patients 
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and the decreased production of TNF-α was not clear in the paper of Siedlar et al [1]. There-
fore, to study whether there may be an effect of the reduced numbers of the non-classical 
monocytes on the levels of TNF-α, we quantified plasma TNF-α levels in our patients. In pa-
tients treated with low-dose IVIg, in which numbers of CD14+CD16++ monocytes decreased 
after IVIg treatment, we did not find a decrease in plasma TNF-α levels immediately after 
IVIg (+45%, p= n.s). Therefore, we do not think that IVIg treatment results in a decreased 
TNF-α production by CD14+CD16++ monocytes in vivo. Of note, when we combined patients 
treated with low-dose and high-dose IVIg (and thereby increased the power), we found 
a significantly higher plasma TNF- α level immediately after IVIg treatment (+37%, p< 0.05). 
Together, similar to Siedlar et al (1), we found that low-dose IVIg diminishes the numbers 
of circulating pro-inflammatory CD14+CD16++ monocytes in CVID patients. However, this 
effect was not observed in patients with inflammatory disorders treated with high “anti-in-
flammatory doses” of IVIg. We therefore postulate that this mechanism does not explain the 
beneficial clinical effect of high-dose IVIg treatment in patients with inflammatory disorders. 
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fIGURE 1 . The percentages of CD14+CD16++ monocytes were significantly reduced immediately after IVIg 
infusion in patients receiving low-dose IVIg (A) (n=7), but not in patients receiving high-dose IVIg (B) (n=7). 
Horizontal lines represent means.
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ABSTRACT
Intravenous immunoglobulin (IVIg) is a therapeutic preparation of polyspecific human 
IgGs prepared from plasma pooled from thousands of individuals. When administered at 
a high dose, IVIg is able to inhibit inflammation and has proven beneficial in the treatment 
of various autoimmune and systemic inflammatory diseases, as well as allograft rejection. 
Importantly, IVIg therapy can ameliorate both auto-antibody-mediated and T-cell medi-
ated immunopathologies. In the last decades, extensive research in murine disease models 
has resulted in the elucidation of several anti-inflammatory mechanisms of action of IVIg. 
Surprisingly, it has only been limitedly studied whether these mechanisms are operational 
in humans treated with IVIg. In this perspective, we focus on the similarities and differ-
ences of the anti-inflammatory properties of IVIg in mice and humans. We examine two 
anti-inflammatory mechanisms that have been extensively studied in recent years: the 
IL-33-Th2-FcγRIIb pathway and stimulation of regulatory T cells. We demonstrate that both 
pathways are activated in humans treated with IVIg, but that incorrect extrapolations from 
mice to men have been made on the molecular and cellular components involved in these 
cascades that warrant for critical re-evaluation of these anti-inflammatory mechanisms of 
IVIg in humans.
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INTRODUCTION
As IVIg contains a wide spectrum of antibody specificities, representative for the natural 
antibody repertoire of the adult human population, IVIg was initially administered to restore 
humoral function of patients with primary or secondary immunodeficiency. After it had been 
shown that high-dose IVIg treatment (4-fold higher than supplementation dose) (1) could 
ameliorate idiopathic thrombocytopenic purpura (ITP) (2), its anti-inflammatory properties 
have increasingly been exploited to treat various autoimmune and systemic inflammatory 
diseases. 
Several non-exclusive mechanisms by which IVIg exerts its anti-inflammatory effects have 
been elucidated over the past decades. These include neutralization of autoantibodies by 
anti-idiotype interactions, increased clearance of pathogenic antibodies by saturation of 
the neonatal FcR (FcRn), prevention of binding of pathogenic immune complexes (ICs) to 
activating Fcγ-receptors (FcγR), modulation of FcγR expression, inhibition of the comple-
ment cascade, reduced pro-inflammatory cytokine production, inhibition of dendritic 
cells (DCs) and B cells, inhibition of T-helper (Th)-1 and Th-17 differentiation, and expansion 
and enhanced suppressive function of CD4+FOXP3+ regulatory T cells (Treg). All these anti-
inflammatory mechanisms of IVIg have been excellently reviewed elsewhere (1, 3-8). It is 
important to realize, that most of these anti-inflammatory mechanisms have been estab-
lished in murine studies, and that extrapolation of these mechanisms from mice to humans 
is far from trivial due to fundamental differences between the murine and human immune 
system that affect the mode-of-action of IVIg within these species. In this perspective, 
we focus on the similarities and differences between the anti-inflammatory mechanisms 
activated by IVIg in mice and humans, but due to size limitations, we cannot cover all 
the anti-inflammatory mechanisms as listed above. Therefore, we will focus on two most 
advertised anti-inflammatory mechanisms in recent years: the IL-33-Th2-FcγRIIb pathway 
and stimulation of regulatory T cells. We will examine the evidence for the involvement of 
their proposed cellular and molecular components in immunomodulation by IVIg therapy in 
humans and, when validation in humans is still lacking or incomplete, discuss their translat-
ability from murine to human studies considering human and murine biology.
Sialylated IVIg and the IL-33-Th2-FcγRIIb pathway
In the last decade, a number of landmark studies has revealed that IgGs with α2,6-sialic 
acid-containing N-linked glycans attached to the IgG Fc-part, display potent anti-inflam-
matory activity in antibody-mediated inflammation. Identification of the anti-inflammatory 
properties of this IgG fraction started with a study in a murine ITP-model in which the pro-
tective effects of IVIg appeared dependent on 1) upregulation of FcγRIIb expression on 
effector macrophages, thereby limiting IC-mediated activation, and 2) the IgG Fc-part (9). 
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In subsequent studies, the protective effect of IVIg in a mouse model of IC-mediated (K/
BxN) arthritis was shown to be mediated by CSF-1-dependent macrophages that act as 
sensors for IVIg and are involved in the induction of inhibitory FcγRIIb expression on CSF-1-
independent effector macrophages, thereby raising the threshold for activation of these 
cells by auto-antibody-IC (10, 11). These CSF-1-dependent IVIg-sensor macrophages were 
identified as splenic SIGN-R1+ marginal zone macrophages (MZM) which were able to bind 
a specific fraction of IgGs having α2,6-sialic acid-containing N-linked glycans attached to 
the IgG Fc (12). Parallel studies meanwhile had demonstrated that these IgGs were essential 
for the anti-inflammatory activity of IVIg in the K/BxN arthritis model in a FcγRIIb-dependent 
manner (13-15). Infusion of α2,6-sialic acid Fc (sialylated Fc, sFc) protected wild type, but 
not SIGN-R1-/- mice from arthritis, suggesting that binding of sFc to SIGN-R1 on MZM was 
required (12). A human orthologue of SIGN-R1, DC-SIGN, was also able to bind sFc ex vivo 
(12). Indeed, the protective activity of sFc and sialylated IVIg (sIVIg) was retained upon in-
duction of arthritis in SIGN-R1-/- mice that transgenically expressed DC-SIGN (15). These data 
suggested that DC-SIGN might be able to mediate the anti-inflammatory properties of sIVIg 
in humans in vivo. Subsequently, it was shown that sIVIg induced the production of IL-33 in 
the spleen of wild-type but not SIGN-R1-/- mice. IL-33 subsequently promoted the produc-
tion of IL-4 and IL-13 by basophils, which enhanced the expression of FcγRIIb expression on 
macrophages and monocytes, thereby providing a link between IVIg-sensor macrophages 
and induction of FcγRIIb expression on effector myeloid cells (Figure 1) (15). 
The elucidation of this mechanism has profoundly improved our understanding of the 
protective effects of IVIg in antibody-mediated inflammation in mice. However, what is 
the current evidence that a similar mechanism mediates the anti-inflammatory effects of 
high-dose IVIg-therapy in humans? In the following sections, we will address the evidence 
for activation of this anti-inflammatory pathway upon high-dose IVIg therapy in humans. 
Moreover, we will discuss the biological differences between mice and men which are 
related to a number of unresolved issues regarding involvement of FcγR modulation, the 
role splenic MZM, the dependence on DC-SIGN, and the importance of IgG sialylation in the 
therapeutic efficacy of IVIg in humans. 
IVIg and the IL-33-Th2 cytokine-Fcγ receptor pathway in humans
Upregulation of inhibitory FcγRIIb expression by IVIg as an effector mechanism by which 
antibody-mediated immune diseases are prevented, has been demonstrated in various 
animal models (9, 10, 13, 16), although in murine studies on ITP and antigen-driven allergic 
airway disease, the beneficial effect of IVIg was also observed in FcyRIIB-/- mice (17, 18). Is 
there evidence for the involvement of FcγRIIb in IVIg-treated humans? Recently, we dem-
onstrated no increase of FcγRIIb expression on circulating monocytes and DCs in patients 
treated with IVIg for diverse autoimmune pathologies (19). These data corroborated findings 
in IVIg-treated patients with ITP (20), Kawasaki disease (21), or common variable immuno-
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deficiency (CVID) (22) that showed no changes in FcγRIIb protein or mRNA expression of 
circulating monocytes. In addition, IVIg did not induce upregulation of FcγRIIb expression on 
human myeloid DCs in vitro (19, 23). In contrast to these studies, a majority of patients with 
chronic inflammatory demyelinating polyneuropathy (CIDP) showed increased expression 
of FcγRIIb on monocytes and B cells after IVIg treatment (24). It has to be noted that the 
untreated CIDP patients in this study showed reduced FcyRIIb expression and the observed 
increase may have reflected a normalization of expression levels upon reduction of overall 
inflammation upon IVIg therapy. So strikingly, whereas IVIg treatment in mice consistently 
has shown to stimulate expression of inhibitory FcγRIIb on myeloid cells (9, 10, 25, 26), this 
effect has not been observed in human studies. 
Do these observations imply that IVIg treatment in humans does not inhibit IC-mediated 
immunity via modulation of FcyRs? Although we did not find increase of FcγRIIb expression, 
after high-dose IVIg treatment in patients with autoimmune diseases, we did find down-
regulation of the activating FcγRIIa expression on circulating myeloid DCs (19). In addition, 
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fIGURE 1 . IVIg-IL-33-Th2-FcγRIIB pathway in mice and humans. 
In mice, sialylated IVIg binds to SIGN-R1 expressed on splenic marginal zone macrophages and induces 
IL-33 production. IL-33 subsequently promotes the production of IL-4 by basophils, which enhances the 
expression of FcγRIIB expression on effector macrophages at the site of inflammation. In humans, IVIg binds 
to an, as of yet, unidentified cell type in lymph nodes. This induces IL-33 production, which in turn enhances 
IL-4 and IL-13 production by basophils resulting in decreased expression of FcγRIIa and IFNγR2 on myeloid 
dendritic cells. MZM, marginal zone macrophages; SA, sialic acid; MØ, macrophage; mDC, myeloid dendritic 
cell.
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we observed an increase in plasma levels of IL-33 and the Th2 cytokines IL-4 and IL-13 upon 
high-dose IVIg treatment in these patients, showing homology between mice and humans. 
Enhanced IL-33 plasma levels were also observed in another cohort of autoimmune 
disease patients treated with IVIg, although IL-4 in plasma was hardly detectable (27). In 
vitro experiments on human myeloid DCs suggested that FcγRIIa downregulation was not 
directly caused by IVIg, but rather indirectly by the elevated levels of IL-4 and IL-13, and 
resulted in suppressed responses of myeloid DCs to IC-stimulation (19). Thus, in humans IVIg 
does stimulate the IL-33-Th2 pathway, but reduces IC-mediated myeloid DC activation by 
downregulation of the activating FcγRIIa, instead of upregulation of the inhibitory FcγRIIb on 
myeloid cells as observed in mice (Figure 1). Interestingly, we found that the same cytokine 
cascade also downregulates expression of the IFN-γ receptor 2 subunit on myeloid DCs in 
humans (19), which may contribute to suppression of cellular immunity by IVIg (28).
Given the differences in expression of FcγRs between mice and men, it is not entirely sur-
prising that the effects of IVIg treatment on FcγR modulation in mice are distinct from those 
in humans. Humans have six different FcγRs, namely FcγRIa, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa 
and FcγRIIIb, while mice have four: FcγRI, FcγRIIb, FcγRIII and FcγRIV (29-31). Thus, FcγRIIa, 
which we showed to be downregulated by IVIg treatment (19), is not present in mice. 
IVIg-sensing cell types in humans
Murine studies have demonstrated the importance of splenic MZM in the IL-33-Th2-FcγRIIb 
pathway. Because the protective effect of sIVIg was lost upon splenectomy or specific 
deletion of MZM, this macrophage subset was suggested to be responsible for binding of, 
and initiating the protection mediated by sIVIg or sFc (10, 12), although it is important to 
note, that it has not been formally proven that MZM are the source of IL-33 production. One 
would expect a similar role for this cell type in IVIg-treated humans, as IL-33 plasma levels 
in humans increased upon IVIg treatment (19, 27). However, the human and murine spleen 
differ to a major extent, both in morphology and the presence of specific cell types. MZM 
are diffusely spread within the marginal zone of the murine spleen (32), they express SIGN-
R1 and cooperate with marginal zone B cells to mount T-cell-independent IgM responses 
(33). Importantly, MZM are not present in the human spleen, suggesting that a different cell 
type is responsible for the IVIg-induced IL-33 production in humans (34). In contrast to the 
spleen in mice, the human spleen contains an additional zone, called the perifollicular zone. 
It is located between the marginal zone and the red pulp (35). In the perifollicular zone, 
branches of the central arteriole terminate without endothelial lining. It contains a special 
subset of macrophages, of which some express DC-SIGN, that form sheats around the capil-
laries (36). Although their anatomical location in the human spleen is different, it is tempting 
to speculate that these perifollicular macrophages are the counterparts of murine MZM.
However, arguing against an indispensable role for the spleen in mediating the anti-
inflammatory effects of IVIg in humans is the observation that IVIg treatment of splenec-
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tomized ITP patients is still effective (37). Therefore, cell type(s) producing IL-33 upon IVIg 
treatment in humans may be present outside the spleen. Indeed, IVIg induces IL-33 mRNA 
expression in primary human lymph node cells in vitro (19), but not in human splenocytes 
(19, 27). In human lymph nodes, medullary sinus macrophages (MSM) (38), which function 
to filter lymph for microorganisms, as well as subcapsular sinus macrophages (SSM), a mac-
rophage subset which is in direct contact with afferent lymph, are likely candidates for the 
IVIg-induced IL-33 production in humans in vivo as they express DC-SIGN (39, 40). Although 
we were not yet able to determine whether MSM an SSM are the cellular sources of IL-33 
in vivo, we did establish that human macrophages produce IL-33 upon IVIg exposure in 
vitro (19). Alternatively, epithelial cells and fibroblasts may also be likely sources as they can 
produce IL-33 (41, 42). 
Recent studies using two different murine models of ITP showed that splenectomy in mice 
did not impair the protective effect of IVIg (17, 43). In one of these models, the protective 
effect of IVIg was even independent of IL-33 and IL-4 signaling, although still dependent on 
SIGN-R1 and sFc (43). This suggests that, as in humans, cells at anatomical locations outside 
the spleen may alternatively mediate the anti-inflammatory properties of sIVIg in mice. 
Collectively, these data indicate the need to study which human tissues and cells are 
involved in stimulation of the IL-33-Th2 cytokine pathway by IVIg. Obviously, availability of 
tissues from IVIg-treated patients is limited, but in vitro studies using human tissues and cells 
can help to clarify which human cell types are able to bind IVIg and produce IL-33.
Contribution of DC-SIGN and Fc sialylation to the anti-inflammatory activity 
of IVIg in humans
Currently, the only evidence that DC-SIGN might be involved in the anti-inflammatory re-
sponse to IVIg in humans is the observation that DC-SIGN can replace its murine orthologue 
SIGN-R1 in IL-33-mediated protection from serum-induced arthritis in mice upon sFc treat-
ment (15). However, in vitro studies on human DC-SIGN expressing cells did not provide 
any indication for involvement of DC-SIGN in the protective effects of sFc. We found that 
stimulation of IL-33 production of human macrophages by IVIg was not inhibited by blocking 
of DC-SIGN (19). Moreover, human splenocytes and monocyte-derived DCs (moDCs), that 
both abundantly express DC-SIGN, did not produce IL-33 upon exposure with IVIg (19, 27). 
Although DC-SIGN was partially responsible for the IVIg-mediated induction of regulatory 
T cells by prostaglandin E2 (PGE2)-producing moDCs, this effect was not Fc- but F(ab’)2-
dependent and therefore not mediated by sFc binding to DC-SIGN (44). 
Collectively, these data ask for a re-evaluation of the involvement of DC-SIGN in mediat-
ing the anti-inflammatory activity of IVIg in humans. Whether DC-SIGN is the proper human 
homologue of SIGN-R1 can in fact be argued. L-SIGN, another C-type lectin, shares stronger 
homology to SIGN-R1 with regard to cellular expression pattern than DC-SIGN. SIGN-R1 
and L-SIGN are both expressed by liver sinusoidal and lymph node endothelial cells (45-47). 
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SIGN-R1 is also expressed on MSM in lymph nodes (48) and MZM in the spleen (32). MSM 
in humans do not express L-SIGN (45) and whether L-SIGN is expressed in human spleen is 
unclear, as no expression was detected in human spleen on mRNA or protein level (46, 47), 
although recently a few scattered L-SIGN-expressing cells were observed in the perifollicular 
zone (15). In contrast, shared DC-SIGN and SIGN-R1 expression has only been observed for 
human and murine MSM in lymph nodes, respectively (32, 40). DC-SIGN is also expressed 
on subsets of monocytes (15), DCs (46), some macrophages in the perifollicular zone of the 
human spleen (36), and SSM in human lymph nodes (39, 40). All three C-type lectins have 
similar glycan binding capabilities, as they are all able to bind high-mannosylated structures 
and fucosylated glycans, with the exception that L-SIGN does not bind Lewisx-containing 
glycans (49, 50). L-SIGN is also able to bind to sFc in vitro, although with reduced affinity 
compared to DC-SIGN, which suggests a possible role of L-SIGN in sensing sIVIg in humans. 
In our opinion, the published results of selective blockade of DC-SIGN in SIGN-R1-/- mice 
that express a transgene containing both DC-SIGN and L-SIGN, do not completely exclude 
involvement of L-SIGN in the anti-inflammatory effects of sFc (15). Therefore, additional stud-
ies using human cells are required to demonstrate whether L-SIGN is involved in mediating 
anti-inflammatory effects of IVIg in humans. 
In addition, whether DC-SIGN or SIGN-R1 can bind sIVIg or sFc with sufficient affinity is still a 
matter of debate. Importantly, binding of sFc to SIGN-R1- or human DC-SIGN-expressing cells 
in vivo, e.g. upon infusion of fluorescently-labeled sFc fragments, has never been shown. 
SIGN-R1 and DC-SIGN do not bind sialylated glycans or glycoconjugates (50-52), suggesting 
that binding of sFc by these lectins must involve non-canonical interactions. A recent study 
suggested that sialylation of the N-linked Fc glycan structurally affects the IgG Cγ2 domain, 
causing a so-called ‘closed’ state of sFc which would enable interaction with DC-SIGN, while 
asialylated Fc has an ‘open’ state, resulting in preferential binding to FcγRs (53). However, 
this model of sFc-DC-SIGN interaction is controversial and has initiated an ongoing scientific 
debate as contradictory evidence shows that Fc sialylation does not induce alterations in 
the Fc conformation (54, 55). Moreover, binding affinity of engineered IgG glycoforms that 
were either hyper-α2,6-sialylated, asialylated or deglycosylated to tetramerized DC-SIGN 
was shown not to differ and, strikingly, was Fab- but not Fc-dependent (56).
In addition to the above-mentioned unresolved issues on binding of sIVIg to DC-SIGN, 
there are now various reports that question whether SIGN-R1 and (Fc) sialylation are required 
for the anti-inflammatory effects of IVIg in mice. SIGN-R1 was found to be dispensable for 
therapeutic amelioration of ITP as well as prevention of antigen-driven airway disease in 
mice (16, 18). In murine models of ITP (57-59) (in contrast to other studies on ITP reporting 
a role for sialylation (13, 16, 43)), arthritis (60) and herpes simplex virus (HSV)-induced en-
cephalitis (26) the anti-inflammatory properties of IVIg, either administered prophylactically 
or therapeutically, were sialylation-independent. Therefore, the beneficial effects of sIVIg 
(in mice) may be disease- and model-dependent, suggesting that clinical application of 
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sialic acid-enriched IVIg in humans may not per se be superior to conventional IVIg regi-
mens. Taken together, there is still limited evidence for a prominent role of DC-SIGN and Fc 
sialylation in mediating the anti-inflammatory activity of IVIg in humans.
Alternative sialylated IgG-binding molecules
CD22 is a sialic acid-binding Ig-like lectin (Siglec-2) family member expressed on murine and 
human B cells and murine DCs (61), and binds α2,6-sialic acid-containing glycans with high 
specificity (62). sIVIg, but not asialyated IVIg, was shown to bind to CD22 on human B cells 
in vitro, resulting in reduced BCR signaling and enhanced apoptosis upon stimulation with 
anti-IgM (63). As in this study sIVIg was enriched by Sambucus nigra agglutinin (SNA) lectin 
fractionation which mainly enriches for F(ab’)2-sialylated IgG, it is likely that the inhibitory 
effects of sIVIg mediated by CD22 are not Fc-dependent (57, 64).
Arguing against a role for CD22 in mediating the anti-inflammatory effects of IVIg is the 
observation that CD22-/- mice were still protected from ITP and serum-induced arthritis by 
IVIg (65). However, it should be noted that murine studies on the involvement of CD22 in the 
effects of IVIg are hampered by the differences between sialic acids in humans and mice. 
Sialic acids are nine-carbon sugars which contain a carbon ring (C2-C6) and an exocyclic 
side chain (C7-C9). One group of sialic acids, called neuraminic acids, are N-acetylated 
at C5 in the carbon ring, yielding N-acetyl neuraminic acid (Neu5Ac). In many vertebrates, 
including mice, this N-acetyl group can be converted by the enzyme CMP-N-acetyl hy-
droxylase (CMAH) to a N-glycolyl group resulting in N-glycolyl neuraminic acid (Neu5Gc). 
Importantly, CMAH is non-functional in humans (66). Therefore, terminal sialic acids attached 
to N-linked glycans like those in human IgG molecules are Neu5Ac and not Neu5Gc. While 
human CD22 binds both Neu5Ac and Neu5Gc, murine CD22 can only bind Neu5Gc ligands 
(Figure 2) (67). Therefore, it can be expected that sIVIg cannot bind to murine CD22, and on 
basis of murine experiments it can therefore not be ruled out that sIVIg modulates immune 
responses in humans via binding to CD22. 
Recently, another C-type lectin, called dendritic cell immunoreceptor (DCIR), was shown 
to specifically bind sIVIg. As a result, DCIR-expressing tolerogenic DCs induced expansion of 
regulatory T cells (Tregs) which attenuated ovalbumin-induced airway hyperresponsiveness 
in mice (18).  Whether DCIR is involved in the anti-inflammatory effects of IVIg in humans 
is still unexplored. Finally, sFc also binds to human CD23, the low-affinity IgE receptor (53), 
but whether this interaction has functional effects has not been studied yet. It is tempting 
to speculate that CD22, DCIR, CD23 or other still unknown receptors for IVIg mediate the 
SIGN-R1-independent anti-inflammatory effects of prophylactic IVIg treatment observed in 
mice, as well (16). In addition, elucidation of the functional role of these alternative ‘IVIg 
receptors’ in the immunomodulatory effect of IVIg in humans deserves scientific effort. 
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Stimulation of regulatory T cells
It has now firmly been established both in mice and humans that IVIg exerts its anti-inflam-
matory effects also by stimulating expansion and suppressive function of CD4+Foxp3+ Tregs. 
Tregs are key players in the maintenance of self-tolerance, involved in controlling autoim-
munity, inflammatory disorders, and immune responses to allogeneic transplants, cancer 
and various infectious agents. Numerous murine studies on a variety of disease models have 
shown an indispensable role for Tregs in mediating the protective effects of IVIg treatment, 
as they expand from normal to supranormal levels and show enhanced suppressive capac-
ity (18, 26, 68-74). A similar expansion of Tregs was observed in humans who were treated 
with IVIg for various diseases, e.g. in Kawasaki disease (75, 76) Guillain Barré Syndrome (77), 
rheumatoid arthritis (78) and eosinophilic granulomatosis with polyangiitis (79), except in a 
study in CVID patients in which no expansion of Tregs was observed upon IVIg-treatment 
(80). We demonstrated that circulating Tregs in patients with various auto-immune diseases 
or immunedeficiencies are selectively activated upon IVIg therapy, as these cells showed 
increased FOXP3 and HLA-DR expression and enhanced suppressive capacity ex vivo, while 
T helper cells were not affected. However, our study did not show an increase of circulating 
Tregs upon IVIg treatment (81). Comparison of the human studies reveals that expansion of 
Treg upon IVIg therapy was only observed in patients with inflammatory diseases in which 
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the levels of Tregs were reduced prior to IVIg infusion, while Treg did not expand in patients 
without Treg deficit. Collectively, these studies demonstrate that IVIg in humans enhances 
the suppressive capacity of Tregs, while expansion only occurs in conditions with deficit 
numbers of circulating Tregs. The latter observation differs from the findings in murine studies, 
which may be explained by the different compartments in which Treg are measured, i.e. 
Treg levels in humans were determined in peripheral blood, and in mice in spleen, lymph 
nodes and inflamed tissues. Collectively, expansion and enhanced suppressive activity of 
Tregs is a common feature of IVIg treatment in mice and humans. 
Interestingly, Treg expansion and enhanced suppressive capacity may be related to 
induction of IL-33 production upon IVIg treatment. Three recent murine studies have shown 
that IL-33 directly stimulates CD4+Foxp3+ Treg expansion (82-84). In allogeneic heart trans-
plant models IL-33 administration resulted in expansion of recipient Tregs in cardiac grafts 
and spleen and in prolonged allograft survival, while depletion of Tregs from recipients 
eliminated any therapeutic benefit from IL-33 therapy (82, 83). In a chronic colitis model, 
administration of IL-33 induced Treg proliferation in vivo, promoted Treg accumulation in the 
spleen and in inflamed tissues, and prevented loss of Foxp3 expression in the inflammatory 
environment (84). Stimulation of Tregs by IL-33 was dependent on expression of ST2, the IL-33 
receptor, on Tregs (82, 84). In vitro experiments showed that IL-33 can serve as a cofactor in 
TGF-β-mediated Treg differentiation (84).
Several other mechanisms by which IVIg may modulate Treg function and expansion 
have been postulated, and these have extensively reviewed elsewhere (Figure 3)(7, 8, 
85). The contribution of IgG sialylation on Treg expansion has been recently addressed in 
several studies. In a murine model of antigen-driven allergic airway disease, induction of 
antigen-specific Treg differentiation was dependent on binding of sIVIg to DCIR on DCs 
(18, 71, 72). Contrastingly, in HSE and EAE mouse models IgG sialylation was not required for 
functional activation of Tregs (26, 59). In vitro, IVIg induced expansion of human Tregs by 
moDCs partially via DC-SIGN in a F(ab’)2-dependent manner, but it is unknown whether IgG 
sialylation was involved (44). In addition, expansion and activation of Tregs upon recogni-
tion of IgG-derived peptides called Tregitopes that are presented by antigen-presenting 
cells is sialylation-independent (86, 87). Collectively, further study is warranted to determine 
the contribution of IgG sialylation and the IL-33-Th2 cytokine pathway on IVIg-driven human 
Treg expansion and function, both in antibody-mediated inflammatory diseases as well as in 
T-cell-mediated autoimmune pathologies.
Towards studying the cellular and molecular pathways required for 
IVIg-mediated immunosuppression in humans
Despite the vast knowledge that has been gained on the anti-inflammatory activity of IVIg 
in mice, it is surprising how little we know of its immunosuppressive mechanisms of action 
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in humans. The IL-33-Th2 pathway identified in mice is also active in humans treated with 
IVIg and results in reduced sensitivity of DCs to activation by ICs and IFN-γ, but there are 
significant differences in cellular and molecular components of this pathway between mice 
and men. In contrast, induction of Treg expansion and suppressive capacity by IVIg is a 
common pathway exploited by IVIg in mice and men. However, the molecular pathway(s) 
used by IVIg to stimulate these anti-inflammatory cascades in humans are unresolved. 
Several murine studies have shown that the anti-inflammatory properties of IVIg reside in the 
minor fraction of Fc-sialylated IgG molecules present in IVIg, but Fc-sialylation was shown 
to be dispensable in others studies. It is however unknown whether sIVIg also has immuno-
modulatory effects in humans, and priority should be given to investigate this important 
question. Moreover, whether the identified sIVIg-binding molecules DC-SIGN, DCIR, CD22 
and CD23 are involved in the anti-inflammatory activity of IVIg in humans in vivo should 
become subject of scrutiny as current evidence thereon is very limited. 
In light of the biological differences between mice and men, we recommend studying 
the immunomodulatory pathways of IVIg in humans using ex vivo measurements, as well 
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immunoreceptor; PGE2, prostaglandin E2; Treg, regulatory T cell.
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as in vitro studies on human cells. To address causality, studies should be initiated using 
immunodeficient mice reconstituted with a human immune system. In the light of the grow-
ing demand for IVIg concomitant with the predicted shortage of human plasma in the 
future and the high costs of IVIg therapy, it is of utmost importance to unravel the molecular 
interactions between IVIg and the human immune system, as such knowledge may enable 
the design of biologicals or small molecule drugs that mimic the anti-inflammatory effects 
of IVIg.
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ABSTRACT
Intravenous immunoglobulin (IVIg), a therapeutic preparation containing pooled human 
immunoglobulin G (IgG), has been suggested to inhibit differentiation and maturation of 
dendritic cells (DCs), however controversies exist on this issue. We aimed to re-investigate 
the effects of IVIg on human DC maturation and cytokine production, and to determine 
whether an artifactual determinant is involved in the observed effects. Human monocyte-
derived DCs or freshly isolated blood myeloid DCs were cultured in the presence of IVIg 
in vitro, and the expression of maturation markers CD80, CD86, CD83 and HLA-DR were 
determined by flow cytometry, while production of IL-12 and IL-10 was measured by en-
zyme-linked immunosorbent assay (ELISA) and T-cell stimulatory capacity was determined 
in co-cultures with allogeneic CD4+ T cells. Interestingly, we observed that IVIg did not inhibit, 
but instead stimulated spontaneous maturation and T-cell stimulatory ability of human DC, 
while leaving lipopolysaccharides (LPS)-induced DC maturation and cytokine production 
unaffected. Strikingly, prevention of IVIg binding to culture plate surface, or blocking of 
the activating FcγRIIa on DC, abrogated the stimulatory effect of IVIg on co-stimulatory 
molecule expression and on T-cell stimulatory capacity of DC, suggesting that IVIg activates 
DC upon IgG adsorption to the plastic surface. This study warrants for careful study design 
when performing cell culture studies with IVIg in order to prevent artifactual effects, and 
shows that IVIg does not directly modulate co-stimulatory molecule expression, cytokine 
production, or allogeneic T-cell stimulatory capacity of human DC. 
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INTRODUCTION
Dendritic cells (DCs) are professional APCs that play a crucial role in initiation of T-cell im-
munity (1). Human DCs express FcγRIIa (CD32a) by which they can sense multimeric IgG 
complexed to antigens or bound to cells and thereby become activated (2-4).
Intravenous immunoglobulins are preparations of IgG isolated from pooled human 
plasma. For its anti-inflammatory properties, IVIg is widely used to treat autoimmune and 
systemic inflammatory diseases. Bayry and colleagues (5) reported that IVIg can inhibit dif-
ferentiation and maturation of human monocyte-derived DCs (moDCs), while in concert 
reducing IL-12 and enhancing IL-10 production. Interestingly, using monocytes from patients 
with X-linked agamaglobulinemia displaying defective DC differentiation, the same group 
found that IVIg promoted moDC differentiation (6). More recently, two reports (7, 8) likewise 
observed stimulation of moDC differentiation by IVIg, particularly when monocytes were 
“primed” with traces of LPS (8). Thus, the effects of IVIg on human DC differentiation are 
controversial. 
Interestingly, a recent study demonstrates that IVIg can activate neutrophils to release 
elastase by artifactual adsorbance of IgG to plastic plate surface. By blocking IgG sur-
face adsorbance, elastase release was prevented (9). Since DCs express the activating 
Fc-receptor FcγRIIa, which has low affinity for monomeric IgG and can be activated only in 
response to multimeric IgG (4), we speculated that DC may be susceptible for activation by 
immobilized IgG rather than by soluble, monomeric IgG within IVIg preparations, and that 
artifactual immobilization of IgG to the culture plate may account for the contradictory 
reports of the effect of IVIg on DCs in vitro. 
Here, we sought to determine whether IVIg affects human DC maturation, T-cell stimu-
latory capacity, and cytokine production, using both moDCs and freshly isolated blood 
myeloid DCs (mDCs). Given that IgG can be adsorbed to plastic solid surfaces, we studied 
whether immobilization of IVIg to the culture plate surface might artificially influence DC 
maturation by crosslinking FcγRIIa.  
METhODS
Reagents
Human IVIg preparations used were Intratect (kind gift from Biotest Pharma, Dreieich, 
Germany), Nanogam (Sanquin, Amsterdam, The Netherlands) and Kiovig (Baxter, Deerfield, 
IL). Human serum albumin (HSA, Sanquin) was used as protein control. Preparations were 
dialyzed against RPMI medium at 4°C to remove stabilizing agents and to obtain neutral 
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pH. Unless otherwise stated, IVIg concentration used was 10 mg/mL (0.06 M), which is similar 
to increments in serum IgG concentration in patients treated with IVIg at 1 to 2 g/kg for 
autoimmune disorders (10, 11). 
Generation of monocyte-derived DCs and isolation of mDCs
CD14+ monocytes were purified from blood of healthy volunteers using a negative selection 
immunomagnetic bead kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
the manufacturer’s instruction. The purity of CD14+ monocytes as analyzed by flow cytom-
etry, defined as 7AAD-CD14+ cells was 97±3%. CD14+ cells were then cultured in 6-wells plate 
(Greiner Bio-One, The Netherlands) with 10 ng/ml GM-CSF and 10 ng/ml IL-4 for 5 days in 
RPMI supplemented with penicillin, streptomycin and heat-inactivated 10% fetal calf serum 
(FCS), and were replenished every 2 days. At day 5, the cells exhibited the phenotypic 
characteristics of DC (CD1a+DC-SIGN+CD14-). BDCA1+CD20- mDCs were purified from blood 
of healthy volunteers by positive selection with PE-conjugated anti-CD1c mAb and anti-PE 
MACS-beads, after depletion of B cells with CD19-conjugated MACS-beads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) (12). The purity of mDCs as analyzed by flow cytometry was 
92±8%.
Cell cultures
Immature moDCs harvested at day 5 or freshly isolated blood mDCs were cultured (80.000 
cells/200 µl) in medium (RPMI supplemented with penicillin, streptomycin and 10% FCS), 
either or not supplemented with IVIg (10 mg/ml) or HSA (4.5 mg/ml), for 24 hours in a 96-wells 
round bottom plate (Corning Costar, Sigma Aldrich, St. Louis, MO). When indicated, LPS (1 
µg/ml, Ultrapure, Invivogen, San Diego, CA) was added to the cultures after 3 hours of initial 
treatment with IVIg or HSA. To prevent IgG binding to the plate surface, wells were pre-
incubated with 200 µl 0.05% poloxamer 407 (Sigma, St. Louis, MO) or heat-inactivated FCS at 
4 °C for 24 hours and aspirated before cells were transferred into the wells. To assess the role 
of activating FcγRIIa on DC maturation by IVIg, we blocked FcγRIIa by pre-incubating the 
cells for 30 min with anti-CD32a blocking antibody (5 µg/ml; Clone IV.3, StemCell technol-
ogy), after which medium, IVIg or HSA were added for the final 24 hour incubation.
Antibodies and flowcytometry
Cells were labeled with anti-CD1a-PE, anti-CD14-PE-Cy7 (both eBioscience), anti-HLA-DR-
APC-Cy7 (BD Biosciences, San Jose, CA), anti-CD83-APC, anti-CD86-Pacific blue (both 
from Biolegend, San Diego, CA), anti-CD80-FITC (Beckman, Brea, CA), and 7-AAD (BD 
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Biosciences) and measured by flow cytometry (FACsCanto, BD Biosciences). Analyses were 
performed by FACS Diva software (BD Biosciences). 
ELISA
Cytokines were quantified in cell-free supernatants using IL-10 and IL-12 ELISA kits (Ready-
set-go, eBioscience).
Allogeneic T-cell stimulation
To determine their T-cell stimulatory ability, moDC were harvested, extensively washed to re-
move IVIg, and co-cultured in 96-wells plates with 1.5x105 allogeneic CD4+ T cells at DC:CD4+ 
T cell ratios of 1:10, 1:20 or 1:40. After 4 hours, 5µg/ml brefeldin A was added, and 16 hours 
later cells from several wells were pooled and stained for surface expression of CD3 and 
CD4, fixed and permeabilized (Fix and Perm cell permeabilization kit, An der Grub, Vienna, 
Austria), and stained intracellularly for IL-2, IFNγ and CD137. At least 4x105 CD4+ T cells were 
measured by flowcytometry to reliably assess intracellular expression of IL-2, IFNγ and CD137. 
CD4+ T cells were purified from PBMC isolated from a buffy coat obtained from a healthy 
blood bank donor using the negative CD4 selection kit of Miltenyi Biotec. 
Statistical analysis
Differences between medium, IVIg or HSA were pair-wise analyzed by using the Student’s 
T-test. Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, 
San Diego, CA).  Data are expressed as mean±SEM. 
RESUlTS
IVIg stimulates human DC maturation 
IVIg (10 mg/ml) added to immature moDC for 24 hours significantly enhanced CD80, CD86, 
CD83 and HLA-DR expression compared to control conditions without IVIg or in the presence 
of HSA (Figure 1A). Using 25 mg/ml IVIg, we found similar effects (data not shown). Expres-
sion of the co-stimulatory molecules was further increased after 48 hours and the stimulatory 
effects of IVIg disappeared (data not shown). However, IVIg did not modulate LPS-induced 
maturation of moDC (Figure 1B) or LPS-stimulated IL-12 or IL-10 production (Figure 1C). The 
observed suppression of IL-12 secretion was not specific for IVIg since it was also observed 
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upon addition of HSA, and should therefore be regarded as non-specific inhibition caused 
by addition of a high amount of protein. When lowering the LPS concentrations to 0.5 - 0.001 
µg/ml, we still did not find any effect of IVIg on LPS-mediated moDC maturation (data not 
shown). Stimulation of spontaneous moDC maturation was also found when moDC were 
cultured with other IVIg brands (Figure 1D). Similar to its effects on moDCs, IVIg stimulated 
freshly isolated CD1c+ mDC maturation (Figure 1E). Our data demonstrate that IVIg does not 
inhibit spontaneous or LPS-induced maturation or cytokine production of human DC, but 
instead stimulates spontaneous maturation.
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fIGURE 1 . IVIg stimulates maturation of human mDC, but does not affect LPS-driven maturation. 
A) moDCs were generated by culturing human monocytes with 10 ng/ml GM-CSF and 10 ng/ml IL-4. At 
day 5, cells were harvested and 80,000 cells/200 μl were cultured in medium alone, with IVIg (10 mg/ml = 
0.06 M), or with an equivalent molar concentration of HSA (4.5 mg/ml = 0.06 M), for 24 hours in a 96-wells 
round bottom plate (n=9). B) moDCs were stimulated with LPS (1 μg/ml) after 3 hours of pre-culture with 
medium, IVIg or HSA, and cultured for an additional 24 hours (n=4). Supernatants were harvested thereafter 
and C) IL-12 and IL-10 production were measured by ELISA (n=10). D) moDCs were treated with Intratect, 
Nanogam or Kiovig (all at 10 mg/ml), HSA (4.5 mg/ml) for 24 hours. E) CD19-CD1c+ mDCs were purified from 
blood of healthy donors and cultured with medium alone, IVIg (10 mg/ml), or HSA (4.5 mg/ml) for 24 hours. 
Maturation markers were measured by flow cytometry (n=9). * p<0.05, ** p<0.01, compared to CTRL and 
HSA, Student’s paired t-test. Data are shown as means ± SEM from the indicated numbers of independent 
experiments. 
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Artifactual IgG surface binding induces DC maturation
In order to study whether IVIg stimulates DC maturation by binding to the plastic surface 
of the culture plates and therefore mimics immune complexes, we have first blocked the 
wells with poloxamer 407 at 0.05%, which is the lowest concentration capable of prevent-
ing IgG binding to plastic (9). However, we found that poloxamer 407 strongly induces DC 
maturation after 24 hours of culture (Figure 2), and therefore we continued by pre-coating 
the wells with FCS overnight to block IgG adsorption. FCS was used because of its high 
protein content and its presence in the culture medium in all conditions. Pre-treatment of 
the wells with FCS did not directly affect moDC maturation (Figure 3A). However, FCS coat-
ing abrogated induction of co-stimulatory molecule expression by IVIg, although expression 
of HLA-DR was still somewhat enhanced, suggesting that moDC maturation was largely 
caused by artifactual binding of IVIg to the culture plastic. Since DC recognizes immobilized 
IgG via FcγRIIa (13), we investigated the effect of blocking FcγRIIa. FγRIIa blocking on moDC 
cultured in non-FCS-pre-coated wells significantly abrogated the stimulatory effect of IVIg 
on moDCs, supporting that stimulation of moDC maturation by IVIg was exerted by binding 
of immobilized IgG to the activating FcγRIIa on moDCs (Figure 3A).
Finally, we determined the effect of IVIg on the T-cell stimulatory ability of moDC. MoDC 
were cultured in the presence or absence of IVIg for 24 hours, and after washing moDC 
to remove IVIg, allogeneic CD4+ T cells were added. To detect allo-reactive CD4+ T cells, 
expression of activation-induced CD137 was determined after 24 hours of co-culture (14, 
15). MoDC stimulated allogeneic CD4+ T cells in a dose-dependent manner (Figure 3B), 
Figure 2 
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fIGURE 2 . Poloxamer 407 induces DC maturation.
To prevent IgG binding to the plate surface, wells from 96-wells round bottom plate were pre-coated with 
0.05% poloxamer 407 in PBS overnight at 4 °C after which PBS was removed. moDCs were generated by 
culturing human monocytes with 10 ng/ml GM-CSF and 10ng/ml IL-4. At day 5, cells were harvested and 
80.000 cells/200 μl were added to wells with or without pre-coating with 0.05% poloxamer 407 and culture 
for 24 hours. * p<0.05, **< 0.01 compared to CTRL, Student’s paired t-test. Data are shown as means ± SEM 
of 4 independent experiments.
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and the cytokine-producing T cells resided within the CD137-expressing fraction, confirming 
that CD137 expression adequately distinguishes allo-responding CD4+ T cells (Figure 3C). 
Concordant with the effects of IVIg on co-stimulatory molecule expression, we found that 
moDC that were pre-cultured in the presence of IVIg activated allogeneic CD4+ T cells 
markedly better compared to moDC that were pre-cultured in the absence of IVIg (Figure 
3B). In contrast, moDC pre-cultured with IVIg in FCS-coated wells did not show enhanced 
allogeneic CD4+ T-cell stimulatory ability. Collectively, these data show that upregulation of 
Figure 3 
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fIGURE 3. The stimulatory effect of IVIg on DC maturation is due to immobilization of IgG. MoDCs were 
generated by culturing human monocytes with 10 ng/ml GM-CSF and 10 ng/ml IL-4. At day 5, cells were 
harvested and 80.000 cells/200 μl were either or not pre-cultured with anti-CD32a (10 μg/ml) for 30 
minutes, after which IVIg (10mg/ml) or HSA (4.5mg/ml) were added to the culture for an additional 24 
hours. To prevent IgG binding to the plate surface, wells were pre-coated with 100% fetal calf serum (FCS) 
overnight at 4 °C after which FCS was removed before DCs were transferred to these wells and cultured 
in the presence or absence of IVIg or HSA (denoted in the graphs by ‘FCS-coating’). A) After 24 hours 
maturation markers were measured by flow cytometry. * p<0.05, compared to CTRL and HSA, Student’s 
paired t-test. Data are shown as means ± SEM of 4 independent experiments.  B) After 24 hours moDC 
were harvested, washed, and thereafter co-cultured for 20 hours in 96-wells plates with 1.5x104 allogeneic 
CD4+ T cells at DC:CD4+ T cell ratios of 1:10, 1:20 or 1:40. During the last 16 hours brefeldin A was added to 
enable intracellular cytokine detection. Allogeneic CD4+ T cell activation was determined by measuring 
activation-induced CD137-expression. A representative experiment is shown. C) Intracellular cytokine staining 
demonstrates that all CD4+ T cells that produce IL-2 and IFNγ in response to allogeneic moDC reside within 
the CD137-expressing cells. 
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co-stimulatory molecule expression and stimulation of allogeneic T-cell stimulatory capacity 
of DC by IVIg in cell culture results from artifactual binding of IgG to the cell culture plate.
DISCUSSION
In the current study, we re-investigated the effects of IVIg on human DC maturation, cytokine 
production, and allogeneic T-cell stimulatory capacity reported by Bayry and colleagues 
(5). Consistent with recent studies on the effects of IVIg on DC differentiation (7, 8), we 
did not observe inhibition of DC, but instead stimulation of the spontaneous maturation of 
both moDCs and blood-derived mDCs by IVIg. In addition, IVIg enhanced the capacity of 
moDC to stimulate allogeneic T cells, similar to the observations of Ballow et al who added 
IVIg to DC during the differentiation from monocytes (8). However, we found no evidence 
for inhibition of LPS-stimulated DC maturation. Interestingly, the stimulatory effect of IVIg 
on the expression of co-stimulatory molecules on DC was abrogated when IVIg binding to 
plastic surface was blocked, suggesting that immobilization of IgG to plate surface caused 
crosslinking of activating FcγRIIa on DCs. Supporting this, when we blocked FcγRIIa ligation, 
stimulation of DC maturation by IVIg was completely abrogated. Apparently, although 
FcγRIIa and FcγRIIb are both expressed on human DC and are probably simultaneously 
ligated by immobilized IgG, the net effect is DC activation, similar to the observations made 
by Boruchov et al (13). Likewise, when binding of IVIg to the culture plate was prevented, 
IVIg did not modulate the T-cell stimulatory capacity of moDC. Collectively, our results 
indicate that adsorption of IgG to the culture plastic significantly influences studies on the 
effects of IVIg on DC maturation.
In agreement with Bayry et al. (5), we observed suppression of LPS-stimulated IL-12 pro-
duction by IVIg. However, this effect appeared to be non-specific, as HSA showed similar 
inhibition. Moreover, we did not observe any modulation of LPS-driven IL-10 secretion, as has 
been previously shown. 
Differences between the study of Bayry et al. (5) and our study, such as the use of different 
IVIg brands, different concentrations of IVIg, and different brands of cell culture plates, may 
account for the opposite results. Bayry et al. (5) added 25 mg/ml IVIg to moDC in vitro, 
while we used 10 mg/ml IVIg, since the increments in serum IgG concentration we observed 
in patients treated with IVIg at 1 to 2 g/kg are about 10 mg/ml (10, 16). However, when we 
tested the effect of 25 mg/ml IVIg on DC maturation, we also found stimulation, and not 
inhibition, of DC maturation. In addition, we and Bayry et al. (5) both tested several brands 
of IVIg. However, it is unclear whether different brands of culture plastic were used, and if 
IgG adsorption to plastic surfaces differs between different polystyrene based surfaces (9). 
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Speculations 
Our results show that IgG surface binding may be a potential artifact when studying the 
effects of IVIg on DC. This warrants for careful study design and critical interpretation of 
results of cell culture studies on the effects of IVIg on cells expressing FcγRs. In most previous 
in vitro studies concluding that IVIg activates human or murine DC (6, 8, 17-20), macro-
phages (21), or neutrophils (22), no precaution was taken to prevent IgG-adsorption to 
the culture plastic. Therefore, these studies did not distinguish between activation caused 
by soluble IgG present within IVIg either in monomeric, dimeric, or polymeric form, and 
artifactual activation by surface-bound IgG. Interestingly, several of these studies showed 
that activation of the cells by IVIg was mediated by activating FcγRs (17-19, 21, 22), like in 
the present study. Our observations demonstrate that prevention of IgG binding to the solid 
surface of the culture plates is required to obtain conclusive results from in vitro studies on 
the effects of IVIg on cells that express activating FcγRs. For this purpose, proteins like human 
serum albumin (23) or bovine serum albumin, protein-containing solutions like FCS or human 
serum, or surfactants such as poloxamer 407 (9), can be used. Importantly, it should first be 
determined which of the potential blocking agents is compatible with the cell type studied. 
Supporting our recommendation, studies that took precautions to prevent adsorption of 
IgG to the culture plastic demonstrated that IVIg does not directly stimulate neutrophils 
functions in vitro (9, 23).  
The final conclusion from our study regarding the direct effect of IVIg on human DC must 
be that IVIg in itself does not modulate their co-stimulatory molecule expression, allogeneic 
T-cell stimulatory capacity, or cytokine production. This conclusion is supported by a recent 
study showing that IVIg does not modulate expression of co-stimulatory molecules on mu-
rine bone marrow-derived DC, but instead inhibits antigen presentation resulting in reduced 
antigen-specific T cell responses, by interference of IVIg with immune complex binding to 
activating FcγRs expressed on DCs (24).
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ABSTRACT
Intravenous immunoglobulin (IVIg) preparations are widely used for anti-inflammatory ther-
apy of autoimmune and systemic inflammatory diseases. Hyperimmunoglobulins enriched 
in neutralizing antibodies against viruses can, in addition to their virus-neutralizing activity, 
also exert immunomodulatory activity. Previously, we observed that Cytotect®, an anti-
CMV hyperimmunoglobulin, was less effective in suppressing human T-cell responses in vitro 
compared to Hepatect® CP, an anti-HBV hyperimmunoglobulin. We hypothesized that the 
poor immunomodulatory activity of Cytotect® results from treatment with β-propiolactone 
during the manufacturing process. The manufacturer of these hyperimmunoglobulins has 
now introduced a new anti-CMV hyperimmunoglobulin, called Cytotect® CP, in which 
β-propiolactone treatment is omitted. Here we show that Cytotect® CP inhibits PHA-driven 
T-cell proliferation and cytokine production with similar efficacy as Hepatect® CP, whereas 
the former Cytotect® does not. In addition, Cytotect® CP inhibits allogeneic T-cell responses 
better than Cytotect®. Our results advocate the use of hyperimmunoglobulins that have 
not been exposed to β-propiolactone in order to benefit from their immunomodulatory 
properties.
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INTRODUCTION
Intravenous immunoglobulins (IVIg) have anti-inflammatory properties and are commonly 
used for the treatment of autoimmune and systemic inflammatory diseases (1, 2). IVIg 
preparations enriched in neutralizing anti-viral antibodies (hyperimmunoglobulins) are used 
for prevention of viral infections. We (3) and others (4) have previously shown that hyperim-
munoglobulins enriched in neutralizing antibodies against CMV or HBV also exert immu-
nomodulatory activity in addition to their virus-neutralizing activity. However, we observed 
that Cytotect®, an anti-CMV hyperimmunoglobulin, was less effective in suppressing human 
T-cell responses in vitro compared to Hepatect® CP, an anti-HBV hyperimmunoglobulin, 
both manufactured by Biotest AG (3). We assumed that the difference in immunomodula-
tory capacity between these two hyperimmunoglobulins was related to differences in their 
manufacturing processes. While Hepatect® CP is virus-inactivated by treatment with ca-
prylic acid, tri-n-butyl phosphate and polysorbat 80, virus-inactivation of Cytotect® includes 
treatment with β-propiolactone, which influences the conformation of IgG by covalent 
modification of amino-groups (5).
Biotest AG has now introduced a new anti-CMV hyperimmunoglobulin, called Cytotect® 
CP, which is manufactured according to the same process as Hepatect® CP, omitting 
β-propiolactone treatment. The aim of the current study is to evaluate the T-cell inhibitory 
capacity of Cytotect® CP in comparison to the former Cytotect® and to Hepatect® CP.
MATERIAlS AND METhODS
Hyperimmunoglobulins and human serum albumin
Cytotect®, Hepatect® CP and Cytotect® CP were obtained from Biotest AG, Dreieich, 
Germany and Human serum albumin (HSA) was purchased from Sanquin (Amsterdam, 
The Netherlands). All agents were dialyzed against RPMI culture medium (Gibco) at 4°C to 
remove stabilizing agents and to obtain physiological pH. 
Cell cultures
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient centrifuga-
tion from buffy coats of six different blood bank donors. Human splenocytes were isolated 
from splenic tissue derived from a multi-organ donor, and mononuclear cells (MNC) were 
isolated by Ficoll gradient centrifugation. PBMC (5x104) in 200 µl RPMI supplemented with 
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10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin, were stimulated 
by addition of phytohemagglutinin (PHA; Sigma) at a final concentration of 5 µg/ml, or by 
addition of 5x104 human splenic MNC. After 5 days of culture in the absence or presence of 
dialyzed hyperimmunoglobulins (5, 10 or 15 mg/ml) or HSA (7 mg/ml; which controls for the 
addition of protein in a molar concentration similar to 15 mg/ml of the dialyzed hyperim-
munoglobulins), 50 µl of culture supernatant was harvested to determine IFN-γ production, 
and 0.5 µCi [3H]-thymidine was added. Eighteen hours later, T-cell proliferation was assessed 
by [3H]-thymidine incorporation into the cells. IFN-γ levels in supernatants were determined 
by ELISA (Invitrogen Life Technologies) according to the manufacturer’s instructions. Each 
condition was tested in triplicate from which means were calculated. These means were 
used in statistical analyses.
Statistical analysis
Results are depicted as means and SEM of 6 independent experiments with PBMC from 6 
different subjects. Differences in measured variables between culture conditions were pair-
wise analyzed by the Wilcoxon Signed-Rank Test using SPSS version 20. p-values <0.05 were 
considered to indicate significant differences. 
RESUlTS
Effects of hyperimmunoglobulins on human T-cell responses to PHA
PBMC were stimulated by PHA for 5 days in the presence of either Cytotect®, Hepatect® 
CP or Cytotect® CP, and proliferation of T cells was assessed by [3H]-thymidine incorpora-
tion. In accordance with our previous findings (3), Cytotect® did not inhibit PHA-driven hu-
man T-cell proliferation, while Hepatect® CP significantly suppressed PHA-stimulated T-cell 
proliferation at all concentrations tested (5-15 mg/ml) (Figure 1A). Interestingly, the new 
anti-CMV hyperimmunoglobulin formulation (Cytotect® CP) inhibited PHA-stimulated T-cell 
proliferation to a similar extent as Hepatect® CP did. Importantly, human serum albumin 
(HSA) did not inhibit T-cell proliferation, implying that inhibition of T-cell proliferation is not 
solely caused by the addition of protein to the cell cultures. The differences in T-cell suppres-
sive ability between the old and new anti-CMV hyperimmunoglobulin formulations were 
confirmed at the level of IFN-γ production, which was significantly suppressed by Hepatect® 
CP and Cytotect® CP, but not by Cytotect® (Figure 1B). Collectively, these data show that 
Cytotect® CP can successfully inhibit mitogen-stimulated human T-cell activation.
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Effects of hyperimmunoglobulins on human T cells upon allogeneic 
stimulation
Subsequently, we compared the effect of the hyperimmunoglobulins on T-cell activation af-
ter allogeneic stimulation by splenocytes. After a 5 day co-culture of PBMC and allogeneic 
human splenocytes, we found that all three hyperimmunoglobulin reduced T-cell prolifera-
tion (Figure 1C). Thus, while Cytotect® did not inhibit PHA-stimulated T-cell proliferation and 
cytokine production, it did suppress allogeneic T-cell activation, which was in accordance 
with our previous findings (3). However, at all concentrations tested (5-15 mg/ml) Cytotect® 
CP inhibited allogeneic T-cell proliferation significantly stronger than Cytotect® (Table 1). 
Likewise, Cytotect® CP suppressed IFN-γ production by T cells upon allogeneic stimulation as 
effectively as Hepatect® CP did (Figure 1D), while Cytotect® inhibited IFN-γ secretion only 
partially when added at concentrations of 10 and 15 mg/ml, and no significant suppression 
was observed at a concentration of 5 mg/ml. These data therefore show that Cytotect® CP 
more potently inhibits allogeneic T-cell responses than the previous anti-CMV formulation, 
Cytotect®.
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fIGURE 1 . Effect of hyperimmunoglobulins on human T-cell responses. 
Human PBMC (5x104) were stimulated with 5 µg/ml PHA (A-B) or by addition of 5x104 human splenic MNC 
(C-D) in the presence or absence of hyperimmunoglobulins or HSA. (A, C) After 6 days proliferation was 
assessed by [3H]-thymidine incorporation. (B, D) IFN-γ was determined in culture medium collected at day 
5 of the cultures. Data are depicted as means and SEM of 6 independent experiments with PBMC from 
different donors. * p < 0.05 compared to PHA-stimulated PBMC (A-B]) or splenocyte-stimulated PBMC (C-D) 
in the absence of hyperimmunoglobulins or HSA.
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DISCUSSION
The current study shows that the ability of Cytotect® CP to inhibit T-cell proliferation and IFN-γ 
secretion is equivalent to Hepatect® CP and significantly better compared to the former 
anti-CMV hyperimmunoglobulin formulation Cytotect®. In a previous study, we reported that 
a polyvalent IVIg formulation (Intraglobin® CP) has a similar potent T-cell inhibitory capacity 
(6). We propose that the differences in T-cell inhibitory effect between Cytotect® on the one 
hand and Hepatect® CP or Intraglobin® CP on the other hand are related to differences in 
their production process. In order to reduce viral contamination, Cytotect® is treated with 
β-propiolactone during the production process (7), while β-propiolactone treatment is not 
included in the production of Hepatect® CP and Intraglobin® CP. β-Propiolactone modifies 
IgG by covalent modification of amino-groups, thereby disturbing Fc-dependent functions, 
like Fcγ-receptor binding, protein A binding, and complement fixation (5). 
Recent studies suggest that IVIg has no direct effect on T cells, but rather modulates 
the activity of antigen-presenting cells (APCs) (8). IVIg can interfere with antigen uptake 
and presentation of antigenic peptides in MHC-molecules (9, 10). However, in allogeneic 
mixed-lymphocyte reactions (MLR), as were used in the present study, T cells do not so much 
respond to antigenic peptides presented on MHC-molecules, but rather to intact alloge-
neic MHC molecules, arguing against interference with antigen presentation as the main 
mechanism by which the hyperimmunoglobulins suppressed T-cell activation in MLR (11). In 
a previous study, we found that a main mechanism by which IVIg inhibits MLR responses is 
by stimulating depletion of APCs via stimulation of NK cell-mediated antibody-dependent 
cellular cytotoxicity (12). This mechanism requires binding of the IgG Fc-parts to Fcγ-receptor 
III on NK cells. The superiority of Cytotect® CP and Hepatect® CP compared to Cytotect® 
in suppressing allogeneic T-cell activation may therefore be due to reduced binding of 
β-propiolactone-treated IgG to Fcγ-receptor III on NK cells. Another mechanism by which 
IVIg can suppress allogeneic T- cell responses by IVIg involves activation of regulatory T cells 
(13), which is hypothesized to be mediated by specific peptides derived from the IgG Fc-
TABlE 1 . Effects of Cytotect® CP and Cytotect® on allogeneic T-cell proliferation 
  proliferation upon allogeneic stimulation
Cytotect® CP vs Cytotect® % inhibition1 P-value2
5 mg/ml 66% 0.028
10 mg/ml 72% 0.046
15 mg/ml 70% 0.046
1 The percentage of inhibition is defined as the average drop in proliferation when cultured in the presence 
of Cytotect® CP compared to Cytotect®. 
2 Depicted P-values were calculated in paired comparisons of [3H]-thymidine incorporation between 
cultures of allogeneic splenocytes and PBMC in the presence of the indicated concentration of either 
Cytotect® CP or Cytotect®. 
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part, called Tregitopes, that are recognized by regulatory T cells via MHC class II (14, 15). This 
mechanism may also be dysfunctional in case of Cytotect® due to chemical modifications 
of the Fc-part. 
Recently, it was shown that inhibition of PHA-induced T-cell activation by IVIg is caused by 
binding of immunoglobulins to PHA. IVIg thereby blocks the interaction between PHA and 
T cells, resulting in diminished T-cell activation (15). Likely, the altered conformation of the 
immunoglobulins present in Cytotect® diminishes their interaction with PHA, resulting in the 
observed inability of Cytotect® to inhibit PHA-driven T-cell proliferation. 
In conclusion, Cytotect® CP and Hepatect® CP have superior capacities to suppress 
human T-cell responses in vitro compared to Cytotect®. This difference is probably related 
to omission of β-propiolactone treatment from their production process. High-dose therapy 
with non-specific IVIg is effective in prevention of antibody-mediated rejection (16) and 
in treatment of acute rejection after kidney transplantation (17, 18). Likewise, treatment 
with hyperimmunoglobulins against HBV or CMV with the aim to prevent viral re-infection 
after organ transplantation is associated with less rejection episodes (3, 19-22). Based on 
our current data, we advocate the use of hyperimmunoglobulins that have not been ex-
posed to β-propiolactone for clinical management of CMV and HBV infection after organ 
transplantation in order to benefit from the immunomodulatory properties of these hyperim-
munoglobulins.
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Liver transplantation (LTx) has developed from an experimental treatment in the sixties to 
a standardized procedure for patients with end-stage liver disease since 1983. In the early 
years, most of the effort was put in improvement of short-term survival after transplanta-
tion. Thanks to improvements in terms of surgical  techniques, procurement, allocation and 
preservation of donor liver, risk stratifications of LTx candidates and peri-operative care after 
LTx, an excellent short-term survival has been achieved (one-year survival of >80%) (1, 2). 
In addition, advances in immunosuppressive drugs have contributed to a better short-term 
survival. However, with the better short-term survival, long-term complications of immuno-
suppressive agents have been uncovered, which include cardiovascular disease, renal 
insufficiency and malignancy. The increased risk for de novo cancer is of particular concern 
and in the first part of this thesis we have studied the incidence of this complication and in 
particular potential influences of implementation of different immunosuppressive regimens. 
1. De novo malignancy after LTx
The higher risk for the development of de novo cancer is a direct consequence of rela-
tive oversuppression of immune surveillance in order to prevent acute rejection. To assess 
whether the increased risk of cancer is related to a certain immunosuppressive regimen, in 
chapter 2 we have performed a retrospective study in our LTx cohort. First we explored the 
incidence of de novo cancer in our LTx patients and calculated the standardized incidence 
ratio. Here we found that the risk for developing cancer after LTx is 2.2-times higher com-
pared to the general Dutch population. This ratio is relatively low compared to other studies. 
The most common cancer types occurring after LTx were non-melanoma skin cancer and 
post-transplant lymphoproliferative disease (PTLD). The overall survival rate of patients who 
developed cancer was significantly lower compared to cancer-free patients (at 10 years: 
51% vs. 79%). However, patients who developed non-melanoma skin cancer and PTLD did 
not show a significantly lower survival rate compared to cancer-free patients. The rather 
good prognosis of PTLD in our center is possibly due to adequate treatment with rituximab, 
chemotherapy and reduction of immunosuppression. In contrast, patients who developed 
other cancer types, such as pulmonal, gastrointestinal or gynaecological cancer had a 
dramatically impaired survival rate (1-year survival rate of <30%). 
Since there is a delicate balance between effective prevention of rejection and overim-
munosuppression, we studied whether improvement of immunosuppressive regimens over 
the years has influenced the risk of de novo cancer over time. According to our expecta-
tions, the first period of LTx in our center (1989-1992) showed the highest incidence of de 
novo cancer. This may be due to aggressive immunosuppressive treatments used in the 
early years. After this initial period, a considerable decline of de novo cancer incidence was 
observed after each period of transplantation (1989-1992 > 1993-1996 > 1997-2000 > 2001-
2004). Strikingly, patients who were transplanted in the most recent time period included in 
168 ChAPTER 9
this study (2005-2007) showed a significant rise in the incidence of de novo cancer. Interest-
ingly, we found that the factor that was significantly associated with this increased cancer 
risk in recent years was the use of cyclosporine. Since cyclosporine therapy was also used in 
the earliest time periods, this finding suggests a change in the period after 2005 regarding 
the use of cyclosporine. Indeed, from 2005, a significant change has been made in terms of 
dosing strategy of cyclosporine compared to earlier time periods, which was dosing adjust-
ment based on 2-hour postdose levels (C2) instead of predose level (C0) monitoring. C2 
dosing strategy was introduced since C2 level was considered to be a better predictor of 
the area under the curve (AUC) of total cyclosporine drug exposure. However, our findings 
suggest that this dosing strategy might have led to overdosing of the immunosuppressant. 
Indeed, patients treated with cyclosporine-C2 showed significantly less rejection, suggest-
ing that C2 dosing strategy leads to relatively higher immunosuppression with consequently 
higher cancer rate. This effect was mainly seen during the induction phase (< 1 year).  Im-
portantly, cyclosporine does not only lead to increased incidence of de novo cancer, but 
also to more aggressive cancer with a higher mortality. Moreover, mainly younger patients 
were affected by cyclosporine in terms of cancer development, while younger patients 
in general have a lower risk. Therefore, our data suggest that cyclosporine treatment is a 
significant determinant for de novo cancer development after LTx. Much more attention is 
needed for improving the long-term outcome of LTx patients by means of minimizing side 
effects of immunosuppressive drugs. Current drugs are very effective in suppressing immune 
responses; however, the balance towards oversuppression is unfortunately delicate, as can 
be seen from the results described in chapter 2. The principal goal is to use an immunosup-
pressive treatment that minimizes the risk of acute rejection while maximizing the long-term 
survival. The aim of current thesis was to investigate the immunomodulatory mechanisms of 
an alternative immunosuppressive agent: intravenous immunoglobulin (IVIg).
2. IVIg as alternative safe immunomodulating treatment
The idea to study the immunosuppressive properties of IVIg was born after the observation in 
our center that liver transplant patients treated with anti-HBs IVIg had significantly lower risk 
of cell-mediated acute rejection (3), which was later on confirmed in a multi-center study 
(4). Similar effects of IVIg have been observed in renal transplant patients (5). The ultimate 
aim of studies in this field is to unravel the immunomodulatory pathways stimulated by IVIg 
and to develop compounds that target these pathways. Such compounds may be suitable 
for safe immunosuppressive maintenance therapy after transplantation. 
In recent years, puzzle pieces have slowly come together regarding the mechanisms 
responsible for suppression of the cellular graft rejection. Inhibition of myeloid dendritic cells 
(mDCs) (3, 6, 7) and stimulation of regulatory T cells (Tregs) (8-10) seem to form the basis of 
the graft protective effect of IVIg. However, today, most of the evidence is derived from in 
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vitro and mouse studies, and evidence from patient studies is limited. Therefore, in the next 
part of the thesis we mainly focus on the effect of IVIg therapy on DC and Treg functions in 
patients in vivo and provide novel mechanistic insights.
3. IVIg modulates mDC function via IL-33-mediated Th2 cytokine 
secretion
A major breakthrough in our understanding of the mechanisms by which IVIg modulates 
antibody-mediated immune responses in the last decade is the finding that sialylated IgG 
binding to macrophages in the mouse spleen results in upregulation of inhibitory FcγRIIb re-
ceptors on effector macrophages, and thereby prevents their activation by auto-antibody 
immune complexes (11). Recent research has uncovered the missing link between these two 
types of macrophages by showing that IVIg stimulates IL-33 production in the spleen, which 
in turn induces IL-4 and IL-13 production by basophils, and thereby enhances expression of 
the FcγRIIb on effector macrophages in the joint in an auto-antibody mediated mice arthritis 
model (12) (see chapter 6, Figure 1). The question raised from this animal study is whether this 
mechanism plays a role in humans in vivo, since there are relevant physiological differences 
between mice and men, among which differences in FcγR expression patterns. In chapter 
3, we investigated whether IVIg therapy affects IL-33, Th2 cytokine and receptor expression 
in patients, and explored the causative links between these phenomena using human cells 
in vitro. We showed that immediately after IVIg infusion, IL-33 and the Th2 cytokines IL-4 and 
IL-13 plasma levels significantly increased in patients. Interestingly, the increase in plasma 
IL-33 was correlated with the rise in plasma IL-4 and IL-13. This finding suggests that IVIg 
stimulates a similar IL-33-Th2 cytokine pathway in humans as in mice. However, in contrast 
to mice, we did not find an increase in inhibitory FcγRIIb on myeloid cells, but a decrease in 
the activatory FcγRIIa on mDCs. 
To investigate whether there is a causal relation between the rise in IL-4 or IL-13 and the 
decrease in the activatory FcγRIIa on circulating mDCs, we treated mDCs with IL-4 or IL-13 
in vitro, which resulted in significantly decreased FcγRIIa expression. The reduced FcγRIIa re-
sulted in a decreased responsiveness of mDCs to immune complexes in terms of maturation 
and pro-inflammatory cytokine (IL-8, TNF-α) production. Thus, in patients, we found evidence 
that stimulation of the IL-33-IL-4/IL-13 pathway may play a role in the clinical benefits seen 
after IVIg treatment in antibody-mediated inflammation, e.g. antibody-mediated rejection. 
However, the final effect of this pathway is not enhancement of inhibitory FcγRIIb, as has 
been shown in mice, but reduction of the activating FcγRIIa expression. The observed differ-
ence in FcγR modulation by IVIg treatment in humans compared to mice is not surprising, 
since there are major fundamental differences in FcγRs expression pattern between mice 
and men. We further elaborated on this subject in chapter 6. 
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An important activator of cellular immune responses is the Th1 cytokine IFN-γ. In terms of 
allograft rejection, IFN-γ contributes to graft injury by direct cytotoxicity and indirectly by 
inducing migration and activation of macrophages and mDC. Moreover, IFN-γ increases 
MHC-class II molecules on APCs, which thus increases the effectiveness of antigen recogni-
tion and enhances graft rejection (13). Previously it has been demonstrated in mice that IVIg 
down-regulates the IFN-γ receptor subunit 2, IFNγR-2, on macrophages, thereby rendering 
the cells refractory to activation by IFN-γ (14). Interestingly, in chapter 3 we also provide 
evidence that this immunomodulatory mechanism is involved in the anti-inflammatory ef-
fects of IVIg in humans. Soon after IVIg treatment, IFNγR2 expression on circulating mDCs 
in patients is diminished. Inhibition of IFNγR2 expression on mDC by treatment with IL-4 and 
IL-13 was demonstrated in vitro. Upon suppression of IFNγR2 expression by IL-4 or IL-13, mDC 
maturation and the production of chemokine IP-10 (CXCL10) was dramatically hampered. 
In the context of allograft rejection, the latter effect is interesting, since intragraft produc-
tion of IP-10 has been shown in cardiac (15), lung (16) and renal (17) allograft rejection. 
Increased IP-10 resulted in attraction of activated T cells and macrophages bearing the 
corresponding chemokine receptor, CXCR3.  Inhibition of chemokine production may result 
in prolonged allograft survival, even when rejection already has begun. Additionally, IFN-γ 
not only induces IP-10, but also other chemokines, such as monokine induced by IFN-γ (Mig/
CXCL9) and IFN-inducible T-cell-α chemoattractant (I-TAC/CXCL11), that may also play a 
role in alloresponsive T cell attraction to the graft (18). 
Since we found that IFNγR2 is downregulated by Th2 cytokines IL-4 and IL-13 in vitro, we 
show for the first time that IFNγR modulation is another effect of the IVIg-IL-33-Th2 cytokine 
pathway. Together with our finding of FcγR modulation, we have demonstrated in patients 
and by using human cells in vitro that IVIg stimulates IL-33 production leading to a cascade 
of IL-4 and IL-13 production resulting in downregulation of FcγRIIa and IFNγR expression on 
mDC (see chapter 6, Figure 1). This cascade may ultimately suppress antibody-mediated 
as well as cellular immune reactions, which both contribute to acute and chronic rejec-
tion after LTx. Also, some cases of hyperacute rejection after LTx in ABO-incompatible liver 
transplant recipients have been described, which were successfully treated with high-dose 
IVIg (19). The underlying mechanism is not fully clear, but enhancement of autoantibody 
clearance by blocking FcRn, neutralizing anti-idiotypic effects and blocking of complement 
activation probably play a role (11, 20). In addition, our findings as demonstrated in chapter 
3 suggest that inhibition of immune-complex-mediated activation by FcγR modulation via 
IL-33-IL-4/IL-3 cascade may have an important contribution to this effect. 
Interestingly, it may be likely that the IVIg-IL-33 cytokine pathway is also (partially) respon-
sible for Treg expansion and enhanced suppressive capacity. This will be further discussed 
in the next paragraph. 
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4. IVIg enhances Treg activation and suppressive capacity in patients
Tregs are the key players in the maintenance of self-tolerance. Many studies have estab-
lished the involvement of natural Tregs in controlling autoimmunity, inflammatory disorders, 
and immune responses to tumors and various infectious agents (21). Importantly, a critical 
role for Tregs in the induction and maintenance of transplant tolerance by suppressing al-
loreactive T cells has been established in experimental transplantation models (22-32) and 
patient studies (33-36). Interestingly, over the last few years, accumulating evidence has 
shown that Treg activation and suppressive function can be induced by IVIg in vitro and 
in experimental animal models, and this effect may contribute to the anti-inflammatory 
effects of IVIg. The first evidence of a positive effect of IVIg on Tregs was provided by in 
vitro experiments. By culturing human CD4+ cells with IVIg in vitro, increased expression of 
FOXP3, TGF-β and IL-10 in CD4+CD25+ Tregs and increased suppressive function were found 
(9). Also, IVIg enhances the number of FOXP3+ T cells among memory CD4+ T cells in vitro 
(37). Following these in vitro observations, several studies in animal models have shown 
that IVIg treatment activates Tregs, stimulating their expansion and/or suppressive capacity 
and thereby preventing the development of inflammatory diseases. These animal models 
include skin transplant rejection (38), experimental autoimmune encephalomyelitis (8) and 
herpes simplex virus-induced encephalitis (39). However, whether this phenomenon holds 
true in humans is largely unknown. To explore this clinically important question, in chapter 
4, we have studied whether IVIg can induce Treg activation in patients and whether it can 
enhance Treg suppressive capacity ex vivo by collecting blood from IVIg-treated patients 
before and after IVIg treatment at different time points. We did not include LTx patients 
who received anti-HBs IVIg, since those patients are on conventional immunosuppressive 
drug treatment, known to inhibit Tregs (40). Instead, we have included patients who were 
treated with IVIg as mono-therapy for several autoimmune diseases and immunodeficient 
patients (see chapter 4, Table 1A and 1B). In exceptional cases, these patients were co-
treated with corticosteroids; but we did not see any significant influence of this drug on Treg 
activation compared to patients not treated with corticosteroids. In this study, we found 
that IVIg enhanced selectively the activation status of circulating Tregs, as reflected by 
increased FOXP3 and HLA-DR expression, while it did not affect conventional T cells. Ex 
vivo, we demonstrated that IVIg enhanced the suppressive capacity of circulating Tregs 
nearly two-fold one week after IVIg infusion. Interestingly, a stimulatory effect of IVIg on Tregs 
was only found in patients who were treated with high-dose IVIg, and not low-dose. This 
observation confirms the generally accepted hypothesis that a high-dose IVIg treatment 
regimen is required in order to gain anti-inflammatory activity. The high-dose requirement 
supports the idea that there is only a minor fraction within IVIg that has immunosuppressive 
activity. From this study we conclude that IVIg not only enhances Treg function in mice, but 
also in humans in vivo. Thus, there is growing evidence that IVIg can enhance Treg function 
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in experimental animal models, in vitro and, as we now have shown, in patients, which may 
contribute to the clinical benefits seen in patients with inflammatory disorders treated with 
IVIg. Since conventional immunosuppressive drugs used for treating autoimmune diseases 
and allograft rejection, in particular calcineurin inhibitors, suppress both Teff and Tregs (40-
47), selective activation of Tregs by IVIg, but not Teff, suggests that IVg may be superior to 
classical immunosuppressive drugs.
Next, we have performed pilot studies in vitro aimed at investigating the mechanism 
by which IVIg stimulates Tregs. We have isolated human CD4+CD25+ Tregs from peripheral 
blood of healthy subjects and treated them with IVIg or HSA with or without the presence 
of allogeneic monocyte-derived DCs (moDCs). Interestingly, from our pilot study we have 
demonstrated that IVIg did not directly stimulate Tregs, but significantly enhanced early-
activation marker CD69 expression on Tregs in the presence of moDC (Figure 1, unpublished 
data). These preliminary data suggest that IVIg can activate Tregs via an mDC-dependent 
manner. Indeed, several recent studies using mouse models or in vitro studies have shown a 
DC-dependent activation of Tregs by IVIg (see chapter 6, Figure 3). A recent study by Trinath 
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CD4+CD25+ Tregs were isolated from healty blood donors and incubated with medium, IVIg (10 mg/ml) or 
HSA (4.5 mg/ml) with or without the presence of immature monocyte-derived dendritic cells (moDCs), 
which were generated by culturing human monocytes with 10 ng/ml GM-CSF and 10 ng/ml IL-4 and cultured 
for 5 days. Cells were co-cultured in a ratio of Tregs: moDC = 50,000:25,000. After 24 h or 96 h, cells were 
harvested and CD69 activation marker was measured on CD4+CD25+ cells by using flow cytometry.  N=4, * 
P<0.05, Student’s paired t-test
SUMMARy AND GENERAl DISCUSSION 173
C
h
A
P
T
E
R
 9
et al. has shown a central role for mDCs in expanding Tregs in an EAE mouse model (48). 
The authors showed that IVIg enhances prostaglandin E2 synthesis by moDCs via induction 
of cyclooxygenase 2, which subsequently stimulates expansion of Tregs. This mechanism 
partially depended on interaction of IVIg with DC-SIGN in a F(ab’)2-dependent manner. 
Another study showed that IVIg induced generation of antigen-specific Tregs from non-
Tregs by inducing tolerogenic DCs in an antigen-driven allergic airway model (49). Recently, 
an immunoreceptor tyrosine-based inhibition motif (ITIM)-linked C-type lecin receptor, the so 
called DC immunoreceptor, has been identified to be responsible for the induction of tolero-
genic DC via sialylated IVIg (50). Alternatively, an interesting hypothesis for DC-dependent 
Treg activation by IVIg is the identification of Tregitopes in human IgG. De Groot et al. 
have demonstrated that Tregs can be activated and expanded via the presentation of 
Treg-activating peptides derived from IgG, the so called Tregitopes, by APCs (51). However, 
arguing against the presence of Tregitopes, in studies in the HSE model, the authors showed 
that purified sialylated IgG was unable to induce Treg, even though sialylated IgG should 
contain Tregitopes (39). Therefore, other mechanisms are probably involved in Treg stimula-
tion by IVIg (see chapter 6, Figure 3). In our pilot study, we studied whether crosslinking of 
natural antibodies within IVIg that may react to molecules on Tregs, such as CD4, CD5, 
CD95, TCR and MHC (52, 53), by FcγR ligation on moDCs is a possibility. Therefore, we have 
co-cultured Tregs with monocytes that also express FcγRs. However, since co-culture with 
monocytes did not show similar activation, crosslinking is less likely to be the responsible 
mechanism.
With regard to the selectivity of IVIg for the activation of Treg, results from in vitro and ani-
mal model studies by other groups corroborate our finding (8, 9, 37, 38). Several hypotheses 
can be postulated why IVIg selectively activates Tregs, but not Teff. First, presentation of 
Tregitopes by APCs towards Tregs might explain the selectivity (51). Second, cytokines that 
specifically activate Tregs may play a role, for example TGF-β. IL-10 is probably not involved 
in this mechanism, as we did not find increased IL-10 after IVIg treatment as described in 
chapter 3. Another interesting cytokine that may play a role is IL-33. It is conceivable that 
Treg expansion and enhanced suppressive capacity are linked to the IVIg-IL-33-Th2 cytokine 
pathway, as described in chapter 3 and reviewed in chapter 6. Three recent studies (54-56) 
in mice have shown that IL-33 not only induces Th2 cytokine production, but also expands 
CD4+FOXP3+ Tregs. Using an MHC-mismatched allogeneic heart transplant model (54, 55), it 
was shown that IL-33 treatment after transplantation resulted in prolonged cardiac allograft 
survival. This protection was dependent on host ST2 expression, the receptor for IL-33 (54). 
Interestingly, heart grafts (54, 55) and spleens (55) from IL-33-treated mice had increased 
numbers of FOXP3+ cells, and depletion of natural Tregs from recipients prior to trans-
plantation eliminated any therapeutic benefit from IL-33 therapy, implying that Tregs are 
indispensable for IL-33-mediated protection from  allograft rejection (54). In a chronic colitis 
model, it was demonstrated that IL-33 possibly serves as a cofactor for TGF- β-mediated Treg 
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differentiation (56).  Since our group previously found that protection against skin allograft 
rejection by IVIg depends on Treg activation and expansion (38), and we now observed 
that IVIg induced IL-33 production in humans in vivo (chapter 3), induction of IL-33 by IVIg 
may potentially cause the enhanced Treg suppressive capacity or expansion leading to de-
creased allograft rejection. It should be studied in the future whether this link indeed exists. 
5. The effects of IVIg on pro-inflammatory CD14+CD16++ monocytes
Throughout the years, investigators are continuously searching for new mechanisms of ac-
tion by which IVIg modulate immune responses. One of the mechanisms that has been 
recently presented is the reduction of the number of pro-inflammatory CD14+CD16++ 
monocytes (57). The amount of these cells are dramatically increased in some inflammatory 
diseases (e.g. Kawasaki disease, sepsis) and therefore reducing the numbers of these cells 
may be an important mechanism that contributes to the benefits of IVIg therapy seen in 
these patients. However, the authors have only studied patients who were treated with low 
“supplementary” doses of IVIg, while this mechanism should be studied in patients receiving 
high “immunomodulatory” doses. In chapter 5 we investigated the effect of IVIg on the 
numbers of circulating pro-inflammatory CD14+CD16++ monocytes in IVIg-treated patients 
and divided the patients into those who received low-dose (average 0.43 g/kg) and those 
who received high-dose (average 1.24 g/kg) IVIg. Consistent with Siedlar et al., we ob-
served a decrease in the number of inflammatory CD14+CD16++ monocytes who received 
low-dose IVIg. However, strikingly, we did not observe a significant effect on the numbers 
of pro-inflammatory monocytes in patients who received high-dose IVIg, while this patient 
group actually requires immunomodulation by IVIg. In addition, the authors suggested that 
reduced TNF -α production as a consequence of lowered number of CD14+CD16++ mono-
cytes is the mechanism behind the anti-inflammatory effect of IVIg. However, in contrast, 
when measuring TNF-α level in plasma, we observed that the level was not decreased after 
IVIg treatment. Therefore, from our observation we postulate that the beneficial clinical 
effect of high-dose IVIg treatment seen in patients with inflammatory disorders cannot be 
explained by a reduction of the frequency of pro-inflammatory CD14+CD16++ monocytes. 
6. Novel insights into the mechanisms of action of IVIg in mice: 
translatable to humans? 
Growing evidence for several mechanisms of action of immunomodulation by IVIg exist. 
However, the majority of these findings have been identified in in vitro experiments or in ani-
mal studies. In chapter 3, 4 and 5, we explored several pathways by which IVIg modulates 
the immune system in humans in vivo. We found some similarities, but also some important 
differences. This latter is not surprising, since there are fundamental differences between the 
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immune systems of mice and men, and animal models may not represent the complexity 
of disease in the human situation. Remarkably, the consequences of these differences on 
the translation of the mechanistic insights in the anti-inflammatory activity of IVIg from mice 
to humans have not been thoroughly explored. In chapter 6 we reviewed several recently 
characterized anti-inflammatory mechanisms of IVIg, and explored whether evidence is 
available for involvement of these anti-inflammatory mechanisms of IVIg in humans. In ad-
dition, we discussed biological differences between mice and humans that may determine 
the translatability of these mechanisms from mice to men. The first evidence that the IL-33-
Th2 pathway might be stimulated in IVIg-treated humans comes from the observation by 
Anthony et al. who demonstrated that human DC-SIGN could replace its murine orthologue 
SIGN-R1 in the serum-induced arthritis mouse model (12). Importantly, in this chapter we 
questioned whether DC-SIGN is indeed the proper human orthologue of murine SIGN-R1, 
since the expression pattern of human DC-SIGN is highly different from that of murine SIGN-
R1. In addition, the question is whether human DC-SIGN can really recognize sialylated Fc-
molecules, as few recent studies have argued against an interaction (58, 59). Furthermore, 
we showed evidence that the postulated source of IL-33 upon IVIg administration in mice, 
marginal zone macrophages in the spleen, is absent in humans. We continued the discussion 
we started in chapter 3 where we discovered that IVIg did not upregulate the expression of 
inhibitory FcγRIIb in patients, which has been one of the key conclusions from recent murine 
studies on IVIg (12, 60, 61). Instead, we found that IVIg downregulated the expression of 
activating FcγRIIa. Importantly, mice do not possess an orthologue of FcγRIIa. The functional 
results of the downregulation of this activating receptor in humans are discussed in this 
chapter. Also, we describe similarities and disparities regarding the possible mechanisms of 
stimulation of Treg expansion and suppressive capacity by IVIg between mice and humans. 
In this chapter we recommend that, although murine studies on IVIg are highly valuable to 
identify causal relationships and to attain mechanistic insights, findings in animal models 
should be verified in humans treated with IVIg in order to draw clinically relevant conclu-
sions. Because IVIg is applied in the clinic, studying the immunomodulatory effects of IVIg in 
humans in vivo is a feasible option and ex vivo functional assays are achievable.
As illustrated, fundamental differences between the immune systems of men and mice 
may explain discrepancies found in the mechanism of action of IVIg using animal models 
and human materials. However, also contradicting data have emerged from in vitro stud-
ies using human cells. In the following chapters, we have uncovered some of the possible 
explanations for these controversies.
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7. Studies on the effects of IVIg on monocyte-derived DCs (moDCs) 
in vitro can be highly influenced by artifactual IgG immobilization
In chapter 3 we described an indirect effect of IVIg on DC activation and function by 
means of stimulation of Th2 cytokine secretion that modulates the expression of activation 
receptors. In order to study the direct effect of IVIg on DC, in chapter 7 we investigated 
the effect of IVIg on maturation, cytokine production and T-cell stimulatory capacity in 
vitro. It has been demonstrated by Bayry et al. that IVIg directly inhibit differentiation 
and maturation of monocyte-derived DCs (moDCs), while reducing IL-12 production and 
T-cell stimulatory capacity (6). In contrast to Bayry et al., in our experiments we did not 
find suppression of moDC activation, but instead stimulation of its maturation and T-cell 
priming capacity. The same effect could be found for freshly isolated mDCs. Our findings 
corroborate another report that showed stimulation of moDC differentiation by IVIg instead 
of inhibition (62). So, how can these controversial observations on the effects of IVIg on 
human DC maturation be explained? Given that IgG can be adsorbed to plastic surfaces 
and given that moDCs express FcγRs abundantly, we asked whether immobilization of IVIg 
to the culture plate surface might artifactually influence DC maturation by binding to FcγRs. 
To examine this we have used fetal calf serum to block potential binding sites for IgG to the 
plate surface. Indeed, when IgG immobilization was blocked, the stimulatory effect of IVIg 
on moDC maturation was abrogated. Since the previous in vitro studies did not take any 
precaution to prevent IgG adsorption to the culture plastic, the stimulatory effects reported 
may be a consequence of artifactual activation. When blocking FcγRIIa, we found that the 
artifactual activation of moDCs was also abrogated, which suggests activation of moDCs 
by binding of immobilized IgG to FcγRIIa. So for a better interpretation of the data and in 
order to provide consistency, we would like to recommend blocking binding sites of the solid 
plate surface for IgG when studying the effects of IVIg on cells expressing FcγRs. Regarding 
the direct effect of IVIg on human DCs, from this study we conclude that IVIg itself does not 
modulate the maturation of DCs directly.
8. The effects of IVIg on T-cell inhibitory capacity is influenced by the 
production process
In chapter 8 we explored another potential factor that can influence the immunomodula-
tory effect of IVIg, which is the manufacturing process. This might explain the differences 
between various brands of IVIg preparations. In a previous study, hyperimmunoglobulins 
against HBV Hepatect® CP showed a strong T-cell suppressive capacity, while an anti-CMV 
hyperimmunoglobulin, Cytotect®, did not (3). An important difference between Hepatect® 
CP and Cytotect® is the process of virus inactivation. While Hepatect® CP is virus-inac-
tivated by treatment with caprylic acid, tri-n-butyl phosphate and polysorbate 80, virus-
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inactivation of Cytotect® includes treatment with β-propiolactone, which influences the 
conformation of IgG by covalent modification of amino-groups. Recently, a new anti-CMV 
hyperimmunoglobulin has been introduced, named Cytotect® CP, which is not exposed 
to β-propiolactone and undergoes the same manufacturing process as Hepatect CP®. In 
order to study the influence of omitting β-propiolactone treatment on the immunomodula-
tory effect of IVIg, we have compared the effects of Cytotect® CP to the former Cytotect® 
and to Hepatect® CP on human T-cell proliferation and cytokine production. Here, we show 
that the ability of Cytotect® CP to inhibit T-cell proliferation and IFN-γ secretion is equivalent 
to Hepatect® CP and significantly better compared to the former anti-CMV hyperimmuno-
globulin formulation Cytotect®. One of the mechanisms behind this difference might be the 
modulation of the Fc-binding site of IgG by β-propiolactone, which may prevent its bind-
ing to FcγRs, for example FcγRIII on NK cells, which was previously shown to be responsible 
for depletion of antigen presenting cells in vitro (7). Thus, our current results show that the 
manufacturing processes can significantly influence the immunomodulatory effects of IVIg. 
This may explain discrepancies in published reports on the immunomodulatory effect of IVIg 
using different IVIg brands. 
9. Overall conclusion and future perspectives
Liver transplantation is a life-saving treatment for patients with end-stage liver disease. While 
over 50 years ago these patients were condemned to death, nowadays LTx is a standardized 
treatment for this significant patient group. Since patient’s short-term survival has strongly 
improved owing to improved surgical techniques and medical care, the next challenge in 
transplantation medicine is to improve the long-term survival. One major obstacle for long-
term survival improvement is the major side effects of current immunosuppressive drugs. 
Although approximately 20% of stable liver transplant recipients  can be withdrawn from all 
immunosuppression therapy and still maintain normal graft function and do not experience 
rejection (63-71), to date, there is no validated tool to identify these patients. Therefore, liver 
graft recipients are still mandated to use life-long immunosuppressive drugs. Because most 
of the long-term complications of LTx are due to side effects of immunosuppressive drugs 
rather than rejection, treatment strategies focus on maintaining a delicate balance be-
tween avoiding immunosuppressive drug toxicity and reducing the risk of acute rejection. 
A promising therapeutic candidate for reducing the toxicity of current immunosuppres-
sive agents is the implementation of IVIg as immunosuppressive treatment after LTx. It is firmly 
established that IVIg has potent anti-inflammatory activity that can modulate autoimmune 
and systemic inflammatory responses. Interestingly, increasing evidence suggests that IVIg is 
effective in preventing allograft rejection. Since long-term administration of IVIg has proven 
not to be accompanied by major side effects (72-74), including IVIg in immunosuppressive 
protocols after LTx is very attractive. In addition to available studies in animal models provid-
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ing mechanistic insights underlying the protection against graft rejection by IVIg, in this thesis 
we have provided new perspectives on the mechanisms of immunomodulation by IVIg in 
human situation. 
In this thesis we suggest that IVIg therapy represents a promising avenue for the develop-
ment of a safe immunosuppressive protocol after LTx. However, implementation of IVIg in 
maintenance immunosuppressive protocols after LTx still faces two obstacles: 1) there is a 
predicted global shortage of donated human plasma due to an increased plasma demand 
(75), and 2) IVIg treatment is accompanied by high costs. Therefore, in order to enable wide 
use of the therapeutic benefits from IVIg, it is of high importance to unravel the molecular 
interactions between IVIg and the human immune system. This may enable the design of 
biologicals or small molecule drugs that mimic the anti-inflammatory effects of IVIg that may 
be suitable for long-term immunosuppressive therapy after transplantation. In current thesis, 
we show that IVIg enhances Treg activation and suppressive capacity in patients. We and 
others show that Treg activation by IVIg is exerted via an indirect route, possibly via DCs (as 
discussed in subparagraph 4). In addition, via binding to cells present in lymph nodes, e.g. 
macrophages, IVIg induces IL-33 production, which eventually leads to FcγR modulation 
on mDCs. Understanding the molecular interaction between IVIg and the Treg-modulating 
cells as well as IL-33-producing cells may enable the identification and purification of the 
compound(s) of IVIg that induce(s) Treg activation and DC inhibition, respectively. For Treg 
stimulation, DC immunoreceptor (DCIR) is interesting (40), as described in chapter 6, but 
there is to date no evidence that this molecule is involved in the mechanism of action in 
humans. DC-SIGN is likely excluded as a candidate receptor via which IVIg induces IL-33 
production, as shown in chapter 3. Immunoprecipitation and mass spectrometry techniques 
may be used in order to identify the IVIg-binding receptor via which IVIg activates Tregs and 
inhibits DCs. Since the interactions are probably complex, it is likely that multiple interacting 
molecules may be identified. Identification of these receptors may enable the design of 
biological or small molecule drugs targeting these receptors.
With regard to clinical implementation of currently available IVIg preparations, clinical 
trials on high-dose IVIg therapy in liver transplant recipients should be the next focus. One 
of the first steps is to determine the optimal dose. Studies in PID patients suggest that serum 
IgG level needed to prevent infections may vary substantially from one patient to another 
(76, 77). In addition, the rise in serum IgG after high-dose IVIg treatment varies significantly 
between patients, as has been demonstrated in patients with Guillain-Barré (78) and CIPD 
(79). Therefore, determining the optimal serum IgG required for prevention of allograft rejec-
tion and the required IVIg dose to achieve that specific IgG level in liver transplant patients 
are important subjects to study. 
Furthermore, clinical trials on IVIg should include protocols minimizing current immunosup-
pressive drugs. Whereas IVIg may not entirely replace current immunosuppressive drugs, 
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it may allow dose reduction of conventional drugs such as tacrolimus and MMF. This may 
reduce the side effects of the current drugs.
Another growing aspect in current studies on IgG therapy is the replacement of intra-
venous administration of IgG by subcutaneous administration. Subcutaneous IgG (SCIg) 
preparations were already introduced in the 1980s in the US and Europe. However, the 
slow infusion technique and the low IgG concentrations in the preparations available at 
that time made SCIg less attractive and were therefore replaced by IVIg. However, ow-
ing to recent technical advances in IgG formulation, pure and highly concentrated SCIg 
preparations have been developed that have relatively low viscosity, and can therefore be 
infused relatively rapidly (80, 81). SCIg has advantages compared to IVIg, since it is easier in 
self-administration and therefore can be administered at home, which  improves quality of 
life and treatment satisfaction (82). Therefore, in future clinical studies using SCIg therapy in 
liver transplant recipients should be considered. 
In transplantation medicine, the ultimate goal is to acquire operational tolerance, de-
fined as acceptance of donor allograft without the need for immunosuppressive drugs, 
while retaining the ability to reject third party allografts (83). Since IVIg is able to modulate 
DCs and Tregs, which both play key roles in operational tolerance after organ transplanta-
tion (22, 84-86), IVIg may not only be capable to suppressing allograft responses, but also in 
promoting operational tolerance. Recent reports showing that IVIg can induce tolerogenic 
DCs that are able to induce antigen-specific Tregs in mice are promising (49, 50). Whether 
donor-specific tolerance can be achieved by IVIg therapy in liver allograft recipients is a 
subject for future studies.
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Sinds de eerste succesvolle levertransplantatie (LTx) in de jaren 80 is LTx uitgegroeid van 
een experimentele behandeling tot een gestandaardiseerde behandelingsprocedure voor 
patiënten met eindstadium leverfalen. In de beginjaren werd er veel inspanning verricht om 
de korte termijn overleving na LTx te verbeteren. Dankzij een aantal verbeteringen in o.a. 
chirurgische technieken en perioperatieve zorg is de korte termijn overleving significant ver-
beterd (1, 2). Echter, met deze verbetering kwamen al snel complicaties op de lange termijn 
aan het licht. Deze zijn met name het gevolg van het levenslange gebruik van immunosup-
pressiva wat gepaard gaat met ernstige bijwerkingen, waaronder hart- en vaatziekten, 
nierinsufficiëntie en maligniteit. De verhoogde kans op het ontwikkelen van maligniteit is 
een belangrijke complicatie. In de eerste deel van dit proefschrift hebben wij onderzoek 
gedaan naar de incidentie van deze complicatie en in het bijzonder is onderzocht of het 
gebruik van verschillende immunosuppressiva protocollen hierop invloed hebben gehad.
1. De novo maligniteit na levertransplantatie
De verhoogde kans op het ontwikkelen van kanker is een direct gevolg van een relatieve 
oversuppressie van het immuunsysteem om acute afstoting te voorkomen. Om te onder-
zoeken of deze verhoogde kans op maligniteit gerelateerd is aan een bepaald immuno-
suppressiva protocol, hebben we in hoofdstuk 2 een retrospectieve studie verricht in ons LTx 
cohort. Wij hebben gevonden dat LTx patiënten een 2,2-maal verhoogde kans hebben op 
het ontwikkelen van kanker na transplantatie in vergelijking met de algehele Nederlandse 
populatie. De meest voorkomende maligniteiten zijn de huidkanker (niet-behorend tot 
melanoom) en post-transplant lymphoproliferative disease (PTLD). De overlevingskans van 
patiënten die een maligniteit ontwikkelde was significant lager vergeleken met LTx patiën-
ten die geen maligniteit ontwikkelden (10-jaars overleving: 51% vs. 79%). 
Gezien er bij het gebruik van immunosuppressiva een delicate balans bestaat tussen 
het voorkomen van afstoting en over-immuunsuppressie, hebben wij bestudeerd of ver-
anderingen van de gebruikte immunosuppressiva protocollen door de jaren heen, waarbij 
doseringen worden geoptimaliseerd, hebben geleid tot een afname van de ontwikkeling 
van kanker. Wij toonden aan dat LTx patiënten getransplanteerd in de eerste periode van 
LTx in ons centrum (1989-1992) inderdaad een verhoogde incidentie hadden op de novo 
kanker, maar dat de incidentie geleidelijk afnam in patiënten die getransplanteerd werden 
in de daaropvolgende perioden. Echter, een verrassende bevinding was dat patiënten die 
getransplanteerd waren in de meest recente periode van deze studie, namelijk tussen 2005 
en 2007, juist weer een verhoogde incidentie van maligniteit vertoonden na LTx. Onderzoek 
naar risicofactoren wees uit dat de verhoogde kans op maligniteit geassocieerd bleek te 
zijn met het gebruik van cyclosporine. Gezien cyclosporine ook gebruikt werd in de voor-
gaande LTx perioden, suggereerde onze bevinding dat er in de periode van 2005-2007 een 
wijziging in het gebruik van cyclosporine was gebracht. Inderdaad, vanaf 2005 is de dosering 
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van cyclosporine veranderd en werd deze gebaseerd op het monitoren van bloedspiegel- 
waarden van dit immunosuppressivum. Oorspronkelijk werden doseringen van cyclosporine 
aangepast aan de bloedspiegel dat direct vooraf aan de volgende dosering is gemeten 
(C0). Echter, omdat de bloedspiegel 2 uur na dosering (C2) een betere voorspelling zou 
geven van de blootstelling aan het medicijn, is het protocol gewijzigd in het aanpassen 
van cyclosporine dosering op basis van de C2 bloedspiegel. Gezien patiënten die via deze 
methode cyclosporine behandeling kregen verhoogde kans op maligniteit vertoonden, 
vermoeden wij dat deze methode resulteert in een relatief hogere mate van immuunsup-
pressie. Deze hypothese wordt ondersteund door onze bevinding dat patiënten behandeld 
met cyclosporine-C2 een verlaagde incidentie van afstoting vertoonden. Een andere 
belangrijke bevinding is dat de gewijzigde cyclosporine dosering niet alleen resulteerde in 
een verhoogd risico op kanker, maar ook in agressievere tumoren met hogere mortaliteit. 
Daarnaast vonden wij dat met name jongere patiënten die cyclosporine gebruikten een 
verhoogde kans hebben op het ontwikkelen van maligniteit. Onze data suggereert dan 
ook dat cyclosporine een belangrijke determinant is in het ontwikkelen van kanker na LTx. 
Er behoeft meer aandacht te komen voor het verbeteren van de lange-termijn uitkomst 
na LTx door de bijwerkingen van immunosuppressiva te minimaliseren. Het algemene doel 
van de behandeling is het minimaliseren van de kans op acute afstoting en het maximalise-
ren van de lange termijn overleving. Huidige medicijnen zijn erg effectief in het onderdruk-
ken van de afweerrespons, maar de keerzijde is dat over-immuunsuppressie gevaren met 
zich meebrengt, zoals gedemonstreerd in hoofdstuk 2. Het doel van het huidige proefschrift 
is het onderzoeken van de immunomodulerende mechanismen van een alternatief immu-
nosuppressivum: intraveneuze immuunglobulinen (IVIg).
2. IVIg: een alternatieve en veilige immunomodulerende behandeling
Het idee om de immunomodulerende mechanismen van IVIg te onderzoeken is geboren 
in ons centrum na de constatering dat LTx patienten die behandeld zijn met anti-HBs IVIg 
een significant verlaagde kans hadden op acute afstoting (3, 4). Soortgelijke effecten van 
IVIg waren ook gevonden in niertransplantatiepatiënten (5). Het grote doel van studies op 
dit gebied is om de onderliggende immunomodulerende mechanismen van IVIg te ontra-
felen. Met deze kennis is het mogelijk om recombinante antilichamen of andere factoren 
te ontwikkelen die deze  anti-inflammatoire mechanismen op een soortgelijke wijze in gang 
kunnen zetten. Zulke recombinante factoren zouden gebruikt kunnen worden als veilige 
onderhoudsbehandeling ter voorkoming van afstoting na LTx. Gedurende de laatste jaren 
komen steeds meer puzzelstukken bij elkaar over het mechanisme dat verantwoordelijk is 
voor het afremmen van het cellulaire afstotingsproces. De inhibitie van myeloïde dendri-
tische cellen (mDCs) (3, 6, 7) en het stimuleren van regulatoire T cellen (Tregs) (8-10) lijken 
de basis te vormen voor het beschermend effect tegen afstoting. Echter, hedendaagse 
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studies naar deze mechanismen zijn vooral uitgevoerd in vitro of in muizenstudies. Bewijzen 
in IVIg-behandelde patiënten zijn echter maar beperkt. Om die reden hebben we ons in het 
volgende deel van dit proefschrift gericht op het bestuderen van de effecten van IVIg op 
DC en Treg functies in patiënten in vivo en brengen wij meer inzicht in nieuwe mechanismen 
van IVIg.
3. IVIg moduleert de functie van mDC door stimulatie van  IL-33-
gemedieerde Th2 cytokine secretie
In het laatste decennium is er een grote doorbraak gemaakt in ons begrip van het me-
chanisme waarop IVIg antilichaam-gemedieerde immuunreacties moduleert. Studies in 
muizen wezen uit dat door binding van gesialyleerde IgG aan “regulatoire” macrofagen in 
de milt  de expressie van inhibitoire FcγRIIb receptoren op perifere “effector” macrofagen 
wordt verhoogd, wat uiteindelijk leidt tot verminderde activatie door auto-antilichaam im-
muuncomplexen (11). Recent onderzoek heeft de ontbrekende schakel tussen deze twee 
cellen geïdentificeerd. Doordat IVIg IL-33 productie door myeloïde cellen stimuleert in de 
milt, worden basofiele granulocyten aangezet tot de productie van IL-4 en IL-13, wat uit-
eindelijk resulteert in verhoogde FcγRIIb op effector macrofagen (zie hoofdstuk 6, Figuur 1). 
Hierdoor krijgen muizen minder symptomen van artritis doordat macrofagen in het gewricht 
niet meer geactiveerd kunnen worden door auto-immuun antilichamen (12). Een belang-
rijke vraag die hieruit voortkomt is of dit mechanisme ook daadwerkelijk plaats vindt in de 
mens. Dit is triviaal omdat  expressiepatronen van receptoren, waaronder FcγRs, significant 
verschillen tussen de mens en de muis. Om deze vraag te beantwoorden hebben we in 
hoofdstuk 3 het effect van IVIg op IL-33, Th2 cytokinen en receptor expressie in patiënten 
onderzocht. Daarnaast hebben we het oorzakelijk verband tussen deze fenomenen onder-
zocht door gebruik te maken van humane cellen in vitro. Wij toonden aan dat IL-33 en de 
Th2 cytokinen IL-4 en IL-13 direct stijgen na IVIg behandeling in het plasma van patiënten 
en de stijging van deze cytokinen was gecorreleerd aan elkaar. Deze bevinding suggereert 
dat IVIg, net als in muizen, een IL-33-Th2 cytokine cascade stimuleert in de mens. Echter, in 
tegenstelling tot de muis, vinden wij in patiënten geen stijging van de remmende FcγRIIb 
expressie, maar een afname in de activerende FcγRIIa expressie op mDCs. Dit verschil zou 
kunnen voortkomen uit verschillen in FcγR expressiepatronen tussen beide soorten en hierop 
wordt verder gediscussieerd in hoofdstuk 6.
Vervolgens hebben wij onderzocht of er een causaal verband zou kunnen zijn tussen de 
stijging van de Th2 cytokinen en de modulatie van FcγRs op circulerende mDCs. In vitro 
vonden we inderdaad een daling van FcγRIIa als we mDCs behandelen met IL-4 of IL-13. 
Functioneel toonden we aan dat deze daling resulteert in verminderde gevoeligheid voor 
activatie van mDCs na blootstelling aan immuuncomplexen. Dus ook in patiënten zou de 
IL-33-Th2 cytokine route een rol kunnen spelen in het klinisch effect van IVIg behandeling in 
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antilichaam-gemedieerde ontsteking, waaronder antilichaam-gemedieerde afstoting. Ech-
ter het effect van deze cytokinenproductie leidt niet tot toename van de inhibitoire FcγRIIb 
expressie, zoals in muizen, maar tot afname van expressie van de activerende FcγRIIa.
Een belangrijke activator van de cellulaire immuunrespons is het Th1 cytokine IFN-γ. Tij-
dens het proces van transplantaatafstoting speelt IFN-γ een belangrijke rol door directe 
cytotoxiciteit, maar ook indirect door het induceren van macrofaag en mDC activatie 
en migratie (13). Eerder is er in muizen aangetoond dat IVIg de activatie door IFN-γ kan 
afremmen door de expressie van een onderdeel van zijn receptor, IFN-γ receptor subunit 2 
(IFNγR2), op macrofagen te verminderen (14). Interessant is dat we ook aanwijzingen heb-
ben gevonden dat dit immunomodulerend effect in de mens plaatsvindt, zoals beschreven 
in hoofdstuk 3. Een dag na IVIg infusie vinden wij een daling van de IFNγR2 expressie op 
circulerende mDCs afkomstig van IVIg-behandelde patiënten. In vitro vonden we dat IL-4 
en IL-13 inderdaad voor afname van IFNγR2 op mDCs kunnen zorgen. Functioneel resul-
teerde deze afname van IFNγR2 expressie tot een verminderde gevoeligheid voor IFN-γ 
gemedieerde DC maturatie en productie van chemokine IP-10 (CXCL10). In de context van 
transplantaatafstoting is dit laatste een interessant gegeven, gezien hoge productie van 
IP-10 een grote rol speelt tijdens de afstotingsreactie van hart (15), longen (16) en nier (17). 
Door verhoogde IP-10 productie worden geactiveerde T cellen en macrofagen aangetrok-
ken tot het transplantaat, die daar hun cytotoxiciteit uitoefenen. Daarnaast induceert IFN-γ 
niet alleen IP-10, maar zou het ook andere chemokinen als Mig (CXCL9)en I-TAC (CXCL11) 
kunnen induceren die een rol spelen bij het aantrekken van alloresponsieve T cellen naar 
het transplantaat (18). Het effect van modulatie van de IVIg-IL-33-Th2 cytokine cascade op 
de expressie van IFN-γ receptor is nog niet eerder aangetoond. 
Kortom, door het effect van de IVIg-IL-33-Th2 cytokine route op de expressie van FcγR 
en IFNγR (zie ook hoofdstuk 6, Figuur 1), tonen wij aan dat deze cascade zowel een rol kan 
spelen bij antilichaam-gemedieerde als bij cellulaire immuniteit, die allebei betrokken zijn bij 
acute en chronische afstoting na LTx. 
Een interessant gegeven is dat de IVIg-IL-33 cytokine cascade mogelijk ook een rol zou 
kunnen spelen in de expansie en inductie van de suppressieve capaciteit van Tregs. Dit 
wordt verder bediscussieerd in de volgende paragraaf.
4. IVIg induceert Treg activatie en suppressieve capaciteit in 
patiënten
Tregs zijn de hoofdrolspelers in het onderhouden van immunologische zelf-tolerantie. 
Verscheidene studies hebben aangetoond dat Tregs betrokken zijn in het reguleren van 
autoimmuniteit, inflammatoire aandoeningen en immuunrespons tegen tumoren en 
verschillende pathogenen (21). Daarnaast is het aangetoond dat Tregs een kritische rol 
spelen in de inductie en behouden van transplantaat tolerantie door het onderdrukken 
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van alloreactieve T cellen in experimentele transplantatie modellen (22-32) en patiënten 
studies (33-36). Zeer interessant is dat er in de afgelopen jaren steeds meer bewijzen zijn dat 
de Treg activatie en suppressieve functie geïnduceerd kunnen worden door IVIg in vitro 
en in muizenstudies. Deze effecten zouden bij kunnen dragen aan de anti-inflammatoire 
effecten van IVIg. Echter, de vraag of deze effecten daadwerkelijk in de mens plaatsvin-
den bleef nog onbeantwoord. Om die reden hebben wij in hoofdstuk 4 onderzocht of 
IVIg behandeling in patiënten resulteert in verhoogde Treg activatie en bestuurden wij het 
functioneel effect van IVIg behandeling ex vivo. Wij hebben in deze studie geen LTx patiën-
ten geïncludeerd die behandeld zijn met anti-HBs IVIg, gezien deze patiënten ook andere 
immunosuppressiva nemen die negatieve effecten hebben op Tregs (40). In plaats daarvan 
hebben wij patiënten geïncludeerd die behandeld zijn met IVIg in verband met immuun-
deficiënties, autoimmuun- of inflammatoire aandoeningen (zie hoofdstuk 4, tabellen 1A en 
1B). In deze studie toonden wij aan dat IVIg selectief Tregs kan activeren, gedemonstreerd 
door verhoogde FOXP3 en HLA-DR expressie, maar dat het de conventionele T cellen niet 
activeert. Ex vivo studie laat zien dat IVIg de functionele suppressieve capaciteit van de 
circulerende Tregs nagenoeg verdubbelt. Opvallend is dat de stimulatoire effecten van 
IVIg op Tregs enkel te zien is bij patiënten die behandeld zijn met hoge dosis IVIg. Deze 
bevinding bevestigt de algemeen geaccepteerde hypothese dat hoge dosis IVIg behan-
deling nodig is om een anti-inflammatoire effect te bereiken. Uit de studie beschreven in 
hoofdstuk 4 concluderen wij dat IVIg niet alleen Treg functie kan stimuleren in muizen, maar 
ook in de mens in vivo. Gezien conventionele immunosuppressiva die gebruikt worden in 
patiënten met autoimmuunziekte en in transplantatiepatiënten om afstoting te voorkomen 
zowel conventionele T cellen als Tregs onderdrukken (40-47), zou gebruik van IVIg superieur 
kunnen zijn aan de klassieke immunosuppressiva. 
Een belangrijke vraag is wat het mechanisme is waarop IVIg Tregs kan stimuleren. Om 
deze vraag te beantwoorden hebben wij enkele pilotstudies in vitro verricht door Tregs 
te isoleren uit gezonde individuen en deze te kweken met IVIg. Wij toonden dat Tregs die 
behandeld zijn met IVIg de activatiemarker CD69 verhoogd tot expressie brengen. Echter, 
dit gebeurde alleen in aanwezigheid van monocyt-afkomstige DC (moDCs) (zie hoofdstuk 
9, Figuur 1, ongepubliceerde data). Deze data suggereert dat IVIg Tregs kan activeren 
op een DC-afhankelijke wijze. Deze bevinding sluit aan bij enkele recent geïdentificeerde 
mechanismen waarop IVIg Tregs kan induceren in muismodellen (zie hoofdstuk 6, Figuur 3). 
In een EAE muismodel is er gedemonstreerd dat IVIg Tregs kan expanderen door middel van 
het aanzetten van prostaglandine E2 (PGE2) productie door DCs (48). Dit mechanisme is 
deels afhankelijk van het F(ab’)2 gedeelte van het IgG molecuul. Een andere studie toonde 
aan dat IVIg antigeen-specifieke Treg kan laten differentiëren uit non-Tregs door het indu-
ceren van tolerogene DCs in een antigen-gemedieerde allergische luchtwegmodel (49). 
Recent is de receptor geïdentificeerd via welk IVIg dit effect mogelijk veroorzaakt, de im-
munoreceptor tyrosine-based inhibition motif (ITIM)-linked C-type lectin receptor, de zoge-
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naamde DC immunoreceptor, DCIR (50). Een andere hypothese is dat de DC-afhankelijke 
Treg activatie verklaard wordt middels de aanwezigheid van Tregitopes in humane IgG. 
De Groot et al. hebben gedemonstreerd dat Tregs geactiveerd en geëxpandeerd kunnen 
worden via de presentaties van Treg-activerende peptiden die afkomstig zijn van IgG, de 
zogenaamde Tregitopes, door APCs (51). Gezien gesialyleerde IgGs, die ook Tregitopes 
moeten bevatten, niet leidt tot Treg activatie (39), zullen ook andere mechanismen een 
rol spelen. Door middel van onze pilotstudies achten wij het minder waarschijnlijk dat DCs 
nodig zijn voor crosslinking van IgG via hun FcγRs die gebonden zijn aan Tregs via het F(ab’)2 
gedeelte, aangezien het kweken met monocyten, die ook FcγRs tot expressie brengen, niet 
tot hetzelfde resultaat leidt.
Betreffende de selectiviteit van IVIg voor Treg activatie sluiten onze bevindingen aan 
op andere studies die verricht zijn in vitro en in diermodellen (8, 9, 37, 38). Verschillende 
hypotheses kunnen worden gepostuleerd met betrekking tot Treg selectiviteit. Zoals eerder 
besproken kunnen presentatie van Tregitopes door APCs specificiek Tregs activeren (51). 
Daarnaast kunnen cytokinen die speciaal Tregs activeren een rol spelen, bijvoorbeeld 
TGF-β. IL-10 is minder waarschijnlijk, gezien wij geen verhoging zagen van IL-10 na IVIg 
behandeling. Een andere cytokine wat een interessante kandidaat is, is IL-33. Het is goed 
mogelijk dat er een link bestaat tussen de Treg expansie en verhoogde suppressieve capa-
citeit en de IVIg-IL-33-Th2 cytokine pathway, zoals beschreven in hoofdstuk 3 en uiteengezet 
in hoofdstuk 6. Drie recente studies in muizen (54-56) hebben laten zien dat IL-33 niet alleen 
Th2 cytokinen productie kan aanzetten, maar ook CD4+FOXP3+ Tregs kunnen expanderen. 
In harttransplantatie muismodellen  (54, 55) wordt er aangetoond dat IL-33 behandeling 
leidt tot verbeterde transplantaat overleving. Deze bescherming was afhankelijk van de 
expressie van ST2, de receptor voor IL-33 (54). Interessant is dat in het harttransplantaat (54, 
55) en in de milt (55) in muizen behandeld met IL-33 een verhoogd aantal FOXP3+ cellen 
vertoont, en dat depletie van Tregs van de ontvanger vooraf aan de transplantatie het 
effect van IL-33 therapie volledig laat verdwijnen. Deze resultaten laten het belang zien 
van IL-33 in het voorkomen van afstoting en dat inductie van Tregs daarbij een belangrijke 
rol speelt. In een recent onderzoek is er ook in een chronische colitis model aangetoond 
dat IL-33 de proliferatie van Treg kan induceren (56). Mogelijk dient de IL-33 als cofactor in 
TGF-β-gemedieerde Treg differentiatie. Gezien er in onze onderzoeksgroep eerder is aange-
toond dat IVIg de afstoting van huidtransplantaat kan voorkomen op een Treg-afhankelijke 
wijze (38) en het gegeven dat IVIg de productie van IL-33 kan aanzetten in mensen in vivo 
(hoofdstuk 4), is het goed voor te stellen dat IL-33 inductie door IVIg een potentiële oorzaak 
kan zijn voor de verhoogde Treg suppressieve capaciteit of expansie. In de toekomst zou 
deze link verder onderzocht moeten worden. 
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5. De effecten van IVIg op de proinflammatoire CD14+CD16++ 
monocyten
Door de jaren heen zijn onderzoekers voortdurend op zoek naar nieuwe mechanismen 
waarop IVIg de immuunrespons kan moduleren. Een van de mechanismen  die recentelijk 
gepresenteerd is, is de inductie van het aantal CD14+CD16++ monocyten (57). Gezien in 
bepaalde inflammatoire aandoeningen (bijvoorbeeld in de ziekte van Kawasaki of sepsis) 
deze aantallen sterk verhoogd kunnen zijn, is een verlaging in aantallen van deze cellen 
mogelijk een belangrijk mechanisme waarop IVIg immunomodulatie geeft in patiënten. 
Echter, de auteurs van dit artikel hebben alleen de patiënten geïncludeerd die IVIg in een 
“supplementaire” dosis geven, terwijl de modulerende effecten bestudeerd moeten wor-
den in de “immunomodulatoire” doseringen. In hoofdstuk 5 hebben wij daarom het effect 
van IVIg onderzocht op het aantal pro-inflammatoire CD14+CD16++ monocyten in IVIg-
behandelde patiënten en deze opgedeeld in patiënten die een lage dosering ontvingen 
(gemiddeld 0,43 g/kg) en patiënten die een hoge dosering kregen (gemiddeld1,24 g/kg). 
Evenals Siedlar et al., vonden wij dat het aantal CD14+CD16++ monocyten waren gedaald 
in patiënten die een lage dosering IVIg ontvingen. Echter, opmerkelijk is dat patiënten die 
een hoge dosering IVIg kregen geen daling vertoonden in het aantal pro-inflammatoire 
monocyten, terwijl deze groep patiënten juist die immunomodulatie nodig hebben. Verder 
vonden wij ook geen verlaging van TNF-α in het serum van IVIg-behandelde patiënten, 
ofschoon er gesuggereerd werd door Siedlar et al. dat afremming van TNF-α productie door 
monocyten wordt bewerkstelligd met IVIg behandeling. Concluderend zijn wij van mening 
dat de gunstige effecten van hoge dosering IVIg die bij patiënten worden gevonden niet 
veroorzaakt worden door verlaging van pro-inflammatoire monocyten. 
6. Nieuwe inzichten in de werkingsmechanismen van IVIg in muizen: 
is het te vertalen naar de mens?
Er komen steeds meer nieuwe aanwijzingen voor verschillende werkingsmechanismen van 
immunomodulatie door IVIg. Echter, het merendeel van deze bevindingen is geïdentificeerd 
in dierenstudies. In hoofdstukken 3, 4 en 5 hebben wij verschillende wijzen van immunomo-
dulatie door IVIg in de mens in vivo onderzocht. Wij vonden enige overeenkomsten, maar 
vonden ook belangrijke verschillen. Dit laatste is niet onverwacht, gezien er fundamentele 
verschillen bestaan in het immuunsysteem tussen de mens en dat van de muis. Opvallend 
is dat de consequenties van deze verschillen in de vertaling van de anti-inflammatoire 
mechanismen van IVIg van de muis naar de mens nooit helemaal uitgekristaliseerd is. In 
hoofdstuk 6 zetten wij enkele recent gevonden anti-inflammatoire mechanismen van IVIg 
uiteen en onderzochten of er ook bewijzen zijn dat deze mechanismen in de mens een rol 
spelen. Daarnaast bediscussiëren wij biologische verschillen tussen de muis en de mens. Het 
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eerste bewijs dat de IL-33-Th2 pathway gestimuleerd kan worden door IVIg in de mens is af-
komstig uit de waarneming van Anthony et al. die demonstreerde dat humaan DC-SIGN het 
muizenortholoog SIGN-R1 in het serum-geïnduceerde artritis muismodel kan vervangen om 
het anti-inflammatoire effect van gesialyleerd IVIg te bewerkstelligen (12). In dit hoofdstuk 
vragen wij ons af of DC-SIGN inderdaad het juiste humane ortholoog is van SIGN-R1, omdat 
het expressiepatroon van DC-SIGN in mensen zeer verschillend is van dat van SIGN-R1 in 
muizen. Daarnaast is het de vraag of de DC-SIGN echt gesialyleerde Fc-moleculen kan 
herkennen, gezien enkele recente studies tegen een mogelijk interactie hebben betoogd 
(58, 59). Verder tonen we aan dat de gepostuleerde bron van IL-33 na IVIg toediening bij 
muizen, de marginale zone macrofagen in de milt, afwezig is in mensen. We vervolgen onze 
discussie die we begonnen zijn in hoofdstuk 3, waar we ontdekten dat IVIg de expressie 
van de inhibitoire FcyRIIb bij patiënten niet verhoogt, terwijl dit één van de belangrijkste 
conclusies is uit recente IVIg studies in muizen (12, 60, 61). In plaats daarvan vonden we 
dat IVIg de expressie van de activerende FcyRIIa verlaagt. Belangrijk in deze discussie is 
dat muizen geen ortholoog van de FcyRIIa bezitten. Verder worden de functionele resul-
taten van de downregulatie van deze activerende receptor bij de mens in dit hoofdstuk 
besproken. Ook beschrijven we de overeenkomsten en verschillen met betrekking tot de 
mogelijke mechanismen van stimulatie van Treg expansie en suppressieve capaciteit door 
IVIg tussen de muis en de mens. In dit hoofdstuk adviseren wij, hoewel muizenstudies over 
IVIg zeer waardevol zijn om causale relaties te identificeren en mechanistische inzichten 
te verkrijgen, om bevindingen in diermodellen te verifiëren in patiënten behandeld met 
IVIg om klinisch relevante conclusies te kunnen trekken. Omdat IVIg wordt toegepast in de 
kliniek, is het bestuderen van de immunomodulerende effecten van IVIg bij mensen in vivo 
realiseerbaar en zou het uitvoeren van ex vivo functionele assays mogelijk moeten zijn.
Zoals in dit hoofdstuk geïllustreerd wordt, kunnen fundamentele verschillen tussen het 
immuunsysteem van de mens en de muis de discrepanties uit verschillende onderzoeken 
naar het werkingsmechanisme van IVIg, die gebruik maken van diermodellen en menselijke 
materialen, verklaren. Er zijn echter ook tegenstrijdige gegevens naar voren gekomen uit 
in vitro onderzoek met menselijke cellen. In de volgende hoofdstukken hebben we een 
aantal van de mogelijke verklaringen voor deze discrepanties beschreven.
7. Studies naar de effecten van IVIg op moDCs in vitro kunnen 
aanzienlijk beïnvloed worden door IgG immobilisatie als artifact
In hoofdstuk 3 hebben we een indirect effect van IVIg op DC activatie en functie be-
schreven door middel van stimulatie van Th2 cytokine secretie die de expressie van de 
activerende receptoren moduleert. Met het oog op de directe werking van IVIg op DC, 
bestudeerden wij in hoofdstuk 7 het direct effect van IVIg op de rijping, cytokine productie 
en T-cel stimulerende capaciteit van DCs in vitro. Het is reeds aangetoond door Bayry et 
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al. dat IVIg de differentiatie en maturatie van moDCs direct afremt. Daarnaast  remt het 
ook IL-12 productie en T-cel stimulerende capaciteit van moDCs (6). In tegenstelling tot 
Bayry et al., vonden wij in onze experimenten geen inhibitie van moDC activatie, maar 
juist stimulatie van moDC maturatie en zijn T-cel-activerende capaciteit. Hetzelfde resultaat 
werd bereikt door gebruik te maken van vers geïsoleerde mDCs. Onze bevindingen be-
vestigen een andere studie die ook stimulatie van moDC differentiatie door IVIg toonde in 
plaats van inhibitie (62). Hoe kunnen deze controversiële resultaten betreffende het effect 
van IVIg op de maturatie van humane DCs worden verklaard? Gezien IgG moleculen kun-
nen worden geadsorbeerd aan kunststof oppervlakken en het feit dat moDCs uitgebreid 
FcγRs tot expressie brengen, vroegen we ons af of immobilisatie van IVIg aan het kunststof 
plaatoppervlakte tijdens het kweken de DC rijping zou kunnen beïnvloeden door binding 
aan FcγRs. Om aan te tonen dat dit artefact daadwerkelijk optreedt, hebben wij gebruik 
gemaakt van het eiwitrijke foetaal kalfsserum om potentiële bindingsplaatsen voor IgG 
aan het plaatoppervlak te blokkeren. Inderdaad, als IgG immobilisatie werd voorkomen, 
was het stimulerende effect van IVIg op moDC maturatie verdwenen. Wanneer we FcyRIIa 
blokkeerden, vonden we dat de activatie van moDCs ook verdween. Deze bevindingen 
suggereren dat moDCs in vitro geactiveerd kunnen worden door IVIg vanwege binding 
van geïmmobiliseerd IgG aan FcyRIIa op moDCs. Gezien er in de voorgaande onderzoeken 
geen voorzorgsmaatregelen zijn genomen om IgG adsorptie aan de kunststof kweekplaat 
te voorkomen, kunnen de gerapporteerde effecten van moDC stimulatie het gevolg 
zijn van artificiële activering. Dus voor een betere interpretatie van de gegevens en met 
het oog op consistentie, zouden we willen adviseren om bindingsplaatsen voor IgG in de 
kweekplaat te blokkeren bij het bestuderen van de effecten van IVIg op cellen die FcγRs tot 
expressie brengen. Ten aanzien van het directe effect van IVIg op de humane DCs kunnen 
we uit deze studie concluderen dat IVIg op zichzelf de DC maturatie niet direct beïnvloedt. 
8. De inhibitoire effecten van IVIg op T-cel activatie wordt beïnvloed 
door het productieproces
In hoofdstuk 8 hebben we een andere mogelijke factor gevonden die het immunomo-
dulerende effect van IVIg kan beïnvloeden, namelijk het fabricageproces van IVIg. Deze 
bevinding kan mogelijk de verschillen in gepubliceerde artikelen verklaren die gebruikma-
ken van diverse merken van IVIg preparaten. In een eerdere studie is er aangetoond dat 
hyperimmunoglobulinen tegen HBV Hepatect® CP een sterke T-cel onderdrukkende capa-
citeit kan bewerkstelligen, terwijl een anti-CMV hyperimmunoglobulin, Cytotect®, dit effect 
niet had (3). Een belangrijk verschil tussen Hepatect® CP en Cytotect® is het proces van de 
virus inactivatie tijdens de productie van deze preparaten. Bij Hepatect® CP wordt de vi-
rusinactivatie verkregen door middel van behandeling met caprylzuur, tri-n-butylfosfaat en 
polysorbaat 80. Echter, bij Cytotect® wordt de virusinactivatie ook verkregen door middel 
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van β-propiolacton behandeling, die de conformatie van IgG beïnvloedt door covalente 
modificatie van aminogroepen. Onlangs is een nieuw anti-CMV hyperimmunoglobuline 
ontwikkeld, genaamd Cytotect® CP, dat niet is blootgesteld aan β-propiolacton en verder 
hetzelfde fabricageproces ondergaat als Hepatect® CP. Om de invloed van de weglating 
van β-propiolacton behandeling op het immunomodulerende effect van IVIg te bestude-
ren, hebben we de effecten vergeleken van Cytotect® CP, Cytotect® en Hepatect® CP 
op humane T-cel proliferatie en cytokine productie in vitro. Hier tonen we aan dat het 
vermogen om T-celproliferatie en IFN-γ secretie af te remmen van Cytotect® CP gelijk is 
aan dat van Hepatect® CP, en dat deze significant beter is dan de voorgaande anti-CMV 
hyperimmunoglobuline formulering Cytotect®. Een van de mechanismen die dit verschil 
mogelijk verklaart is de modulatie van de Fc staart van IgG door β-propiolacton, waardoor 
de binding aan FcγRs wordt aangetast. Dit zou mogelijk een rol spelen bij binding aan de 
FcγRIII op NK cellen, welke eerder was aangetoond betrokken te zijn bij depletie van APCs 
in vitro (7).  Kortom, dit resultaat toont aan dat de productieprocessen de immunomodule-
rende effecten van IVIg aanzienlijk kunnen beïnvloeden. 
9. Algemene conclusie en toekomstperspectieven
LTx is een levensreddende behandeling voor patiënten met eindstadium leverziekte. De 
korte termijn overleving van patiënten is sterk verbeterd dankzij verbeterde chirurgische 
technieken en medische zorg, en de volgende uitdaging in orgaantransplantatie is dan 
ook het verbeteren van de lange termijn overleving. Een belangrijk obstakel voor de ver-
betering hiervan is de levenslange behoefte aan immunosuppressiva, die gepaard gaat 
met ernstige bijwerkingen. Over het algemeen is het levertransplantaat relatief gezien een 
immunologisch tolerogeen orgaan. Dit wordt geïllustreerd door de lage incidentie van 
levertransplantaat verlies door acute of chronische afstoting en het bestand zijn tegen 
antilichaam-gemedieerde schade (87). Ongeveer 20% van LTx patiënten kunnen stoppen 
met alle immuunsuppressieve behandeling en een normale transplantaatfunctie behou-
den zonder dat afstoting plaatsvindt. Echter, gezien er tot op heden geen gevalideerde 
test is om deze patiënten te identificeren, zijn LTx patiënten nog steeds genoodzaakt om 
levenslang immuunsuppressieve medicatie te gebruiken. Omdat het merendeel van de 
complicaties op lange termijn  na LTx te wijten is aan de effecten van immunosuppressiva, 
zijn de therapeutische strategieën gericht op het handhaven van een delicaat evenwicht 
tussen het vermijden van toxische effecten van immunosuppressiva en het reduceren van 
het risico op acute afstoting. 
Een veelbelovende therapeutische kandidaat voor het verminderen van de toxiciteit 
van de huidige immunosuppressiva is de implementatie van IVIg als immunosuppressieve 
behandeling na LTx. Het is bewezen dat IVIg sterke anti-inflammatoire effecten heeft die 
autoimmuunziekten en systemische ontstekingsreacties kunnen moduleren. Interessant is 
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dat er steeds meer aanwijzingen zijn dat IVIg ook effectief is in het voorkomen van trans-
plantaatafstoting. Aangezien het gebruik van IVIg op lange termijn geen ernstige bijwer-
kingen geeft (52), is het includeren van IVIg in het immunosuppressiva protocol na LTx zeer 
aantrekkelijk. In dit proefschrift leveren wij, in aansluiting op de beschikbare mechanistische 
inzichten van studies in diermodellen, nieuwe perspectieven op de mechanismen van im-
munomodulatie door IVIg in de mens, die ten grondslag liggen aan de bescherming tegen 
afstoting. 
In dit proefschrift pleiten we voor het gebruik van IVIg therapie als een veilige immunosup-
pressieve behandeling na LTx. Echter, de implementatie van IVIg in een standaard immu-
nosuppressiva protocol na LTx stuit op twee hindernissen: 1) er is een voorspeld wereldwijd 
tekort aan IVIg als gevolg van een toename van de vraag naar humaan plasma (75), en 
2) IVIg behandeling gaat gepaard met hoge kosten. Teneinde de brede toepassing van 
IVIg mogelijk te maken, is het van groot belang de moleculaire interacties tussen IVIg en het 
menselijke immuunsysteem te ontrafelen. Dit maakt het ontwerp van alternatieve of recom-
binante moleculen mogelijk die de anti-inflammatoire effecten van IVIg kunnen nabootsen 
en het geschikt maakt voor langdurige immunosuppressieve therapie na transplantatie. 
In dit proefschrift laten we zien dat IVIg Treg activatie en de suppressieve capaciteit kan 
stimuleren in patiënten. Samen met anderen laten we zien dat Treg activatie door IVIg 
waarschijnlijk indirect wordt uitgeoefend, mogelijk via DCs (zoals beschreven in paragraaf 
4). Daarnaast kan IVIg via binding aan cellen in lymfeknopen, bijvoorbeeld aan macrofa-
gen, IL-33 productie induceren, wat uiteindelijk leidt tot het moduleren van FcyR expressie 
op DCs. Inzicht in de moleculaire interactie tussen IVIg en Treg en IL-33-producerende cellen 
maakt het wellicht mogelijk een component van IVIg te identificeren die Treg activeert en 
DCs afreemt, en deze op te zuiveren. Voor Treg stimulatie is DCIR een interessante kandidaat 
(40), zoals beschreven in hoofdstuk 6, maar er is nog geen aanwijziging dat dit molecuul be-
trokken is bij de werking van IVIg in de mens. DC-SIGN lijkt uitgesloten als kandidaat receptor 
voor IVIg-gemedieerde IL-33 productie, zoals bestudeerd in hoofdstuk 3. Immuunprecipitatie 
en massaspectrometrie kunnen worden gebruikt om de IVIg-bindende receptor waarmee 
IVIg Tregs stimuleert en  DCs inhibeert te identificeren. Het is zeer waarschijnlijk dat er meer-
dere betrokken moleculen worden geïdentificeerd. Identificatie van deze receptoren kan 
het ontwerp van een alternatieve behandelingstherapeutica mogelijk maken die op deze 
receptoren aangrijpen. 
Met betrekking tot de klinische toepassing van de huidige beschikbare IVIg preparaten 
moeten er eerst klinische trials worden uitgevoerd naar het gebruik van hoge dosis IVIg 
in LTx patiënten. Een van de eerste stappen is om de optimale dosis te bepalen. Huidige 
onderzoeken in PID patiënten suggereren dat een bepaald serum IgG spiegel nodig is om 
infecties te voorkomen en dat de benodigde spiegel aanzienlijk kan verschillen tussen pati-
enten (76, 77). Daarnaast is de toename van serum IgG na hoge doses IVIg sterk variërend 
tussen patiënten, zoals is aangetoond bij  Guillain-Barre (78) en CIPD (79) patiënten. De 
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bepaling van de optimale serum IgG die nodig is ter voorkoming van transplantaatafstoting 
en de vereiste dosis IVIg om deze IgG spiegel te bereiken in LTx patiënten dient daarom 
eerst onderzocht te worden.
Daarnaast dienen er klinische trials naar IVIg uitgevoerd te worden met het oog op het 
minimaliseren van de huidige immunosuppressieve geneesmiddelen. Het is mogelijk dat de 
huidige immunosuppressiva niet geheel vervangen kunnen worden door IVIg. In dat geval 
kan IVIg het mogelijk maken om de dosering van huidige immunosuppressiva te reduceren 
en daarmee de toxische effecten van de medicatie, zoals in het geval van tacrolimus en 
MMF, af te doen nemen.
Een ander aspect in huidige studies omtrent IgG therapie is de verandering van intrave-
neuze naar subcutane toediening van IgG. Subcutane IgG (SCIg) preparaten waren al in 
de jaren 1980 in de VS en Europa geïntroduceerd. Echter, de langzame infusie en de lage 
concentratie in de beschikbare preparaten maakten SCIg minder aantrekkelijk waardoor 
ze uiteindelijk vervangen werden door IVIg. Als gevolg van recente technische ontwikke-
lingen in IgG formulering is het mogelijk om zuivere en geconcentreerde SCIg preparaten 
te ontwikkelen die een relatief lage viscositeit hebben en die dus relatief snel kan worden 
toegediend (80, 81). SCIg heeft voordelen ten opzichte van IVIg, omdat het gemakkelijker 
is zelf toe te dienen en dus thuis gebruikt kan worden. Dit verbetert de kwaliteit van leven en 
de tevredenheid over de behandeling (82). Daarom zou het gebruik van SCIg therapie in 
toekomstige klinische trials in LTx patiënten overwogen moeten worden. 
Op het gebied van orgaantransplantatie-immunologie is het uiteindelijke doel om 
operationeel tolerantie te verkrijgen, gedefinieerd als de acceptatie van het donor -or-
gaan zonder het gebruik van immunosuppressieve middelen, maar wel met behoud van 
afstotingsreactie tegen het donororgaan van een derde partij (83). Aangezien IVIg DCs 
en Tregs kan moduleren, die beiden een sleutelrol spelen bij operationele tolerantie na 
orgaantransplantatie (22, 84-86), zou het gebruik van IVIg niet alleen kunnen leiden tot het 
onderdrukken van de afstotingsreactie, maar ook tot het bevorderen van operationele 
tolerantie. Recente studies die aantonen dat IVIg tolerogene DCs kunnen induceren die in 
staat zijn antigeen-specifieke Tregs te induceren in muizen zijn zeer veelbelovend (49, 50). 
Of donor-specifieke tolerantie kan worden bereikt door IVIg therapie in LTx patiënten zal 
moeten blijken uit toekomstige studies.
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